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Summary 
Breast cancer is the third most common cause of cancer death in the UK, 
accountable for more than 11000 deaths in 2010 alone (www.cancerresearchuk. 
org). Developmental pathways commonly required for normal development are 
often hijacked during tumour progression, so a better understanding of 
mammary gland development is necessary to fully understand the roots of breast 
cancer. The Runx gene family are known to be important regulators of 
development in different lineages. In particular RUNX1 and RUNX2 have been 
widely studied in the context of haematopoiesis and osteogenesis respectively, 
but their role in epithelial tissue is much less well understood. In this thesis a 
role for RUNX1 and RUNX2 in mammary development and breast cancer has been 
identified. 
The first part of this study is focused on characterizing the expression and 
function of the Runx genes in the mammary epithelium. RUNX1 and RUNX2 
protein levels fluctuate during embryonic and adult mammary development, and 
an in vivo conditional knockout strategy shows that both genes are important for 
maintenance of mammary epithelium homeostasis. Moreover, combined loss of 
RUNX1 and RUNX2 significantly perturbs the normal mammary architecture with 
an expansion of the basal population in vivo and the appearance of 
preneoplastic lesions in aged mammary glands.  An exciting new role for RUNX2 
in mammary stem cells has also been revealed showing that RUNX2 is important 
for the regenerative potential of mammary epithelial cells in vitro.  Evidence is 
also presented to indicate that RUNX2 could be linked to regulation of 
quiescence and Wnt signalling in the stem cell compartment and during 
transformation.  
Finally, the role of these genes in breast cancer is discussed demonstrating 
involvement of RUNX1 and RUNX2 specifically in the triple negative (ER-PR-
HER2-) subtype. In particular, for the first time, RUNX1 is revealed as an 
independent prognostic indicator correlating with poor prognosis in triple 
negative tumours.  Meanwhile, evidence from various mouse models 
demonstrates that RUNX2 may be specifically involved in the squamous 
metaplastic form of this disease.  
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1 Introduction 
 
1.1  Mammary gland development 
To introduce mammary gland development nothing could be more appropriate 
than the inspiring and elegant words of Daniel Medina, a pioneer of mammary 
gland research (Medina 1996):   
“The problems of mammary gland development and function have 
attracted the attention of scientists for over a century. Since the 
complete anatomical description of the gland in 1845, it has been 
studied by physiologists to understand milk and milk secretion, by 
cell and electron microscopists to understand structure and secretory 
function, by developmental biologists to understand organ 
development in the postnatal organism, by endocrinologists to 
understand hormone action, by molecular biologists to understand 
regulation of gene expression, by biotechnologists to develop in vivo 
bioreactors, by cancer biologists and virologists to study the causes 
and processes of neoplastic transformation, and by clinical scientists 
to examine, treat, and cure breast cancer. The organ interests and 
excites the experimental scientist because of its unique development 
and function, its experimental applicability, its complex biological 
and cellular interactions, and, despite all this, its inherent simplicity 
and beauty.” 
 
1.1.1  Function and evolution 
The mammary gland is the organ designated to the production, secretion and 
delivery of milk to the newborn offspring. In 1758, Linnaeus was the ﬁrst to 
recognize the uniqueness of mammary glands and on this basis he created the 
class Mammalia, or creatures with ‘mammae’ or ‘breasts’. Several theories have 
been proposed to explain the origin and the evolution of this glandular organ. On 
one side it is thought that the mammary gland evolved through the combination 
of different skin gland populations into a new functional organ (Blackburn 1993) 
while others support the view that the mammary gland most likely derives from 
an ancestral apocrine-like gland (Oftedal 2002). However, the exact evolutionary 
origin of the mammary gland is still unknown due to the absence of any direct 
fossil evidence of mammary glands.  
16 
 
1.1.2  Mammary gland development: an overview. 
The mammary gland is a very dynamic tissue which undergoes dramatic changes 
during different developmental phases (Richert, 2000; Hennighausen & Robinson, 
2005; Watson & Khaled, 2008). From a small ectodermal invagination during the 
first phases of embryonic development, the mammary gland develops into a 
highly plastic and expanding duct tree under the influence of pubertal hormones 
(Brisken & O’Malley 2010). The ductular appearance of the virgin epithelium is 
then replaced during pregnancy and lactation through a massive event of cell 
proliferation and differentiation which lead to the formation of mature alveoli, 
the milk-producing unit of the mammary gland. The end of lactation sees the 
beginning of involution, a strictly regulated process involving apoptosis and 
tissue remodelling, which will bring the mammary gland back to a virgin-like 
state (Watson & Kreuzaler 2011).  Several cell types take part in this process; 
comprising epithelial cells forming the ductal structures which themselves are 
surrounded by a fatty stroma made up by adipocytes, vascular endothelial cells, 
blood vessels, fibroblasts and a variety of immune cells (Wiseman & Werb 2002). 
Given the high complexity and plasticity of this organ, the creation of a 
mammary gland requires the coordination of many biological processes such as 
proliferation, invasion and cell death among others. Interestingly all of these 
developmental pathways are hijacked during the development of breast cancer. 
Hence a better understanding of the basic biological mechanism regulating 
normal mammary gland development will help to shed more light on the 
neoplastic transformation. Given its advantages as an experimental model 
(Smith, 2012), much of the characterization of mammary gland development has 
been done in mice.  Despite some unavoidable differences, such as tissue 
architecture and hormonal control, the mouse mammary gland shares similar 
developmental features with the human one.  
1.1.3  Embryonic development 
During early embryogenesis, the ectoderm represents the external germ layer, 
which is composed of the surface ectoderm, neural crest, and neural tube. The 
surface ectoderm gives rise to the epidermis and other stratified epithelia such 
as the oral epithelium (Jiménez-Rojo et al. 2012). Then, in those new-formed 
tissues, a continuous cross-talk between the epithelium and the mesenchyme 
17 
 
gives rise to diverse specialized structures, called ectodermal appendages, such 
as hair follicles, mammary glands, salivary glands and teeth (Jiménez-Rojo et al. 
2012). Interestingly all ectodermal appendages share common morphological 
features and similar developmental processes during early organogenesis, while 
later stages of development are characterized by structure-specific 
morphogenetic programs (Mikkola & Millar 2006).  
Embryonic mammary development starts on embryonic day (E) 10.5, with the 
formation of the milk or mammary lines, ectodermal ridges running between the 
fore and hind limbs in both male and females embryos (for excellent reviews on 
embryonic mammary development see Robinson 2007; Watson & Khaled 2008; 
Cowin & Wysolmerski 2010). Around E11.5, the mammary line resolves into five 
pairs of placodes, lens-shaped thickenings of the surface ectoderm, 
symmetrically positioned along the milk line in characteristic locations (three 
thoracic and two inguinal). Each pair of placodes develops symmetrically 
following a characteristic temporal sequence. Interestingly different placodes 
seem to be specified by different molecular determinants as shown by genetic 
studies on mice; for example Lef1-deficient animals do not form placodes 2 and 
3 (van Genderen et al. 1994). 
Wnt signalling is necessary for the specification of the mammary line and 
placode development (Chu et al. 2004). The mammary line can be visualized in 
situ by Wnt10b staining (Veltmaat et al. 2004). Moreover the use of transgenic 
mice expressing the Wnt reporter gene TOPGAL, confirmed Wnt activation in 
mesenchymal and epithelial components of the mammary line followed by an 
increased expression in the placodes until E15.5 (Chu et al. 2004). Activation of 
Wnt signalling through lithium chloride treatment on embryonic skin caused an 
increase in placode number and size while disruption of Wnt signalling through 
transgenic expression of the secreted Wnt inhibitor DKK1 inhibited placode 
formation (Chu et al. 2004). The placode-specific functions of Wnt signalling 
seem to be mediated by LEF1 as in Lef1 knock-out embryos, Wnt signalling is not 
activated and placodes do not form or degenerate, resulting in lack of mammary 
epithelium (Boras-Granic et al. 2006). Wnt signalling is also necessary for hair 
follicle and tooth development, as shown by suppression of all placodes 
development after in vivo blockade of Wnt signalling through expression of Wnt 
inhibitor DKK (Andl et al. 2002). This result suggests that Wnt signalling is a key 
18 
 
lineage specifier during ectodermal appendage development where it acts to 
induce multipotent ectodermal cells to adopt a generic placodal cell fate.  
Fgf signalling seems to act in parallel to Wnt signalling in specifying the 
mammary line as Fgf10-/- and Fgfr2b-/- mice fail to develop all but mammary 
bud #4 (Mailleux et al. 2002). While Fgfr2b is expressed in the mammary buds as 
early as E11.5, Fgf10 is not detectable in the embryonic mammary epithelium 
but is first seen in the somites underlying the milk line (Mailleux et al. 2002). 
Fgf10 is thought to exert its key role on milk line specification and positioning  
through paracrine signalling originating from somites and acting on a subset of 
ectodermal cells expressing its receptor Fgfr2b (Veltmaat et al. 2006). The role 
of Fgf10 as the critical somitic factor required for mammary line specification is 
further supported by the phenotype of Gli3 deleted mice (Hatsell & Cowin 
2006). Gli3 loss causes a reduction of Fgf10 expression, abrogation of TOPGAL 
expression in the mammary line in the region of placode 3 and loss or 
misplacement of buds 3 and 5. In the current view, somitic Gli3 represses 
Hedgehog signalling and regulates expression of Fgf10, which in turn signals to 
ectodermal Fgfr2b and then to Wnt10b to specify mammary line formation 
(Veltmaat et al. 2006).  
Another key regulator of mammary placode specification and positioning is Tbx3, 
a member of the T-box family of transcription factors (Rowley et al. 2004). 
Interestingly embryos deleted for Tbx3 do not develop mammary buds and fail to 
express Wnt10b and Lef1 (Davenport et al. 2003). Interestingly in humans, TBX3 
haploinsufficiency is associated with the ulnar-mammary syndrome, a dominant 
developmental disorder characterized by abnormal forelimb and apocrine gland 
development which lead sometimes to complete loss of mammary glands 
(Bamshad et al. 1997). Transgenic overexpression of Ectodysplasin (Eda), a 
member of the tumour necrosis factor family, in the ectoderm causes the 
development of supernumerary glands (Mustonen et al. 2003) while deletion of 
GATA3, a transcription factor involved in T-cell development, caused a variable 
loss of placodes and a failure to develop the nipple sheath (Asselin-Labat et al. 
2007). Overall these studies have uncovered a web of molecular mechanisms 
underlying mammary line and placode specification. 
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By E13.5, morphologically distinct epithelial placodes are present along the 
mammary line in mouse embryos, and by E14.5 these buds have invaded into the 
underlying dermis. At this point signals generated from the mammary epithelium 
push the surrounding mesenchymal cells to differentiate into a mammary-
specific mesenchyme (Robinson 2007). The mesenchymal cells become arranged 
in concentric layers around the epithelial bud and start to express receptors for 
oestrogen and androgens. The primary mammary mesenchyme plays a key role in 
mammary development; maintaining mammary epithelial cell identity, 
supporting ductal morphogenesis and in male mice causing the destruction of the 
mammary epithelial bud in the presence of testosterone (Robinson 2007). 
Parathyroid hormone-related protein (PTHrP), produced by the epithelial bud 
has been identified as a key inducer of mammary mesenchyme identity 
(Wysolmerski et al. 1998; Foley et al. 2001).  PTHrP is expressed by the 
mammary epithelial bud as it starts to invaginate into the mesenchyme while its 
receptor, PTH1R, is expressed in the mesenchyme surrounding the placode. 
Deletion of PTHrP or PTH1R, leads to a failure of ductal growth into the 
mesenchyme resulting in arrest of mammary development at the late bud stage 
(Foley et al. 2001). In addition the epithelial cells lose their mammary-identity 
and revert to an epidermal fate as shown by expression of keratinocyte-specific 
keratins (Foley et al. 2001). Moreover, mammary placodes fail to regress in male 
embryos indicating that PTHrP production in the epithelium is required to induce 
androgen receptor expression within the mammary mesenchyme (Dunbar et al. 
1999). PTHrP signalling is also necessary for the mammary mesenchyme to 
induce the overlying epidermis to form the nipple (Foley et al. 2001). These data 
underline the importance of epithelial/mesenchymal interactions during 
mammary morphogenesis and the pivotal role of PTHrP as a determinant of 
mammary mesenchyme. 
The next phase of development, which starts around E16, is characterized by the 
beginning of ductal branching morphogenesis. In a tightly coordinated process of 
invasion, a solid cord of epithelial cells emerges from the mammary bud and 
extend down through the primary mammary mesenchyme into the final stromal 
compartment, the mammary fat pad (Cowin & Wysolmerski 2010). At this time 
two other morphological processes take place: ductal lumen formation and 
nipple morphogenesis. By E18.5 all the mammary placodes have developed into 
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small immature glands that bear between 10 and 15 small branches. At the 
conclusion of embryonic development, the mammary gland consists of a short 
primary duct ending in a small ductal tree that is embedded in one end of larger 
mammary fat pad. The branching morphogenesis of the embryonic mammary 
gland is hormone independent as shown by normal embryonic mammary 
development of mice that are deficient in either oestrogen, prolactin, growth 
hormone or progesterone receptor (Cowin & Wysolmerski 2010). Instead 
embryonic ductal morphogenesis requires soluble factors that are supplied by 
the mammary fat pad precursor, such as PTHrP (Hens et al. 2007).  
1.1.4  Virgin mammary development 
The rudimentary epithelial tree in the mammary fat pad remains quiescent until 
puberty, growing at a very slow rate to keep up with normal body growth 
(allosteric growth).  Allosteric growth stops with the onset of puberty when 
ovarian steroid hormone production induces the complex process of pubertal 
ductal morphogenesis (Watson & Khaled 2008). At the tips of the ducts, highly 
proliferative structures, called terminal end buds (TEBs) develop and start to 
invade into the fat pad driving ductal elongation (Sternlicht 2006). TEBs 
bifurcate, forming secondary branches which will further invade into the fatty 
stroma until the entire fat pad is filled with a network of branched ducts. The 
fully grown mammary gland will then start cycling under the influence of the 
oestrous-induced hormones with waves of side-branching followed by apoptosis 
occurring within each oestrous cycle (Schedin et al. 2000). Thus the adult virgin 
mammary gland is an active remodelling tissue constantly involved in cycles of 
proliferation and apoptosis. In the pubertal mammary gland, the initial drive for 
ductal morphogenesis comes from three main circulating hormones: ovarian 
hormone oestrogen and progesterone and the pituitary growth hormone (GH) 
(Brisken & O’Malley 2010).  
Oestrogen 
Pubertal ductal outgrowth of the mammary gland requires oestrogen, a steroid 
hormone synthesized by the ovaries. Oestrogen binds to two distinct receptors, 
oestrogen receptor (ER) α and ERβ, which become activated and function as 
transcription factors when bound to the steroid hormone (Heldring et al. 2007). 
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Ovariectomized mice, which cannot produce oestrogen, fail to develop a 
mammary ductal network and this phenotype is rescued upon implantation of 
slow-release oestrogen pellets into the mammary gland (Daniel et al. 1987). 
Moreover the ductal network in pubertal mice deficient in ERα fails to grow and 
invade the fat pad (Korach et al. 1996) while no effect is seen after ERβ deletion 
(Krege et al. 1998). Although ERα is expressed both in the mammary epithelium 
and stroma, transplantation experiments showed that only epithelial ER is 
required for pubertal outgrowth (Mallepell et al. 2006). 
Progesterone 
At puberty, the rise in gonadotrophin levels leads to progesterone secretion from 
the ovaries. Progesterone receptor (PR) is a member of the nuclear hormone 
receptor family of ligand-dependent transcription factors which regulates 
specific target genes through binding to cis-acting progesterone response 
elements (Li & O’Malley 2003). PR is expressed in both epithelial and stromal 
compartments in the mouse mammary gland (Haslam & Shyamala 1981). Several 
studies showed that epithelial PR is not required for primary ductal growth but is 
a key regulator of ductal branching and proliferation in the virgin mammary 
gland (Obr & Edwards 2012). The mammary glands of young virgin PR-deleted 
females have no obvious defect of ductal development (Lydon et al. 1995). 
However, since PR deleted females are unable to ovulate, the effects of PR loss 
on oestrous-induced branching could not be investigated. To overcome this 
defect, oestrous cycles where artificially simulated by treating WT and PR-
deleted virgin females with estradiol and progesterone: interestingly the WT 
breast tissue responded with increased side-branching and lobuloalveolar 
development, whereas the mammary glands of PR deleted females remained 
essentially unchanged (Brisken et al. 1998). This suggested that PR is not 
required for initial ductal growth but it is essential for oestrous-dependent side-
branching and alveologenesis. The essential role of progesterone during the 
expansion of the alveolar compartment during pregnancy is discussed below. 
Growth Hormone 
Although pubertal mammary development is started by the surge of oestrogen 
levels, the action of oestrogen depends on the presence of growth hormone 
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(GH). Experiments in the 1940s demonstrated that the pituitary gland was 
required for mammary gland development and that oestrogen-driven ductal 
development fails in hypophysectomised rodents (Reece et al. 1936; Kleinberg & 
Ruan 2008). Moreover transgenic mice lacking GH receptor displayed severely 
impaired mammary ductal outgrowth at puberty (Gallego et al. 2001). 
Interestingly GH signalling is required in the stroma since ductal epithelium 
arising from GH receptor null glands transplanted into the cleared fat pads of 
WT mice develop as normal (Gallego et al. 2001).  
Other factors required in pubertal growth 
Several other growth factors are required for pubertal ductal morphogenesis 
(reviewed in McNally & Martin 2011). During pubertal mammary development, 
the action of oestrogen depends on the presence of GH to drive ductal 
outgrowth. Further experiments showed that the IGF-1 signalling pathway is 
necessary downstream of GH to induce pubertal mammary development (Wood 
et al. 2000).  IGF-1 deleted mice have a defective pubertal mammary 
development characterized by impaired ductal outgrowth (Ruan & Kleinberg 
1999). Moreover IGF1-R null embryonic mammary buds transplanted into WT 
hosts possess limited outgrowth potential and show defects in TEB proliferation 
(Bonnette & Hadsell 2001). Rescue experiments also showed that IGF-1 is 
downstream of GH and oestrogen signalling where IGF-1 treatment rescued 
ductal development in oestrogen deficient (ovariectomized) and GH-deficient 
(hypophysectomized) animals (Ruan et al. 1992), while GH or oestrogen 
treatment did not rescue IGF-1-null glands (Ruan & Kleinberg 1999).  
Fibroblast growth factor (FGF) signalling has been implicated in the control of 
postnatal mammary development (Hynes & Watson 2010). During ductal 
outgrowth multiple FGFs as well as FGFR1 and FGFR2 are expressed. TEBs have 
high levels of FGFR2, which is essential at this stage because FGFR2 null glands 
have a severe delay in adolescent ductal development, penetrating the fat pad 
more slowly and showing fewer branch points compared with WT controls (Lu, 
2008). Moreover an analysis of genetic mosaicism reveals that epithelia without 
FGFR2 are eliminated from the ducts that do develop (Lu et al. 2008). Other 
FGF-deficient models (e.g., FGF-7) showed no mammary phenotype indicating 
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the presence of possible compensatory mechanisms between FGF family 
members (Sternlicht 2006).  
Epidermal growth factor (EGF) ligands are produced as transmembrane 
precursors that after cleavage bind and activate EGF-R receptors. Several EGF-
family ligands and all of the EGF-R receptors are expressed in the mammary 
gland during mammary development (Schroeder & Lee 1998). Interestingly, slow-
release pellets delivering EGF restored ductal development in ovariectomized 
(Coleman et al. 1988) and ERα-deficient mice (Kenney et al. 2003) while 
exogenous oestrogen drives EGF-R activation in ovariectomized mice (Sebastian 
et al. 1998). These results suggest that EGF-R promotes mammary ductal 
outgrowth downstream of ERα. Moreover reciprocal transplant experiments 
between WT epithelium and EGF-R mutant stroma, revealed that only stromal 
EGFR is required for ductal morphogenesis (Wiesen et al. 1999). Amphiregulin 
(AREG) has been found to be the key EGF-family ligand to bind EGF-R and to 
mediate pubertal morphogenesis downstream of ER signalling. Ductal 
morphogenesis is not supported in Areg deleted mice (Luetteke et al. 1999) 
while ductal outgrowth can be induced in ovariectomized mice by treatment 
with recombinant AREG (Kenney et al. 1996).  
Together with hormones and growth factors, immune cells are also important for 
pubertal mammary gland development (Coussens & Pollard 2011). Work from 
Pollard’s laboratory showed that eosinophils and macrophages are recruited 
around the growing terminal end buds during postnatal development (Gouon-
Evans et al. 2000). Furthermore, in vivo ablation of eosinophils and macrophages 
resulted in impaired TEBs development and reduced mammary branching 
demonstrating the requirement of immune cells during pubertal development 
(Gouon-Evans et al. 2000). 
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1.1.5  Pregnancy and lactation 
Unlike the majority of other organs which mainly develop to a mature state 
during the embryonic phase, the mammary gland only reaches a mature fully 
functional state during the pregnancy-lactation cycle in the adult female. 
Undoubtedly lactation is the most important developmental stage of the breast 
as shown by the very high metabolic demand, requiring about 25% of daily 
maternal energy intake during lactation to produce milk (Hassiotou & Geddes 
2013). Although a mini-remodelling of the breast occurs at each menstrual cycle 
it is only during the processes of pregnancy and lactation that the ductular 
appearance of the virgin epithelium is replaced through a massive event of cell 
proliferation and differentiation which lead to the formation of mature alveoli, 
the milk-producing unit of the mammary gland.  Alveolar morphogenesis is 
initiated by coitus which provides nervous stimulation inducing prolactin 
secretion from the pituitary gland which in turn, sustains ovarian progesterone 
secretion (Exton et al. 2001). These hormones induce rapid proliferation of 
mammary epithelial cells followed by alveoli differentiation to form the 
secretory alveolar epithelium, capable of milk production and secretion during 
lactation.  
Prolactin 
Prolactin (PRL), produced by the lactotrophic cells of the anterior pituitary, is 
the major driver of development during pregnancy (Oakes et al. 2008). Grafting 
experiments with prolactin receptor (PRL-R) deleted epithelium showed no 
defects in ductal outgrowth and side branching (Brisken et al. 1999). However 
Prl signalling pathway is required for alveologenesis and differentiation of MECs 
into milk producing cells as showed by the total absence of alveolar 
differentiation and milk production in transplanted Prl-null epithelium (Ormandy 
et al. 1997). Confirming an epithelial role for prolactin signalling, WT epithelium 
grafted into Prl-R deleted stroma developed normally (Ormandy et al. 2003). 
Jak2 and Stat5 knockout mice showed failed lobuloalveolar development like 
Prl-R deleted mammary glands, indicating their critical role in Prl-R-mediated 
alveolar morphogenesis (Liu et al. 1997; Wagner et al. 2004). PRL binds the 
prolactin receptor, leading to receptor dimerization, phosphorylation and 
activation of the JAK2 kinase which in turn recruit and phosphorylates STAT5. 
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Phosphorylated STAT5 then dimerizes and translocates to the nucleus where it 
can activate the transcription of genes involved in alveolar morphogenesis 
(Wakao et al. 1994). The transcription factor ELF5 acts downstream of the PRLR 
to modulate alveolar morphogenesis and milk production, as shown by the 
impaired alveolar morphogenesis of transgenic mice heterozygous for Elf5 (Zhou 
et al. 2005). Confirming their key role in alveologenesis, STAT5 and ELF5 have 
also been shown to regulate the specification of luminal progenitors, the cell 
population which will generate the alveolar lineage during pregnancy (Yamaji et 
al. 2009; Chakrabarti et al. 2012).  
Progesterone 
The ovarian hormone progesterone is required together with prolactin for the 
process of alveologenesis. Since PR knock-out mice are infertile (Lydon et al. 
1995), transplantation of mammary epithelial cells derived from PR deleted mice 
into the cleared mammary fat pad of wild type female recipients has been used 
to study this.  Transplanted mouse mammary epithelial cells (MMECs) from PR 
deleted mice into WT hosts, failed to undergo alveolar morphogenesis during 
pregnancy proving the essential role of PR signalling in the epithelial 
compartment during alveologenesis (Brisken et al. 1998). Progesterone is 
thought to act on PR positive epithelial cells stimulating the production of a 
paracrine signal which, in turn, induces the proliferation of neighbouring cells 
(Ismail et al. 2002). One candidate molecule likely responsible for this paracrine 
signalling is receptor activator of nuclear factor κB (NF-κB)-ligand (RANKL). In 
fact RANKL mRNA is induced by treatment with oestrogen and/or progesterone, 
in the mammary gland of ovariectomized adult mice, but not in PR-null mice 
(Mulac-Jericevic et al. 2003). Moreover ectopic expression of RANKL using a 
MMTV transgene results in side branching stimulation in the absence of 
pregnancy (Fernandez-Valdivia et al. 2009). These data suggested that RANKL is 
a paracrine mediator of progesterone-induced proliferation. Another molecule 
which has been suggested as a possible paracrine effector of progesterone 
signalling is WNT4. MMECs extracted from Wnt4-deleted mice showed lack of 
branching in transplanted outgrowth during pregnancy (Brisken et al. 2000). 
Further experiments showed that WNT4 expression is PR dependent; WNT4 is 
induced in the mammary gland of adult ovariectomized mice by progesterone 
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treatment while PR deleted cells showed loss of WNT4 expression (Mulac-
Jericevic et al. 2003; Fernandez-Valdivia et al. 2008). 
1.1.6  Involution 
The end of lactation sees the beginning of involution, a strictly regulated process 
involving apoptosis and tissue remodelling, which will bring the mammary gland 
back to a virgin-like state (Watson 2006; Stein et al. 2007; Watson & Kreuzaler 
2011). In the last decades conditional knock-out animal models have been used 
extensively to unveil the molecular regulators of the involution process. Since 
natural weaning is often a long and gradual process not easily controllable, 
investigators have used forced weaning as a model for the study of involution. In 
this protocol pups are removed from the lactating dam after 7-10 days of 
lactation initiating the involution process which gives a controllable model in 
which to study the morphological and molecular features regulating this process. 
Teat sealing is another technique that has been used for the study of involution 
(Watson & Kreuzaler 2011). In particular this protocol allows the study of local 
regulators of involution (such as effects of milk accumulation) since the lactating 
hormonal milieu is maintained by the continued presence of suckling pups 
(Watson 2006). 
Involution in the mouse mammary gland can be divided into two discrete phases 
called first phase and second phase (Watson, 2006; Watson & Kreuzaler, 2011). 
The first phase lasts approximately 48 h and can be reversed through re-
suckling. The second phase instead is characterized by an irreversible 
remodelling programme which will bring the gland to a pre-pregnant state (Lund 
et al., 1996).  Morphologically the first phase of involution is marked by 
accumulation of milk in the alveoli and the appearance of shed, dying cells 
within the alveolar lumen (Richert et al. 2000).  The first phase of involution 
depends on local factors and probably it is triggered by the accumulation of milk 
into the alveoli (Li et al. 1997). Milk retention could lead to accumulation of 
secreted factors in the milk or to mechanical stretch of the alveolar epithelium 
which could signal the start of the involution process (Quaglino et al. 2009). 
Likely these processes are not mutually exclusive and in fact some evidence 
indicates that they could be mutually linked. For example, the plasma 
membrane calcium-ATPase 2 (PMCA2), which transports 60–70% of milk calcium 
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outside the alveolar cells, is regulated by changes in the shape of mammary 
epithelial cells (VanHouten et al. 2010) and it is dramatically downregulated 
during involution (Reinhardt & Lippolis 2009). Furthermore, mice deleted for 
PMCA2 exhibited precocious cell death at day 18 of pregnancy (VanHouten et al. 
2010). In this scenario milk stasis could induce mechanical stress in the alveoli 
leading to a sharp drop in PMCA2 expression. This in turn could cause 
accumulation of calcium into the alveolar cells and initiation of calcium 
mediated cell death. Together with PMCA2 other factors have been found to 
play a role in the induction of involution. Not surprisingly involution is affected 
by interference with well-known regulators of the apoptotic program: for 
example deletion of the anti-apoptotic Bcl2l1 gene accelerates involution while 
a delay is seen after loss of the pro-apoptotic BAX protein (Schorr et al. 1999; 
Walton et al. 2001). Moreover expression of constitutively active AKT in the 
mammary gland under the control of the MMTV promoter caused a delay in 
involution and a decrease in apoptosis (Schwertfeger et al. 2001). Work on 
genetically modified mice has found others factors which are involved in 
involution such as LIF, serotonin and TGFβ-3 (Nguyen & Pollard 2000; Matsuda et 
al. 2004; Kritikou et al. 2003). Most of these studies exhibit a subtle involution 
phenotype, indicating that complex compensatory mechanisms are taking place 
in this phase of development. However two pathways seem to be crucial for 
involution: the JAK/STAT and the NF-kB pathways. Conditional deletion of STAT3 
in the mouse mammary epithelium causes a block in cell death and tissue 
remodelling (Chapman et al. 1999), extending the reversible phase of involution 
until at least 6 days after forced involution (Humphreys et al. 2002). Similarly, 
conditional deletion of IKKβ/2, the upstream regulator of the NF-kB pathway, 
caused a delayed involution and a reduction of cell death (Baxter et al. 2006). 
Since both pathways are necessary but not sufficient to trigger involution, these 
results indicate that cooperation between JAK/STAT and NF-kB pathways is 
required for a correct involution. The mechanism responsible for cell death 
during the first phase of involution has always presumed to be apoptosis. 
However the morphology of the dying cells that shed into the lumen is not 
classically apoptotic: shed cells are swollen, they lack any membrane blebbing 
and they have two hypercondensed nuclei (Watson & Kreuzaler 2011). Recently, 
a study from the Watson laboratory clarified this issue. A caspase-independent 
lysosomal pathway of cell death was found to be necessary for post-lactational 
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regression of the mammary gland (Kreuzaler et al. 2011). Interestingly the 
lysosomal pathway of cell death is independent of caspases 3, 6 and 7, but it 
requires STAT3 which upregulates the expression of intra-lysosomal specific 
proteases (cathepsin B and cathepsin L). Then leaky lysosomes leads to release 
of cathepsins into the cytoplasm and the initiation of cell death (Chwieralski et 
al. 2006). As a result cells are shed into the lumen where caspases are cleaved, 
probably in response to anoikis.  
The overall structure of the mammary gland is not affected during the first 
phase of involution (Richert et al. 2000). However after 48 hours, the reversible 
phase ends and an irreversible process of widespread cell death and tissue 
remodelling signals the transition to the second phase. In this phase the alveoli 
start to collapse while adipocytes re-differentiate and begin to fill the fat pad 
(Richert et al. 2000). At the molecular level this phase is characterized by an 
increased protease activity which is responsible for the extensive tissue 
remodelling observed. Stromal cells increase their expression of MMP-2, MMP-3, 
MMP-9 and MMP-11 which will act on the tissue extracellular matrix causing 
alveolar collapse, cell detachment and cell death for anoikis (Pullan et al. 1996). 
Since the removal of extracellular matrix by MMPs is the main trigger of cell 
death in the second phase of mammary involution, fail-safe mechanism needs to 
be in place during the first phase to avoid early activation of MMPs. Tissue 
inhibitors of metalloproteinases (TIMPs) are direct inhibitors of zinc-dependent 
proteinases such as MMPs and key regulators of involution (Fata et al. 2001). In 
vivo loss of function of TIMP3, an inhibitor of MMP2, causes accelerated 
involution with loss of the reversible first phase (Fata et al. 2001). The wave of 
apoptosis generated by MMPs action creates a vast number of tissue and cell 
debris which needs to be removed in order to create space for the regenerating 
adipocytes; this process involves autophagy and phagocytosis carried out by 
activated mammary cells and recruited macrophages (Monks et al. 2005) and 
inflammatory cells. In fact different types of immune cells are recruited in the 
involuting mammary gland, starting with neutrophils at day 1 involution followed 
at day 4 by plasma cells, eosinophils and B-lymphocytes (Stein et al. 2004). The 
involvement of inflammation is also supported by microarray data that identified 
an immune cascade response during involution (Stein et al. 2004; Clarkson et al. 
2004). 
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1.2  Mammary stem cells 
The normal adult mammary gland is composed of a bi-layered structure 
consisting of an inner layer of luminal cells, and an outer layer of basal cells on 
a laminin-containing basement membrane. The luminal compartment consists of 
different subpopulations of hormone positive and negative progenitors which 
during pregnancy can differentiate into alveolar cells, the milk producing unit of 
the mammary gland (Richert et al. 2000). Besides its localization, the luminal 
population can be identified by the expression of cytokeratins (CK8, 18 and 19), 
MUC1 and EpCAM (Richert et al. 2000). The basal/myoepithelial population is 
responsible for the secretion of basement membrane components during all 
developmental stages and for the movement of milk through the alveoli and the 
ducts during lactation. These cells are characterized by the expression of CK14, 
CK5, smooth muscle actin and P63 (Moumen et al. 2011). However, under this 
apparently simple and dualistic structure of the mammary epithelium derived by 
histological studies, lies a complex hierarchical cellular system which has 
emerged from studies focused on mammary stem cells (Visvader & Smith 2010). 
Stem cells are emerging as fundamental players in both embryonic development 
and adult tissue homeostasis, especially in those organs characterized by high 
regenerative potential and cell turnover (Biteau, 2011). Stem cells are 
multipotent cells characterized by two unique features: self-renewability and 
wide differentiation capability. In adult organs the majority of the stem cell 
population is in a state of quiescence, which is necessary for stem cell 
maintenance preserving them from oxidative stress, accumulation of mutations 
and telomerase shortening (Blanpain et al. 2012). However, under appropriate 
stimuli, stem cells are able to enter a proliferation phase characterized by self-
replication and lineage differentiation,  (Biteau et al. 2011). The mammary 
gland is a very dynamic tissue which undergoes extensive cellular remodelling 
and changes in morphology throughout different developmental phases 
(Hennighausen & Robinson 2005).  In such a dynamic context, different 
mammary epithelial cell populations with different specialized functions are 
continuously generated and replaced.  This high tissue turnover implies the 
existence of a population of mammary stem/progenitor cells characterized by a 
high degree of self-renewability which are able to differentiate into the various 
cell types constituting the mammary epithelium. The existence of a mammary 
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stem cell (MaSC) population has been postulated since DeOme’s transplantation 
studies in the late 50’s (DeOme, 1959) but only in the last 10 years has solid 
evidence of their existence been found. These seminal experiments and the 
current status of the field are discussed.  
1.2.1  Birth of the mammary stem cell concept 
DeOme in the 1950s (DeOme, 1959) pioneered a technique which has become 
the standard assay in mammary stem cell biology: the cleared fat-pad 
transplantation. This procedure allows the identification of mammary stem cells 
by transplanting cells in limited dilution in a virgin fat pad cleared of the 
endogenous epithelium. It is based on the assumption that only cells 
characterized by high degree of self-renewal and regenerative potential will be 
able to proliferate and give rise to a fully functional new mammary epithelium. 
At 3 weeks of age, the mouse mammary fat pad is largely devoid of mammary 
epithelium: the rudimental epithelial tree consists of only a few branches 
confined to the vicinity of the nipple. Therefore, if the region between the 
nipple and the lymph node is surgically removed, no endogenous epithelium will 
be left to repopulate the mammary fat pad which is then described as "cleared". 
At this stage mammary cells can be injected in the cleared tissue where they 
can grow and repopulate the entire fat pad. DeOme and colleagues published 
the first successful mammary gland reconstitution experiment showing that 
small pieces of mammary epithelium could recreate a fully functional 
reconstituted gland (DeOme et al., 1959).  Follow up experiments showed that 
the regenerative potential of normal mammary cells is limited. Daniel and 
colleagues performed up to seven serial transplantations over the course of two 
years showing that the ability of normal mammary epithelium to reconstitute a 
gland  declines with time (Daniel, 1968). In the same paper, 5 independent serial 
transplants showed considerable variation in overall lifespan between individual 
outgrowths suggesting that mammary epithelial cells could differ in their 
regenerative potential (Daniel 1968). Interestingly the regenerating capability of 
mammary epithelial cells is independent of donor’s age indicating the existence 
of precursor cells throughout the entire life span of the mammary gland (Hoshino 
& Gardner, 1967; Young, Medina, DeOme, & Daniel, 1971). Moreover fragments 
taken from different regions of the mammary gland, such as primary and tertiary 
branches, alveoli and terminal end buds were able to reconstitute fully 
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functional outgrowths, indicating the presence of repopulating cells throughout 
the ductal epithelial tree (Smith & Medina 1988). The development of tissue 
dissociation techniques allowed the transplant of dissociated mammary 
epithelial cells rather than tissue fragments (DeOme et al. 1978) and was 
followed by the introduction of the limiting dilution transplantation, the “gold 
standard” for defining stem cell activity. Using the limiting dilution 
transplantation technique Smith and co-workers, showed the existence of 
distinct mammary progenitor populations characterized by specific limited 
differentiation potential during pregnancy (Smith 1996). This experiment was 
the first suggestion of the existence of a cell hierarchy in the mammary 
epithelium with various degree of regenerative potential. Limiting dilution 
experiments suggested that a limited number of mammary cells were able to 
generate a duct tree. The first evidence that this regenerative activity could be 
attributed to a single cell came from experiments where fragments of MMTV-
infected mammary tissue were transplanted into cleared mammary fat pads of 
uninfected mice.  The ability of the MMTV virus to integrate randomly in the 
genome was used to investigate clonal expansion during the regenerative 
process. In particular the MMTV integration pattern was analysed through 
Southern blot in serially transplanted outgrowths, indicating that the majority of 
epithelial tissue in the reconstituted glands was likely to be derived from a 
single mammary cell (Kordon & Smith 1998). Further studies based on X-
chromosome inactivation patterns in human samples showed that entire lobules 
and large ducts of normal breast tissue have the same X chromosome inactivated 
suggesting that clonal expansion was also responsible for human mammary gland 
development (Tsai et al. 1996).  Taken together these early experiments 
provided a solid proof for the existence of a population characterized by high 
regenerative capability. These studies represent the foundations on which future 
mammary stem cell research was built and which resulted in the exciting 
discoveries of the last decades.  
1.2.2  The troubled pathway towards isolation of MaSCs 
Various experimental approaches have been carried out to characterize and 
isolate MaSCs (Smith et al. 2012). A first approach tried to identify cells with 
stem cell characteristics through cytological examination (Smith & Medina 1988).  
Smith and Medina identified a population of pale coloured cells with large nuclei 
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and clear cytoplasm. These cells were distributed sporadically among the 
mammary duct tree and generated cells capable of differentiating in the 
presence of lactogenic stimuli. Another morphological study identified potential 
mammary stem cells using electron microscopy techniques: a mammary 
epithelial subpopulation constituted by small light cells was proposed to be the 
putative stem cell compartment based on size, mitotic activity, absence of 
organelles and ability to give rise to darker cells, which were thought to be the 
differentiated population of cells (Chepko & Smith 1997). Furthermore, several 
independent studies identified long-term label retaining subpopulations in the 
mammary epithelium thought to represent stem cells (Zeps et al. 1996; Smith 
2005). However none of these methods showed that a single label-retaining cell 
or pale cell could reconstitute a fully functional gland in vivo. In fact both the 
morphological and the label retention methods shared a common limitation: 
they do not allow the isolation of large numbers of relatively pure MaSC 
populations which can be further tested in in vitro or in vivo assays. To address 
this issue, lessons learned from haematopoietic stem cells were applied to the 
mammary stem cell field. In particular the use of fluorescence-activated cell 
sorting (FACS) allowed the isolation of different cell populations from 
dissociated mammary gland preparations, based on the expression of surface 
marker proteins. The subpopulations obtained were then assayed for 
repopulating ability in vivo by cleared fat pad transplantation of limiting 
numbers of cells. In 2006, a study from Visvader’s laboratory (Shackleton et al. 
2006) identified a subpopulation of cells that are enriched for mammary stem 
cells on the basis of high expression of CD29 (β1-integrin) and moderate levels of 
CD24 (heat stable antigen). When CD24+ CD29hi cells were transplanted into 
cleared fat pads of virgin mice, they were able to generate a functional gland 
with high efficiency. Indeed transplantation of single CD24+ CD29hi cells was 
sufficient to regenerate an entire mammary gland (6/102 transplants) which 
could undergo full alveolar differentiation during pregnancy. Interestingly the 
transplanted epithelial tree contained daughter stem cells with the same in vivo 
repopulating activity as the original CD24+ CD29hi population (Shackleton et al. 
2006). At the same time, Stingl and co-workers, using a different set of markers, 
high expression of CD49f (α6-integrin) and moderate levels of CD24, identified a 
subpopulation of the mammary gland enriched for stem cells (Stingl et al. 2006). 
Again, the purified CD24+ CD49fhi population was able to generate the complete 
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functional mammary gland from a single cell (Stingl et al. 2006). Meanwhile 
CD24, used as a single marker, allowed the enrichment for fat pad repopulation 
capacity in the CD24Low population (Sleeman et al. 2006). However, based on 
CD24, CD29 or CD49f markers, the maximum enrichment for MaSCs achievable is 
far from purity (less than 1 MaSC in 100 cells). Placing GFP under the control of 
the s-SHIP promoter, which is expressed in embryonic and hematopoietic stem 
cells but not differentiated cells, allowed the isolation of a MaSC-enriched 
GFP+CD49fhi population (Bai & Rohrschneider 2010). These cells are 
characterized by an increased frequency of MaSC (1/48 cells). Recently another 
study reported an improved protocol for MaSC purification with the combination 
of an additional marker, CD1d, to further enrich the CD24+CD29hi population. 
The CD24+CD29hiCD1d+ population showed an enrichment frequency to nearly 
single-cell level of 1 MaSC per 8 cells (dos Santos et al. 2013).   
Besides being used to characterize the mammary stem cell population, FACS 
profiling of the mammary epithelium has also unveiled the different lineages 
which make up the mature mammary gland. The luminal cell compartment is 
very heterogeneous, being composed of a mixture of progenitor and 
differentiated cells which fluctuate in response to hormones  (Schedin, 2000). 
FACS sorting has been used to isolate luminal progenitors based on the 
expression of CD61 (Asselin-Labat et al. 2007), c-KIT (Regan et al. 2012) and 
CD14 (Asselin-Labat et al. 2011). Luminal progenitor populations are 
characterized by high in vitro colony forming and proliferative potential, but 
limited ability to repopulate a cleared fat pad. Moreover Asselin-Labat and co-
workers showed a dramatic decline in the proportion of CD61+ progenitor cells 
during pregnancy (Asselin-Labat et al. 2007). Overall these studies have shown 
that luminal progenitors are a highly dynamic population of the virgin mammary 
epithelium which is lost during pregnancy, through their differentiation into 
alveolar cells (Asselin-Labat et al. 2007). Like the luminal compartment, the 
basal lineage is also likely to be constituted by different subpopulations with 
various degrees of regenerative potential and differentiation; however the 
characterization of this compartment is still lagging behind. Only recently two 
different studies identified a subpopulation of  LGR5+ cells with increased 
regenerative potential when compared to other basal cells and which were 
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necessary for postnatal mammary organogenesis (Plaks et al. 2013; Van 
Keymeulen et al. 2011).  
Cell surface analyses have led to the concept of an existing differentiation 
hierarchy among mammary epithelial cells where a mammary stem cell 
population, which resides in the basal layer of the mammary gland, gives rise to 
progressively restricted progenitors which will finally differentiate into the 
mature luminal and basal mammary lineage  (Visvader & Smith 2010).  However 
this model has been challenged by lineage tracing experiments. Recently an 
elegant study from Blanpain’s laboratory showed the existence of two lineage 
restricted mammary stem cell populations in the adult mammary gland: a basal-
restricted and a luminal-restricted unipotent stem cell (Van Keymeulen et al. 
2011). Furthermore, the only mammary multipotent stem cell capable of 
generating both basal and luminal population was detected uniquely during the 
embryonic mammary development (Van Keymeulen et al. 2011). Another lineage 
tracing study which followed the Wnt responsive population during mammary 
development reached the same conclusion showing that the basal cell layer in 
the mature virgin gland does not contribute to the luminal cell layer 
(van Amerongen et al. 2012). These evidences support the view that both 
luminal and basal compartments, under normal physiological conditions, are 
maintained by separate stem/progenitor compartments. Moreover these studies 
demonstrate a critical limitation of fat pad transplantation experiments: the 
regenerative potential showed by transplanted cells is not reflecting their real 
physiological behaviour in the intact tissue. This raises the question of whether 
previous studies using FACS sorting and fat pad transplantation to demonstrate 
the existence of multipotent mammary stem cells are indeed mere artefact. 
However it should be realised that lineage tracing has its own limitations.  For 
example the reporter may not be expressed in stem cells (epigenetic silencing) 
or could alter stem cell function in vivo (Baens et al. 2006). Moreover MaSCs may 
not be targeted by the promoters used to drive the reporter expression. Along 
these lines it is interesting that none of the previous studies have reported 
labelled cap cells in terminal end buds.  
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1.2.3  MaSCs and pregnancy 
MaSCs have also been studied during pregnancy. The first evidence for the 
involvement of a stem cell population during pregnancy came from experiments 
using the WAP-Cre model in combination with the Rosa26LacZ reporter mice. In 
this model a LacZ-marked lobular-limited progenitor, which was able to persist 
after involution and take part in the remodelling of the involuting mammary 
epithelium, was identified in the pregnant mouse mammary gland (Wagner et al. 
2002). These LacZ-positive cells, called parity-identified mammary cells (PI-
MEC), showed self-renewal and multipotent potential, producing outgrowth with 
both luminal and basal cells, following serial transplantation in epithelium-free 
mammary fat pads (Boulanger et al. 2005). Progesterone is one of the key 
hormonal regulators of mammary epithelium alveolar development and 
interestingly MaSC pool increases 14-fold during maximal progesterone levels at 
the dioestrus phase of the mouse oestrous cycle (Joshi et al. 2010). Moreover the 
stem-cell-enriched CD49fhi population expands after treatment with exogenous 
progesterone, demonstrating a key role for progesterone in driving MaSCs 
expansion (Joshi et al. 2010). Confirming these data, work from the 
Visvader/Lindeman laboratory showed that the MaSC pool increases under the 
hormonal milieu of pregnancy, with a significant 10- fold increase in mid-
pregnancy (Asselin-Labat et al. 2010). By the end of pregnancy, the number of 
stem cells return to levels observed in virgin mice, suggesting that the MaSC 
expansion is necessary to sustain the high proliferative first phase of pregnancy 
but it is not required during the terminal differentiation phase (Asselin-Labat et 
al. 2010). These results indicate that MaSCs undergo strict hormonal regulation 
during oestrous cycle and pregnancy. However, using FACS sorting techniques it 
was shown that MaSCs do not express oestrogen receptor or progesterone 
receptor (Asselin-Labat et al. 2006). Hence MaSCs are likely under control of 
paracrine signalling molecules which are secreted from other mammary 
compartments in response to hormones. A study from Joshi and co-workers 
suggested a mechanism for this paracrine signalling where pregnancy-induced 
progesterone activates a subset of luminal cells, which in turn secrete WNT4 and 
RANKL signals. These molecules act on the basal and MaSC population which 
respond by upregulating transcriptional targets and cell cycle markers (Joshi et 
al. 2010). Intriguingly, a recent study provides evidence confirming the link 
between pregnancy, Wnt signalling and MaSC expansion (van Amerongen et al. 
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2012).  Van Amerongen and co-workers showed the existence of multipotent 
stem cells residing in the basal layer which become Wnt-activated during 
pregnancy and contribute to both basal and luminal lineages. Taken together 
these data are suggesting the existence of MaSC with multipotent potential 
which, in normal physiological conditions are restricted to unipotency but can 
switch from unipotent to multipotent potential under particular circumstances 
such as pregnancy.  
1.2.4  In vitro assays for the study of MaSCs 
In vivo mammary transplantation and lineage tracing experiments, besides the 
limitations listed before, are relatively costly and time consuming. These 
restrictions have driven the development of in vitro 2D or 3D assays as simplified 
models for investigating mammary stem cell properties (Smith et al. 2012). One 
of the first assays to be developed was based on plating mammary cells in 2D at 
low density, using media containing epidermal growth factor and adding a layer 
of irradiated fibroblasts to achieve maximal cloning efficiencies (Stingl et al. 
2006). In this culture model, robust growth of colonies with luminal, basal or 
bipotent characteristics, based on cytokeratin expression, can be achieved 
(Stingl et al. 2006; Shackleton et al. 2006). In 2D assays colony-forming cells are 
at least 100-fold more numerous than cells detected in fat pad transplantation 
showing that the more permissive conditions of this assay probably allow the 
expansion of more differentiated progenitor cells (Makarem et al. 2013). 
Mammosphere culture is another in vitro culture technique which allows the 
enrichment for MaSC. It is based on the use of non-adherent conditions which 
induce anoikis on differentiated cells and serum free media supplemented with 
EGF and bFGF (Dontu et al. 2003).  This assay was first developed in the neural 
stem cell research field, allowing the growth of a multipotent population of 
neural cells in suspension which were called neurospheres. Neurospheres were 
shown to consist of 4%–20% stem cells, the rest of the population representing 
progenitor cells in various stages of differentiation (Reynolds & Weiss 1996). 
Applying the same technique to the mammary field, Dontu and colleagues 
showed that human mammary cells cultivated in low adherent and serum free 
conditions formed floating colonies which were called mammospheres (Dontu et 
al. 2003). Interestingly whereas freshly isolated mammary cells contain only 8% 
multilineage progenitors, mammosphere cultures are enriched to ∼68% in 
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primary mammospheres, and virtually 100% in secondary and later-passage 
mammospheres.  A key result confirming the enrichment for cells with high 
regenerative capability achievable with this assay was obtained by the Pelicci’s 
laboratory demonstrating that cleared fat pad injection of a single sphere was 
able to generate mammary outgrowth in 11 out of 18 transplantations (Cicalese 
et al. 2009). However several limitations are linked to this assay.  For example 
the floating culturing conditions and the absence of any matrix means mammary 
stem cells are grown in extremely artificial conditions which could influence 
their behaviour. Moreover given the very strong tendency of mammary epithelial 
cells to adhere to one another, it can be difficult to distinguish between 
aggregation versus clonal growth (Pastrana et al. 2011). To overcome the 
clonogenicity issue mammary cells have been immobilized in a semi-solid matrix 
such as Matrigel were they can grow and develop ducts-like structures. These 
colony-forming assays in Matrigel allow assessment of the clonal growth of 
mammary cells in a 3D environment which more closely resembles the 
physiological conditions (Zeng & Nusse 2010; Guo et al. 2012). 
1.2.5  MaSCs regulators: signalling pathways and transcription 
factors. 
Over the past few years the role of various signalling pathways has been 
evaluated in the context of mammary stem and progenitor cells. Several studies 
indicated Wnt signalling to be involved in MaSC regulation. Overexpression of 
Wnt1 using the mammary-specific MMTV promoter resulted in a 6-fold increase 
in the number of MaSCs (Shackleton et al. 2006). Moreover treatment with 
recombinant WNT protein leads to an expansion of mammary stem cells in vitro 
as shown by their ability to reconstitute functional glands in transplantation 
assays (Zeng & Nusse 2010). In addition LGR5+ cells have recently been 
identified as a basal subpopulation characterized by high regenerative potential, 
underlying the key regulatory role of Wnt pathway in MaSCs (Plaks et al. 2013). 
On the other hand Notch pathway normally plays a role in restricting expansion 
of MaSCs. In fact deletion of Cbf-1, a canonical effector in the Notch pathway, 
caused higher stem cell repopulating activity in vivo, accompanied by aberrant 
terminal end buds and ductal branching development (Bouras et al. 2008). In 
addition the Notch pathway is required for luminal cell fate determination by 
promoting commitment of MaSCs to the luminal cell lineage at the expense of 
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the basal lineage (Bouras et al. 2008). Hedgehog signalling also appears to play a 
negative regulatory role in MaSCs. Expression of constitutive activated human 
SMO (SmoM2) under the MMTV promoter in transgenic mice caused a decrease in 
the frequency of regenerative stem cells in MMTV-SmoM2 epithelium relative to 
wild type (Moraes et al. 2007).  
The concept of a mammary epithelial hierarchy implies that specific 
transcription factors are needed to determine the correct specification of the 
different mammary subpopulations.  Indeed several transcription factors have 
been found to play a role in mammary stem cells and lineage differentiation 
(Siegel & Muller 2010). For example the transcription factor p53 regulates the 
self-renewal of MaSCs, with loss of p53 leading to increased symmetric cell 
division and expansion of the stem cell pool (Cicalese et al. 2009). Slug and Sox9 
have also been found to be key determinants of the mammary stem cell fate 
with transient co-expression sufficient to convert differentiated luminal cells 
into MaSCs with long-term mammary gland-reconstituting ability (Guo et al. 
2012). The list of transcription factors found to be involved in the regulation of 
mammary stem cells is constantly expanding and now includes MYC, C/EBPβ, and 
STAT3 among others (Staniszewska et al. 2012; Moumen et al. 2012; LaMarca et 
al. 2010). Nevertheless, given the emerging complexity of the mammary 
epithelial hierarchy, it is tempting to predict the existence of several other 
transcription factors involved in the mammary stem cell differentiation process. 
The identification of new transcription factors with a role in mammary lineage 
specification could translate to important advances in breast cancer research, 
allowing the identification of new potent regulators of mammary epithelium 
cell-fate which could be hijacked during the neoplastic process.  In fact 
transcription factors, due to their biological role as regulators of wide arrays of 
target genes and as convergence nodes of different pathways, represent very 
promising therapeutic targets (Koehler 2010). 
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Figure 1-1  The mammary cell hierarchy 
Diagram showing an overview of the mammary cell hierarchy. A multipotent stem cell can give 
rise to two lineage-restricted progenitors (luminal and basal). The luminal progenitor can further 
differentiate into mature ductal cells and, during pregnancy, into alveolar cells. The basal 
progenitor can differentiate into mature basal cells. Only bipotent stem cells and progenitors 
have self-renewal capacity as opposed to terminally differentiated cells (A). Cartoon showing 
how luminal and basal mammary lineages are heterogeneous populations composed of different 
cells with variable proliferative and self-renewal potential (B). 
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1.3  Breast cancer  
Breast cancer is the leading cause of cancer death in women, accounting for 22% 
of all female cancers (Jemal et al. 2010). Every year more than 1.3 million 
women worldwide are diagnosed for breast cancer, making it the second most 
common type of cancer behind lung cancer (Kamangar et al. 2006). In the last 
decades much investment in funding has led to a research boost into our 
understanding of breast cancer origin, pathology and treatment options. These 
efforts have resulted in a marked improvement in the survival rates for breast 
cancer where in the sixties, only 35% of women diagnosed with breast cancer in 
the United States would have been alive ten years later whereas that percentage 
increased to 77% by the mid-nineties. However half-a-million women still die 
from this disease each year indicating that further improvements in breast 
cancer treatment are still needed.  
1.3.1  Aetiology, progression of disease and treatment 
Although the aetiology of human breast cancer remains largely unknown, risk 
factors associated with this disease can be grouped into three broad categories: 
hereditary, hormonal and reproductive factors, and environmental (Hankinson et 
al. 2004). Family history is one of the strongest determinants of risk. Hereditary 
factors are associated primarily with early-onset premenopausal breast cancer. 
In particular the BRCA1 gene has been implicated in the pathogenesis of 
hereditary breast cancer whereby women with mutations in either BRCA1 or 
BRCA2 have a 60% to 85% lifetime risk for developing breast or ovarian cancer 
(Fackenthal et al. 2007). Germline mutations in p53 account for 1% of early 
onset breast cancer (Gasco et al. 2002). Interestingly women with Li-Fraumeni 
syndrome (carrying a mutated p53 gene) who survive childhood cancers often 
develop breast cancer, underlying the genetic connection between loss of p53 
and this pathology (Gasco et al. 2002). A link between hormonal and 
reproductive status of patients and breast cancer is strongly suggested by the 
association between the incidence of this tumour and the age of menarche, 
menopause and first pregnancy (Guinee et al. 1994). In particular nulliparous 
women, or those who become pregnant after the age of 35, have a twofold to 
threefold higher risk of breast cancer than those women whose pregnancy 
occurred before age 25. Several environmental factors have been found to 
41 
 
influence breast cancer risk such as smoking, dietary factors and chemical 
compounds (DeBruin & Josephy 2002).  
The natural history of breast cancer involves progression through defined 
pathological and clinical stages, beginning with ductal hyperproliferation, which 
can then evolve into in situ and invasive carcinomas (Allred et al. 2001). Invasive 
breast cancer spreads regionally by direct extension through the chest wall or 
via lymphatic channels to regional lymph nodes (Lee, 1983). The axillary lymph 
nodes are the most common site of regional metastasis and breast cancer 
patients are usually stratified into node negative or positive based on excision of 
axillary lymph nodes (Devitt, 1965). Metastatic breast cancer can then spread 
from regional sites to colonize distant organs; the most common sites of distant 
metastasis are lung and pleura, liver, bone, skin, adrenal and brain (Lee 1983). 
Interestingly, unlike many tumours, breast cancers can recur and metastasize 
decades after primary tumour excision (Gerber et al. 2010). Not surprisingly the 
presence of distant metastasis correlates with poor prognosis since no 
treatments currently exist for metastatic breast cancer.  
Several factors determine the choice of treatment for a newly diagnosed breast 
cancer such as the age of the patient, involvement of axillar lymph nodes, the 
size of the tumour, histological grade, expression of hormonal receptors and 
HER2 status. The first type of treatment for breast cancer is usually surgery 
followed by adjuvant chemotherapy, radiotherapy or in some cases, hormone or 
targeted treatments. The choice of treatment is strictly dependent on the type 
of breast cancer identified. Focusing on the receptor status human breast cancer 
can be subdivided into three main groups: oestrogen receptor positive (ER+), 
epidermal growth factor receptor 2 positive (HER2+) and triple negative (ER-
/PR-/HER2-).  ER+ and HER2+ patients benefit from targeted treatments such as 
Tamoxifen and Trastuzumab which have consistently improved disease outcome 
(Howard et al. 2012). On the other hand, the triple negative subtype lacks any 
specific targeted therapy and it has been associated with worse overall prognosis 
in comparison with the other subtypes (Foulkes et al. 2010).  
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1.3.2  Molecular classification of breast cancer 
Human breast cancers have been categorized by pathologists into various 
histological subtypes based on a set of features of the primary tumour at the 
time of diagnosis such as lesion size, necrosis, nuclear grade and mitotic index. 
However clinical responses of patients to therapy showed considerable 
heterogeneity among the same subtype, indicating the need for a new, better 
classification method (Stingl & Caldas 2007). In fact the histological 
classification of human breast tumours is confounded by a number of factors 
including scoring subjectivity and intra-inter tumour heterogeneity. In recent 
times a new way to classify human breast tumours, based on gene expression 
profiling by microarray analysis, has provided a new perspective on breast 
cancer. Breast cancer is no longer a single disease but a collection of distinct 
malignancies which vary from the clinical, morphological and molecular point of 
view (Stingl & Caldas 2007). A pivotal study from Perou and co-workers was the 
first to provide a molecular classification for breast cancer (Perou et al. 2000). 
Gene expression profiling of 38 breast cancer cases revealed four distinct 
molecular subtypes: luminal, HER2, basal-like and normal breast (Perou et al. 
2000). A follow-up study using a larger cohort of patients refined this 
classification showing that the luminal subgroup could be divided into at least 
two groups (luminal A and B), and that different molecular subtypes were 
associated with different prognosis (Sorlie et al. 2003).  The main molecular 
subtypes are described below. 
Luminal A 
The luminal A group comprises 50–60% of all diagnosed breast tumours, 
representing the most common subtype. It is characterized by the expression of 
genes typically expressed in the luminal epithelium and which are linked to ER 
transcriptional regulation (Prat & Perou 2011). In particular the 
immunohistochemistry profile of the luminal A subtype is characterized by 
expression of ER, PR, Bcl-2, GATA3 and cytokeratin CK8/18, and absence of 
HER2 expression. Moreover these tumours show a low rate of proliferation and a 
low histological grade. Luminal A patients have a generally good prognosis with a 
relapse rate significantly lower than that of other subtypes (27.8%) (Colleoni et 
al. 2012). However this subtype of breast cancer has the higher incidence of 
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bone metastases (18.7%) compared to other sites such as liver and lungs 
(Kennecke et al. 2010). The treatment of luminal A tumours is mainly based on 
hormonal aromatase inhibitors, which work by inhibiting the action of the 
enzyme aromatase, responsible for the synthesis of oestrogen, and selective 
oestrogen receptor modulators like Tamoxifen, a competitive inhibitor of the 
oestrogen-oestrogen receptor binding (Guarneri & Conte 2009). 
Luminal B 
The luminal B group makes up 10–20% of all breast tumours. Compared to the 
luminal A group, they have a more aggressive phenotype, higher histological 
grade and worse prognosis (Colleoni et al. 2012). Both luminal A and B express 
ER and the main biological difference between the two subtypes is an increased 
expression of proliferation genes, such as Ki67 and cyclin-B1, and growth factor 
receptors EGFR and HER2 in the luminal B group. Bone is still the most common 
site of recurrence (30%), together with a high recurrence rate in other organs 
such as the liver (Kennecke et al. 2010). Luminal B tumours are treated with 
Tamoxifen and aromatase inhibitor. However the worse prognosis compared to 
luminal A tumours, underlines the need of new therapeutic options for this 
subgroup. 
HER2 positive 
HER2 positive tumours represent 15-20% of breast cancers. They are 
characterized by a high expression of the HER2 gene and other genes associated 
with the HER2 pathway. Morphologically, these tumours are highly proliferative, 
with a high histological grade and frequent p53 mutations (Montemurro et al. 
2013). HER2 amplified tumours are a heterogeneous group and have been further 
subdivided into three separate subtypes; one characterized by worse prognosis 
with 12% of patients alive after 10 years, compared to the 50–55% survival in the 
other two groups (Staaf et al. 2010). From the clinical point of view, the HER2 
subtype is characterized by a poor prognosis, although the introduction of anti-
HER2 treatment has substantially improved survival in both primary and 
metastatic diseases (Slamon et al. 2001). 
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Basal-like and triple negative  
The basal-like subtype accounts for 15% to 20% of newly diagnosed breast cancer 
cases. One of the most relevant features of this subtype is the lack of the three 
key receptors in breast cancer: oestrogen, progesterone and HER2. For this 
reason the basal-like group is also defined as triple-negative breast cancer 
(TNBC). However some controversies exist on the definition of TNBC and basal-
like breast cancers (Gusterson 2009) and although triple-negative is not 
synonymous with basal-like tumours both groups show a wide range of 
similarities (Rakha et al. 2007). At the morphologic level, TNBC and basal-like 
tumours share similar characteristics such as larger tumour size, higher grade, 
presence of necrosis, pushing borders of invasion, and lymphocytic infiltrate 
(Livasy et al. 2006). The majority of TNBCs are invasive ductal carcinoma, but 
less common histologic subtypes (for example medullary and metaplastic) are 
also represented in this group (Bertucci et al. 2006; Weigelt et al. 2009). Basal-
like and TNBC tumours usually express genes characteristic of mammary 
myoepithelial cells, including cytokeratins CK5, CK14 and CK17, P-cadherin, 
Caveolin 1 and 2, Vimentin and EGF-R (Nielsen et al. 2004). However low levels 
of genes characteristic of luminal epithelium such as CK8/18 and cKIT can be 
found in these subtypes (Livasy et al. 2006). Moreover TNBC and basal-like 
tumours frequently show high expression of proliferation markers (Ki67) and 
activation of the beta-catenin pathway (Geyer et al. 2011; Arnedos et al. 2012). 
Interestingly, tumours with germ-line mutations in the BRCA1 gene belong to 
these groups (Sorlie et al. 2003).  
From a clinical point of view they are characterized by appearance at an early 
age (<40 years old), and predominantly in women of African origin (Metzger-
Filho et al. 2012). The pattern of metastatic relapse is aggressive, mainly 
localized to lungs, central nervous system and lymph nodes (Kennecke et al. 
2010). Basal-like tumours have a worse prognosis compared to the luminal 
subgroups, with a higher relapse rate in the first 3 years despite showing a high 
response to chemotherapy (Rouzier et al. 2005). Hence the identification of new 
therapeutic targets and treatment strategies for TNBC is urgently needed. Given 
the extreme heterogeneity of TNBC and basal-like tumours, effort has been put 
into trying to identify biologically distinct TNBC subgroups. In 2007, a new triple 
negative molecular subtype named claudin-low, was identified (Herschkowitz et 
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al. 2007). These distinct tumours were characterized by the low gene expression 
of tight junction proteins claudin 3, 4 and 7 and E-cadherin. A follow up study 
showed that claudin-low tumours are enriched in epithelial-to-mesenchymal 
transition (EMT) features, immune system responses, and stem cell-associated 
genes (Prat et al. 2010). In addition four independent gene clusters were 
identified in the TNBC subgroup using the transcriptome data from 21 
independent breast cancer studies (Lehmann et al. 2011). These clusters were 
defined by mesenchymal features, immune system–related genes, DNA damage 
response genes and activated androgen receptor signalling.  
1.3.3  Understanding the molecular portrait of breast cancer 
The implementation of high throughput technologies has opened our eyes on the 
intimate molecular heterogeneity of breast cancer. However the complete 
molecular portrait of breast cancer is still far from being completed. The 
continuous development and improvement of high-throughput techniques means 
that more powerful, fast and reliable methods are available every year, helping 
to dig more deeply into the molecular architecture of breast cancer (Gray & 
Druker 2012). In 2012, five independent whole-genome analyses, through 
massively parallel DNA and RNA sequencing of various breast cancers, refined 
our current tumour-classification system with the finding of new subtypes among 
the categories established by early transcriptome profiling studies (Ellis et al. 
2012; Stephens et al. 2012; Shah et al. 2012; Curtis et al. 2012; Banerji et al. 
2012). For example Curtis and co-workers identified new breast-cancer subtypes 
that are associated with different patient outcomes, based on the combination 
of copy number and gene expression analysis (Curtis et al. 2012). Banejerji and 
co-workers instead, identified three new molecular aberrations implicated in 
breast cancer (mutations in the genes CBF-β, RUNX1 and the MAGI3–AKT3 gene 
fusion) (Banerji et al. 2012). In a recent study, a diverse set of breast tumours 
were assayed using DNA methylation, microRNA (miRNA) expression and protein 
expression, combined with mRNA expression profiling, DNA copy number analysis 
and massively parallel sequencing (Cancer Genome Atlas Network 2012). The 
information generated was then integrated across platforms demonstrating the 
existence of four main breast cancer classes, each of which shows significant 
molecular heterogeneity. Moreover somatic mutations in only three genes (TP53, 
PIK3CA and GATA3) occurred in more than 10% of all breast cancers while 
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several subtype-specific and novel gene mutations were identified (Cancer 
Genome Atlas Network 2012). Overall these studies show that individual breast 
cancers typically carry a few consistent characterized abnormalities, along with 
tens to thousands of other changes that are rare or unique to the individual 
tumour and about which little is known. The challenge in the future will be to 
understand which of these genes are responsible for tumourigenesis and how this 
ensemble of aberrations collaborates to drive tumour growth and response to 
therapy.  
1.3.4  The origin of breast cancer subtypes 
The previous studies showed that breast cancer can be viewed as a collection of 
multiple different diseases, each one characterized by specific molecular, 
histological and clinical features. Two competing models have been suggested to 
explain this extensive heterogeneity: the clonal evolution and the cancer stem 
cell hypotheses (Shackleton et al. 2009). According to the clonal evolution 
hypothesis breast cancer subtypes do not mirror the features of normal cell 
populations and the unique subtype-specific gene expression patterns are rather 
generated by evolution of transformed cells during decades of clonal selection 
influenced by a particular tumour genetic background. According to the cancer 
stem cell hypothesis instead, accumulation of specific mutations in a particular 
cell type of the normal mammary epithelium generates transformed multipotent 
cells (cancer stem cells) which will then give rise to a specific breast cancer 
subtype (Smalley et al. 2003). In this view the molecular features of each 
subtype are mirroring the characteristic of the cell type which was originally 
transformed. For example MaSC are thought to be the cell of origin of triple 
negative breast cancer based on their shared features such as lack of expression 
of hormone receptors and expression of basal cytokeratins (Perou 2010). On the 
other hand luminal A tumours, are thought to derive from relatively well-
differentiated cells of the ER+ lineage, whereas luminal B tumours are believed 
to develop from less differentiated luminal progenitors (Polyak 2007). The 
theory of the cell of origin of breast cancer is still controversial and further 
studies are needed to corroborate this hypothesis. In particular a better 
characterization of the mammary epithelial cell hierarchy, through the 
identification of new markers to identify stem, progenitor and differentiated 
cells of the mammary epithelium, is essential to allow a better understanding of 
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the cellular targets of breast cancer mutations. By determining the identity of 
the original cell population that was transformed to form the cancer stem cell 
population, investigators will be able to identify early key steps in the formation 
of breast cancer, which could potentially translate into novel therapeutic 
targets. 
 
1.4   The RUNX Genes 
The Runx genes represent a family of different transcription factors 
characterized by a common feature: a highly conserved 128 amino acid sequence 
known as the Runt domain. The Runt domain, located in the amino-terminal 
region of these proteins, is required for their DNA binding activity and for 
protein-protein interactions (Levanon & Groner 2004). Runx genes regulate the 
transcription process binding the DNA as a multicomponent complex together 
with the DNA binding partner CBF-β cofactor and a wide variety of tissue specific 
co-repressors and co-activators (Chuang et al. 2012). RUNX transcription factors 
are involved in several fundamental processes during animal development, 
playing a key role in the regulation of cell differentiation and proliferation 
(Coffman 2009). In addition and strictly connected to this decision, Runx genes 
have been found to take part in cancer development, although their ambiguous 
roles of oncogenes or tumour suppressors have yet to be clarified  (Blyth et al., 
2005; Blyth et al., 2010).   
1.4.1  The Runx genes: evolution, structure and regulation 
1.4.1.1  The Runx genes: an evolutionary look. 
The RUNX proteins are well represented among metazoan organisms, from 
mouse to sea urchin and sponges, underlining the importance of this 
transcriptional regulatory system (Braun & Woollard 2009; Sullivan et al. 2008).  
While lower organisms such as C. elegans usually have a single Runx gene, more 
evolved organisms possess additional Runx genes probably deriving from ancient 
duplication events. These genes have then acquired different lineage and tissue 
specificity while becoming intertwined to distinct cell regulatory systems. As a 
result RUNX family members have developed exclusive gene-specific functions. 
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The first Runx gene to be discovered, runt, was identified as a major player in 
Drosophila early segmentation process (Gergen & Butler 1988) and later in 
neuronal development and sex determination (Duffy et al. 1991). Another 
Drosophila Runx homolog, lozenge, was found to regulate cell fate specification 
during haematopoiesis and to control cell patterning during eye development 
(Daga et al. 1996; Lebestky et al. 2000). Moreover the Drosophila genome 
project identified 2 additional Runx homologs, CG34145 and CG42267, whose 
function is still unknown (Rennert et al. 2003).   
The sea urchin S. purpuratus has two Runx genes but only one, called SpRunt-1 
has been characterised so far (Fernandez-Guerra et al. 2006). SpRunt-1 is 
involved in the regulation of both cell proliferation and terminal differentiation 
in all major tissues during different stages of embryogenesis (Coffman et al. 
2004). In particular SpRunt-1 is generally required in early embryonic 
development to support cell division, and it is required later on to activate 
expression of structural genes involved in terminal differentiation in a specific 
subset of tissues (Coffman et al. 2004). Further studies in sea urchin have 
unveiled an anti-apoptotic role for RUNX during gastrulation (Dickey-Sims et al. 
2005) and the existence of a crosstalk between Runx and Wnt signalling during 
early development (Robertson et al. 2008). 
Since its genome contains only one Runx gene, rnt-1, C. elegans is an 
invertebrate model organism commonly used for investigating the role of Runx in 
development avoiding redundancy problems. Genetic analysis have shown a key 
role of rnt-1 as a regulator of cell division patterns in seam cells, a population of 
well characterized neuroectodermal stem cells located in the worm epidermis 
(Nimmo & Woollard 2008). In particular in rnt-1 mutants, symmetrical cell 
division of seam stem cells is drastically impaired, leading to a reduction in their 
number in adult animals (Nimmo et al. 2005). Moreover overexpression of either 
rnt-1 or bro-1, a homologue of mammalian CBF-β, leads to increase of both 
asymmetrical and symmetrical divisions among seam cells, resulting in massive 
hyperplasia and a tumour-like phenotype (Kagoshima et al. 2007).    
The key role of Runx genes as important regulators of stem cells is also emerging 
from studies on Planarians (Rink 2013). Planarian flatworms are capable of 
regenerating any missing body part and represent an attractive model for the 
49 
 
investigation of the molecular pathway underlying tissue regeneration. Planarian 
regeneration uses a population of regenerative cells (neoblasts) which includes 
pluripotent stem cells. Interestingly, after wounding runt-1 is activated directly 
within neoblasts where it is necessary for specifying different cell types during 
regeneration (Wenemoser et al. 2012). 
The recurrent theme of Runx genes as specific lineage determinants is further 
confirmed in more complex vertebrate animal models. In particular in Zebrafish 
and Xenopus Runx1 is expressed in hematopoietic progenitors where it controls 
stem cell specification (Tracey et al. 1998; Kalev-Zylinska et al. 2002; Burns et 
al. 2005). Moreover in Xenopus, Runx1 is also required for the development of 
Rohon/Beard neurons, a particular class of sensory neurons which mediate 
response to touch in the larval stage (Park et al. 2012). In both fish and frogs, 
Runx2 is detected in developing skeletal elements where it regulates 
chondrogenesis (Flores et al. 2004; Flores et al. 2006; Kerney et al. 2007) while 
in Zebrafish, Runx3 has been studied in the context of haematopoiesis and 
chondrocyte differentiation (Kalev-Zylinska et al. 2003). 
The mammalian genome contains three different Runx genes: Runx1, Runx2 and 
Runx3. These genes maintain strong structural similarities but they have 
acquired lineage-specific roles. RUNX1 is required for the development of 
hematopoietic lineages; RUNX2 is a master regulator of bone formation while 
RUNX3 has a role in neuronal development (Cohen 2009). Taken together, the 
evidence gathered from different animal models, separated by millions of years 
of evolution, helps to build a general picture of Runx genes as key transcription 
factors involved in the regulation of lineage determination and self/renewal 
through a finely tuned action on cell proliferation and differentiation. Such a key 
role in diverse developmental processes implies that Runx genes need to be 
tightly controlled at the transcriptional and post-transcriptional level.  
1.4.1.2 The Runx Genes: genomic and protein structure.  
Runx genes are located on different chromosomes which are species-specific. 
RUNX1 is localised on human chromosome 21, RUNX2 on chromosome 6 and 
RUNX3 on chromosome 1 while in mouse they are located on chromosomes 16, 
17 and 4 respectively (Stock & Otto 2005). The three mammalian RUNX genes 
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share a similar genomic structure which can also be found in two neighbouring 
paralog genes outside the RUNX locus: CLIC and DSCR (Levanon & Groner 2004). 
RUNX1 is the biggest gene with 9 exons and 12 possible isoforms, RUNX2 has 8 
exons and 12 possible isoforms, while RUNX3 is the smallest one with 6 exons 
and few isoforms (Bangsow et al. 2001).  
RUNX proteins have an average size of 50 KDa, ranging from the 44 KDa of RUNX3 
to the 57KDa of RUNX2. Despite the difference in size, RUNX proteins contain 
several conserved regions. At the N-terminus is the highly conserved Runt 
domain, which is shared by all members of the RUNX family with a degree of 
homology close to 90%. RUNX proteins bind through their Runt domains, to a 
conserved nucleotide sequence (R/TACCRCA). Structural studies have 
determined the three-dimensional conformation of the Runt domain in its DNA-
bound state showing that it forms an immunoglobulin (Ig) fold (Nagata et al. 
1999). The Ig fold is a common domain, mainly involved in molecular recognition 
and binding, that can be found in the DNA-binding domain of other transcription 
factors such as P53, NF-kB, NFAT, and STAT (Williams & Barclay 1988). However, 
unlike other transcription factors, the Runt domain uses loop regions located at 
the end of the Ig fold for DNA binding (Berardi et al. 1999). Since the Runt 
domain has a low DNA-binding affinity, during the transcriptional process DNA 
binding usually occurs together with the heterodimeric binding partner CBF-β.  
In addition to the Runt domain, necessary for protein-DNA binding capability, 
RUNX proteins share other common features. All these proteins have a large C-
terminal transactivation domain and a C-terminal inhibitory domain (ID) which 
downregulates protein expression. Other domains, localized in the C-terminal 
region, further contribute to RUNX regulation: a NMTS sequence, required for 
nuclear targeting of RUNX activated proteins (Zaidi et al. 2001), a VWRPY 
sequence, which binds to the co-repressor Groucho/TLE (Imai et al. 1998) and a 
PY sequence, a proline-rich motif required for protein interactions (Terry et al. 
2004).   Studies conducted on RUNX1 also show transactivation properties in the 
N-terminal and the α-helix of Runt domain (Liu et al. 2006). Interestingly RUNX 
family members show less homology in the areas outside the Runt domain: the 
presence of isoform-specific regulatory elements and protein binding sequences 
may account for the functional differences observed between RUNX proteins 
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(Levanon & Groner 2004). For example, RUNX2 is the only RUNX protein with a 
specific glutamine-alanine repeat domain (QA), localized in N-terminal, which is 
required for osteoblast lineage specification (Thirunavukkarasu et al. 1998).   
1.4.1.3 Transcriptional regulation of RUNX genes. 
Given their essential role in development, RUNX genes are integrated into a 
complex regulatory network which acts both at the transcriptional and post-
transcriptional level. RUNX genes have two different promoters, P1 (distal) and 
P2 (proximal), resulting in two main isoforms with distinct 5’-UTRs sequences 
(Levanon & Groner 2004). Interestingly, both P1 and P2 genomic regions contain 
several RUNX binding sites suggesting the possibility of cross-regulation between 
the RUNX genes (Otto et al. 2003). Indeed cross-regulation has been reported 
whereby RUNX3 overexpression downregulates RUNX1 in human B cell lines 
(Spender et al. 2005) while RUNX2 represses RUNX3 in tooth development (X.-P. 
Wang et al. 2005). Moreover autoregulation of RUNX genes has been shown in 
vitro with overexpression of RUNX2 in NIH3T3 cells downregulating RUNX2 
transcription in a negative feedback loop (Drissi et al. 2000).  
1.4.1.4 Translational and post-translational regulation of RUNX genes. 
RUNX gene expression is tightly regulated at the translational level through the 
two distinct 5’UTRs sequences (called P1-5’UTR and P2-5’UTR) of the P1 and P2 
isoforms. In RUNX1 P1-5’UTR directs cap-mediated translation while P2-5’UTR 
contains an internal ribosomal entry sequence (IRES) which regulates its 
translation (Pozner et al. 2000). In RUNX2 both P1 and P2-5’UTR contain IRES 
sequences (Xiao et al. 2003) and RUNX3 P2-5’UTR exhibits internal translation 
initiation capability (Bone et al. 2010). IRES elements are involved in 
translational regulation when cap-dependent system is impaired, such as during 
mitosis, suggesting a particular role for these isoforms in proliferating cells 
(Vagner et al. 2001).   
Transcription factors can be further regulated through a wide variety of post-
translational modifications such as phosphorylation, acetylation, ubiquitination, 
SUMOylation, and methylation, which are necessary for fine-tuning of 
transcriptional regulation. These modifications control various aspects of 
transcriptional factors activity such as auto inhibition, dimerization, proteolytic 
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cleavage, cellular localization and ubiquitin-mediated degradation. Not 
surprisingly, RUNX activity is dynamically regulated by a growing list of post-
translational modifications (reviewed in Wang et al. 2009). RUNX proteins can be 
regulated through phosphorylation mediated by various kinases such as ERK, SRC 
and Cyclin/Cdks (Chuang et al. 2012). For example ERK1/2 dependent 
phosphorylation of RUNX2 is critical for osteoblast-specific gene expression (Xiao 
et al. 2000) and RUNX2 activity is stimulated after phosphorylation by ERK1/2 
and p38 MAP kinase (Ge et al. 2012). Moreover, the serine/threonine kinase PIM-
1, which has been implicated in cytokine-dependent signalling in hematopoietic 
cells, interacts and phosphorylates RUNX1 and RUNX3 enhancing their 
transactivation activity (Aho et al. 2006), while SRC-mediated phosphorylation 
causes a re-localization of RUNX3 to the cytoplasm in breast cancer cells (Goh et 
al. 2010).  Acetylation of transcription factors, mediated by histone 
acetyltransferase (HAT) proteins, leads to changes in protein-protein and 
protein-DNA interaction, which subsequently influence gene expression (Sterner 
& Berger 2000). All mammalian RUNX proteins can be acetylated by p300 
resulting in increased DNA binding ability, protein stability and stimulated 
transactivation properties (Yamaguchi et al. 2004; Jin et al. 2004; Jeon et al. 
2006). The necessity of a fine control on RUNX activity in response to different 
stimuli means that RUNX proteins levels are controlled post-translationally by 
ubiquitin-mediated proteasome degradation.  Various  E3 ubiquitin ligases such 
as MDM2, promote degradation of RUNX proteins (Zhao et al. 2003; Chi et al. 
2009), while proteins such as CBF-β and SIN3A interact with RUNX preventing 
their proteasomal degradation (Huang et al. 2001). 
1.4.1.5 Co-repressor and co-activators. 
RUNX and CBFβ heterodimers are relatively weak transcriptional factors but they 
can increase their efficiency through recruitment of a wide array of co-
activators and co-repressors. Moreover the vast array of these co-regulators is 
pivotal to guarantee specificity and accuracy in RUNX-mediated transcriptional 
regulation. Several transcription factors have been found to interact with RUNX 
genes to drive transcriptional activation or repression depending on the context. 
The list of transcription factors interacting with RUNX proteins contains several 
which play key roles in development such as AP1 (c-Fos and c-Jun), BMP-
responsive SMADs (SMAD1 and SMAD5), Hes1, GATA-1, STATs and Oct-1 among 
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others (Chuang et al. 2012).  Interestingly many of these transcription factors 
such as STAT5 and SOX9, interact with RUNX via the Runt domain, suggesting 
that they may compete with each other for binding to RUNX (Zhou et al. 2006; 
Ogawa et al. 2008). It is generally believed that transcription factors cooperate 
with RUNX proteins to facilitate the recruitment of additional co-regulators and 
the assembly of higher-order transactivation complexes. In fact, other RUNX 
interactors do not bind to the DNA directly, but are recruited to the template by 
DNA-bound RUNX proteins which act as a scaffold. TLE proteins, the human 
homologs of Drosophila Groucho and Grg proteins in mice, are broadly expressed 
co-repressors which are recruited to promoters/enhancers by numerous 
transcription factors (Cinnamon & Paroush 2008). The TLE/Groucho family is one 
of the first characterized groups of co-repressors, found to interact with RUNX 
through the highly conserved VWRPY sequence, present at the C-terminus of all 
Runt domain proteins (Aronson et al. 1997). Interestingly the interaction 
between TLE/Groucho and RUNX proteins results in transcriptional repression of 
osteoblast (Javed et al. 2000) and T-cell specific genes (Seo et al. 2012). In 
addition RUNX proteins can also recruit different co-repressors such as mSIN3A 
(Lutterbach et al. 2000) and CoAA (Li et al. 2009). The mechanism whereby 
those co-repressors inhibit RUNX-mediated transcription is still not clear.  
A growing list of chromatin-modifying proteins has been shown to interact with 
RUNX proteins acting as both activator and repressor. RUNX proteins interact 
with the acetyltransferase p300 through their C-terminal region, leading to 
stimulation of RUNX-mediated transcription (Kitabayashi et al. 1998; Jin et al. 
2004; Boumah et al. 2009). Others acetyltransferases, such as PCAF (Wang et al. 
2013), MOZ and MORF (Pelletier et al. 2002; Kitabayashi et al. 2001) physically 
interact with RUNX proteins, strongly stimulating their transactivation activity. 
RUNX proteins can also associate with histone-modifying enzymes, such as 
histone acetyltransferase HDAC, to induce transcription repression (Ali et al. 
2012). RUNX proteins have also been shown to collaborate with the SWI/SNF 
chromatin modelling complex for transcription activation. In particular RUNX1 
and RUNX2 recruit the SWI/SNF complex to specific target genes to regulate 
respectively hematopoietic and osteoblast specific genes (Villagra et al. 2006; 
Bakshi et al. 2010). The repertoire of proteins that cooperate with RUNX in 
54 
 
transcriptional regulation continues to increase year after year, reflecting the 
necessity of fine tuning of RUNX activity according to specific cell contexts. 
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Figure 1-2  Post-transcriptional regulation of RUNX proteins. 
RUNX proteins can be regulated through various post-transcriptional modifications and by 
interactions with tissue-specific co-repressors and co-activators. In addition RUNX proteins can 
interact and cross-regulate with each other. Thus RUNX-mediated transcription is highly context 
dependent. 
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1.4.2  RUNX Genes in Development 
RUNX genes are fundamental in mammalian development, as underlined by the 
severity of individual gene knockout phenotypes in transgenic mice. In particular 
Runx1 is required for haematopoiesis (Okuda et al. 1996), Runx2 for osteogenesis 
(Otto et al. 1997) and Runx3 for neurogenesis (Inoue et al. 2002). Several studies 
have also uncovered various developmental roles for Runx genes in a wide 
variety of tissues and organs. 
1.4.2.1 RUNX1  
RUNX1 has a primary role in haematopoiesis (reviewed in Swiers et al. 2010) 
since Runx1 null mice fail to generate haematopoietic cells of all lineages 
(Okuda et al. 1996). Runx1 deficient embryos die at E12.5 with diffuse 
haemorrhages within the ventricle of the central nervous system and vertebral 
canal. Interestingly blood cells in the sites of haemorrhaging consist only of 
primitive erythrocytes, since all definitive blood cells are absent from Runx1 
deficient embryos.  This failure is due to a blockage in haematopoietic stem cell 
differentiation during embryo development (North et al. 1999). Further studies 
revealed the precise step of definitive haematopoiesis where Runx1 is required: 
Runx1 is expressed in a specific subset of endothelial cells where it is essential 
for the formation of intra-aortic haematopoietic clusters and their 
differentiation into haematopoietic progenitor and stem cells (Chen et al. 2009). 
This key finding helped to confirm the highly debated theory of “hemogenic 
endothelium” (Jordan 1916): during embryogenesis, haematopoietic stem and 
progenitor cells are generated, in a Runx1-dependent way, from a unique 
population of vascular endothelium termed hemogenic endothelial cells (Antas 
et al. 2013). Others studies using conditional knockout mouse models have 
confirmed the master role of Runx1 in haematopoiesis, not only at an embryonic 
stage but also during differentiation of various adult lineages. Haematopoietic 
precursors differentiate into mature T-cells through discrete stages which can be 
defined based on expression of T-cell surface antigens CD4 and CD8. Immature 
thymocytes lacking CD4 and CD8 co-receptors (CD4-CD8-), progress through a 
double positive stage (CD4+CD8+), and are then selected to become either T-
helper cells (CD4+CD8-) or cytotoxic T-cells (CD4-CD8+). Runx1 is necessary for 
T-cell specification with a role in repressing CD4 expression in immature 
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thymocytes (Taniuchi et al. 2002). Moreover inducible Runx1 deletion in the 
bone marrow showed that Runx1 is necessary for megakaryocytic maturation and 
differentiation of T- and B-cells (Ichikawa et al. 2004; Niebuhr et al. 2013). 
In addition to its role in the haematopoietic system Runx1 takes part in 
developmental processes regulating lineage specification and differentiation in 
other organs. During embryonic bone development Runx1 is expressed in pre-
chondrocytic tissue, after birth it is expressed in resting zone chondrocytes and 
suture lines of the calvarium, and in the adult, in periosteal and perichondral 
membranes of all bones but is absent in mature cartilage or mineralized bone 
(Yamashiro et al. 2002; Lian et al. 2003). The expression of Runx1 at sites of 
cartilage growth, suggests that Runx1 expression may be related to 
chondroprogenitor cell differentiation (Y. Wang et al. 2005; Soung et al. 2012). 
However, in vivo, Runx1 conditional knockout mice showed that Runx1 is not 
essential for major skeletal growth, but plays a role in the development of the 
sternum and some skull elements (Kimura et al. 2010; Liakhovitskaia et al. 
2010).  
Genetic studies on Drosophila demonstrated that Runx genes are involved in 
neuronal development (Duffy et al. 1991) with expression in neural cells of the 
developing nervous system of Zebrafish and mouse (Zagami et al. 2009). Dorsal 
root ganglion neurons (DRG) convey peripheral somatosensory stimuli to the 
spinal cord. They can be subdivided in three major subpopulations – nociceptive, 
mechanoreceptive, and proprioceptive.  Runx1 is specifically expressed in DRG 
nociceptive neurons where it controls lineage specification and regulates axonal 
outgrowth and guidance in the developing embryo (Kramer et al. 2006; 
Marmigère et al. 2006). Outside DRG neurons, Runx1 plays a role in regulating 
survival of post-mitotic neurons of the embryonic central and peripheral nervous 
system (Theriault et al. 2004) and regulates neural progenitor cell proliferation 
in olfactory receptor neurons (Theriault et al. 2005). 
In recent years, studies on the hair follicle linked RUNX1 to lineage 
differentiation of epithelial tissues (Scheitz & Tumbar 2012). Runx1 is expressed 
in a subset of cells during embryonic and adult hair follicle formation (Osorio et 
al. 2011). Interestingly, lineage tracing experiments showed that embryonic 
Runx1 positive epithelial cells contribute to all lineages of hair follicle during, 
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morphogenesis and adult homeostasis, proving that Runx1 expressing cells are 
precursors of adult hair follicle stem cells (HFSCs) (Osorio et al. 2011). 
Moreover, while the majority of adult epithelial Runx1 expressing cells are short-
lived progenitors (Osorio et al. 2011), Scheitz et al. 2012 showed that the adult 
bulge cells expressing Runx1 are HFSCs since they contribute long-term to HF 
homeostasis as well as to physical injury repair. Induced epithelial knockout of 
Runx1 has been used to characterize the role of Runx1 in skin development. 
However Runx1 loss was only found to affect hair structure (Raveh et al. 2006) 
and to cause a temporary delay in morphogenesis and hair cycle which is 
overcome with age and injury (Osorio et al. 2008). Remarkably, a much more 
profound effect on hair follicle integrity was caused by Runx1 loss in the 
embryonic skin mesenchyme, an important HFSCs niche component. After Runx1 
deletion in the mesenchyme, the hair follicle shows no abnormalities during 
morphogenesis, but in the first hair cycle, when adult stem cells generate the 
differentiated hair lineages, hair follicles are converted to enormous sebaceous 
cysts (Osorio et al. 2011). Overall these studies identified RUNX1 as a key 
transcriptional factor regulating hair follicle differentiation. Focusing on 
different epithelia, RUNX1 expression has been observed in other tissues 
specifically in the basal layer of the oral epithelium, and in LGR5+ cells of the 
intestinal crypt and in the more differentiated villus cells (Scheitz et al. 2012). 
RUNX1 expression has been detected also in mammary epithelium as will be 
discussed in detail in Section 1.5. 
1.4.2.2 RUNX2 
RUNX2 has a primary developmental role as a key lineage determinant for 
osteoblast differentiation. In fact Runx2 knockout mice exhibit complete lack of 
bone formation and die soon after birth because of asphyxia caused by lack of 
ossification in the ribs (Komori et al. 1997; Otto et al. 1997). Moreover, deletion 
of a nuclear targeting signal located in the C-terminal domain of Runx2 
phenocopied Runx2-null mice, highlighting the importance of proper nuclear 
localization of this transcription factor (Choi et al. 2001). Mutations of RUNX2 
resulting in a hypomorphic allele, are linked to a congenital human disease, 
cleidocranial dysplasia (CCD), characterized by abnormal clavicles, 
supernumerary teeth, short stature, and a variety of other skeletal changes  
(Mundlos et al. 1997). These mutations affect only one allele of RUNX2 leading 
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to a decrease in wild-type RUNX2 levels and activity. Interestingly Runx2 
haploinsufficiency in mice causes similar phenotypes as observed in CCD families 
(Komori et al. 1997). Moreover RUNX2 is one of few genes undergoing specific 
modifications in the modern human lineage compared to Neanderthal genomes 
(Green et al. 2010) suggesting that an evolutionary change in RUNX2 was 
involved in the determination of morphological traits which characterize modern 
human skeletal development. Those evolutionary observations are confirming 
the key role for RUNX2 as a main regulator of cranial and skeletal features. 
Studies have clarified the role of Runx2 in osteoblast differentiation (Long 2011). 
During embryonic development Runx2 is expressed in osteochondroprogenitors; 
bipotent progenitors which have the capacity to differentiate into osteoblasts or 
chondrocytes (Marie 2008). Then Runx2 expression decreases in cells which will 
differentiate into chondrocytes while remains expressed at high levels in cells of 
the osteoblast lineage and perichondrium. Interestingly, the perichondrium, 
which normally contains bipotent osteochondroprogenitors, becomes hypoplastic 
in Runx2-null mice demonstrating its requirement for the production and/or 
maintenance of the bone progenitors (Komori et al. 1997). Thus during skeletal 
development Runx2 activates a differentiation pathway in bone marrow-derived 
mesenchymal stem cells which is necessary for osteoblast differentiation. Runx2 
expression needs to be downregulated to guarantee correct osteoblast terminal 
differentiation exemplified by mouse models where bone formation is impaired 
by Runx2 overexpression (Liu et al. 2001). In particular overexpression of Runx2 
results in increased osteoblast number but inhibits their terminal maturation, 
resulting in accumulation of less mature osteoblasts and consequent osteopenia 
(Liu et al. 2001). Moreover osteoclastogenesis is stimulated, possibly by the 
increased production of RANKL and MMP-13 by the immature osteoblasts 
(Geoffroy et al. 2002). In addition Runx2 is also necessary for the proper 
function of terminally differentiated osteoblasts: mature mice in which active 
Runx2 levels have been reduced, exhibit decreased expression of the genes 
encoding several bone matrix proteins such as BSP, Osteocalcin and Osteopontin 
(Ducy et al. 1999). These results indicate that RUNX2 proteins levels need to be 
finely tuned throughout the entire process of osteoblast differentiation to 
guarantee a correct skeletal development.  
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Runx2 is also expressed in extra-skeletal tissues where its function is less well 
understood. Expression of Runx2 is high in the haematopoietic stem cell 
population, where it is expressed at higher levels than Runx1, and sharply 
decreases during myeloid differentiation (Kuo et al. 2009). Moreover forced 
Runx2 expression in in vitro differentiation assays, blocks myeloid progenitor 
differentiation capacity (Kuo et al. 2009). Besides myeloid differentiation, Runx2 
is also involved in the regulation of the lymphoid lineage. Runx2 is expressed at 
the earliest stage of thymocyte development (Satake et al. 1995; Blyth et al. 
2010) and enforced expression of Runx2 in transgenic mice under the CD2 
promoter affects T cell development, resulting in an expansion of double-
negative and CD8 immature single-positive cells (Vaillant et al. 2002). Moreover 
additional evidence suggests a role for Runx2 in B-cell differentiation since 
Runx2 transcripts are enriched in a subpopulation of memory B cells (Ehrhardt et 
al. 2008).  
The development of ectoderm-derived appendages results in several highly 
specialized organs such as hair follicles, mammary glands and teeth (Jiménez-
Rojo et al. 2012). Interestingly Runx2 is emerging as a common regulator of 
ectodermal-derived epidermal appendages development. It is found expressed 
during tooth development (Jiang et al. 1999; Bronckers et al. 2001) where it is 
necessary for tooth morphogenesis and odontoblast differentiation (Camilleri & 
McDonald 2006). Runx2-deficient mice have an impaired tooth development, 
which is blocked at late bud stage (D’Souza et al. 1999). Moreover, patients with 
RUNX2 mutations show a wide variety of dental disorders, with supernumerary 
teeth, abnormal tooth eruption, and tooth hypoplasia (Mundlos et al. 1997). 
Runx2 is not involved in the initiation of tooth formation, but it is necessary for 
the regulation of the epithelial –mesenchymal crosstalk required to control tooth 
morphogenesis (Aberg et al. 2004). Only one study so far has analysed the role of 
Runx2 in skin and hair follicle development. Glotzer et al., 2008 found that 
Runx2 is expressed in embryonic and adult hair follicles, and it cycles during hair 
follicle development. Moreover hair follicle maturation is slightly delayed in the 
absence of Runx2 and overall skin and epidermal thickness of Runx2 null 
embryos is reduced (Glotzer et al. 2008). The role of Runx2 in mammary 
development will be discussed in a separate chapter. 
61 
 
In addition RUNX2 expression has been found in vascular endothelial cells, testis, 
sperm and other reproductive organs such as placenta, ovary, Mullerian duct and 
prostate  (Sun et al. 2001; Jeong et al. 2008; Blyth et al. 2010). A functional role 
for Runx2 in those tissues however has yet to be clarified. 
1.4.2.3 RUNX3 
In the vertebrate somatosensory system, stimuli are transmitted from the 
periphery to the spinal cord by sensory neurons located in dorsal root ganglia 
(DRG) that flank the spinal cord. Two independent studies demonstrated that 
Runx3 knockout mice manifest severe limb ataxia due to defective development 
of proprioceptive neurons in the dorsal root ganglia (DRG) (Inoue et al. 2002; 
Levanon et al. 2002). During DRG neurogenesis, proprioceptive tyrosine kinase 
receptor C + (TrkC+) and mechanoreceptive (TrkB+) neurons are derived from a 
common bipotent precursor (TrkB+, TrkC+). During segregation of the two 
complementary sensory populations, Runx3 is specifically expressed in TrkC+ 
neurons where it represses TrkB expression, acting as a lineage specifier for 
proprioceptive neurons (Inoue et al. 2002; Levanon et al. 2002). Runx3 also 
regulates axonal outgrowth and/or axonal guidance of proprioceptive DRG 
neurons (Levanon et al. 2002; Chen et al. 2006). As with Runx1 and Runx2, 
Runx3 has been found to play a role in T-cell development (Durst & Hiebert 
2004). Runx3 knockout mice have reduced numbers of CD8+ T-cells in the 
thymus and in the circulating T-cell population together with increased 
expression of CD4 in the peripheral CD8+ cells (Woolf et al. 2003). In addition, 
when T-cells were analysed in immunodeficient mice reconstituted with 
haematopoietic stem cells from the foetal livers of embryos lacking Runx3 mice, 
CD4 was de-repressed in the peripheral cytotoxic T cells (Taniuchi et al. 2002). 
Those studies show how Runx3 is necessary for CD4 silencing and CD8 T-cell 
maturation during T-cell development. 
In addition to neuronal defects, Runx3 deleted mice from Ito’s group developed 
hyperplasia of the gastric mucosa and died shortly after birth apparently due to 
starvation (Li et al. 2002). The increased proliferation rate in the gastric 
epithelia of Runx3 knockout mice was attributed to suppression of apoptosis and 
reduced sensitivity to the growth inhibitory effects of TGF-β1 (Li et al. 2002). 
These results suggest a possible role for Runx3 in regulation of gastric epithelium 
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homeostasis. However, this phenotype was not found in the Runx3 knockout 
mice produced by Levanon et al (2002). The reason for the discrepancy between 
the different Runx3 knockout phenotypes is still not clear, but one factor could 
be the different genetic backgrounds used in these studies (Bae & Ito 2003).  
This overview of Runx genes in developmental processes shows how the field has 
progressed in recent years, moving from a confined view of RUNX proteins as 
master gene regulators of a few specific lineages to a wider role for RUNX 
transcription factors in multiple tissues and cell types. Consequently future 
studies using conditional knockout strategies, will likely find new developmental 
roles for this widely conserved family of transcription factors. We are just 
beginning to discover and understand a more global role for the RUNX proteins 
as regulators of tissue function and maintenance. 
1.4.3  RUNX Genes and Cancer: an Overview. 
As shown previously, RUNX genes act as important regulators during mammalian 
development in a lot of different tissues, through regulation of cell proliferation 
and differentiation. In addition RUNX genes are deeply involved in tuning stem 
cell fate and lineage determination (Appleford & Woollard 2009; Wang et al. 
2010). Therefore it is not surprising that RUNX genes have been implicated in 
cancer. One of the interesting features of RUNX genes in cancer is their 
contrasting behaviour as both oncogenes and oncosuppressors in different types 
of cancers (Blyth et al. 2005; Pratap et al. 2006; Chuang et al. 2012).  An 
overview is presented here of the evidence linking RUNX genes to different types 
of tumours while the role of RUNX genes in breast cancer will be discussed later. 
1.4.3.1 RUNX1 
The first evidence that linked RUNX genes and cancer was the discovery of 
RUNX1 as one of the genes most frequently targeted by chromosomal 
translocation in acute myeloid leukaemia (AML) (Miyoshi et al. 1991) with three 
of the most common chromosomal translocations in acute leukaemia involving 
RUNX1 (Lam & Zhang 2012). The first translocation to be discovered, present in 
10–20% of adult AML, is the t(8;21) chromosomal translocation, which results in 
fusion of the N-terminal portion of RUNX1, including the Runt domain, to a 
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heterologous partner protein, ETO (Miyoshi et al. 1991). Another common 
translocation, TEL-RUNX1, is a result of t(12;21) and it is present in about 25% of 
patients with childhood pre-B cell acute lymphoblastic leukaemia (ALL).  TEL-
RUNX1 produces a fusion with the N-terminal domain of the TEL protein and 
almost the entire RUNX1 protein, including its DNA binding and transactivation 
domains (Golub et al. 1995). The third most common translocation involving 
RUNX1 is t(3;21), which causes the fusion of the N-terminal portion of RUNX1 
including its Runt domain with one of three genes on chromosome three 
including EVI, MDS1, or EAP. This translocation was first discovered in patients 
affected by chronic myelogenous leukaemia and in approximately 3% of therapy-
related myelodysplastic syndrome (MDS) and AML (Rubin et al. 1987). There is 
strong evidence that the products arising from translocations involving RUNX1 
have dominant negative activity with respect to the endogenous RUNX1 product. 
For example fusion of RUNX1 to ETO leads to recruitment of co-repressors and 
active repression of RUNX1-mediated gene transcription while TEL–RUNX1 has 
also been shown to function as a constitutive repressor of RUNX target genes 
(Meyers et al. 1995; Hiebert et al. 1996). Some in vivo genetic studies are also 
supporting the dominant negative function of RUNX1 translocation as shown by  
RUNX1– ETO knock-in mice which produced a very similar phenotype to loss of 
RUNX1 (Yergeau et al. 1997). In the current view, RUNX1 translocations cause 
the block of haematopoietic stem/progenitor cells at an immature 
developmental stage, where the accumulation of additional collaborating 
mutations is required to drive the malignancy. Supporting this hypothesis, two 
studies showed that expression of RUNX1–ETO in human haematopoietic stem 
cells or primary erythroid cells greatly increases their survival and self-renewal 
in vitro (Mulloy et al. 2002; Tonks et al. 2003). In addition to translocations, 
RUNX1 is also targeted by somatic point mutations that have been identified in 
de novo and therapy-related AML and MDS (Osato et al. 1999; Harada et al. 
2003). Again the majority of these mutations were found to be clustered within 
the Runt domain probably resulting in dominant-negative forms of RUNX1, while 
other mutations have been found in the C-terminal portion. Additional hints 
pointing for a tumour suppressor role for RUNX1 in the haematopoietic system 
come from the hereditary disease familial platelet disorder (FPD), an autosomal 
dominant condition characterized by platelet defects, and propensity to develop 
AML (Song et al. 1999). FPD patients frequently show monoallelic RUNX1 
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mutations, and biallelic mutations resulting from a second hit are often 
associated with progression to AML (Preudhomme et al. 2009). Besides a clear 
tumour suppressive role, several evidences show how RUNX1 can function as an 
oncogene in haematopoietic malignancies (Blyth et al. 2005). Retroviral 
mutagenesis studies identified Runx1 as a common insertion site for murine 
leukaemia virus (MLV), mostly in T- or B-cell lymphomas (Li et al. 1999). Those 
insertions result in overexpression of a full-length, gene product (Wotton et al. 
2002). Supporting the data coming from murine models, human cancers also 
manifest evidence of a possible oncogenic role for RUNX1. The strongest 
indication so far comes from a small subset (3–5%) of childhood B-ALL with poor 
prognosis, in which RUNX1 is affected by amplification of a large segment of 
chromosome 21q (Niini et al. 2000; Robinson et al. 2003). RUNX1 amplification 
has also been reported, although much more rarely, in myeloid leukaemias 
(Roumier et al. 2003). Interestingly in vitro studies showed that Runx1 
overexpression causes senescence in wild-type mouse embryonic fibroblasts but 
induces a transformed phenotype in the absence of functional p53 (Wotton et al. 
2004). These observations suggest a scenario where the oncogenic consequences 
of RUNX1 overexpression are manifested only in the presence of a specific 
genetic background.  In addition to haematopoietic malignancies, RUNX1 has 
also been linked to various epithelial cancers, including breast cancer (discussed 
in Chapter 3). 
1.4.3.2 RUNX2 
The oncogenic potential of RUNX2 has been demonstrated in lymphoma models, 
with the discovery of Runx2 as a frequent target for viral insertions in T-cell 
lymphomas of CD2-MYC mice (Stewart et al. 1997). Follow up studies confirmed 
that Runx2 overexpression interferes with murine immature T-cell 
differentiation but other collaborating mutations such as Myc activation or p53 
deletion are required for cancer development (Vaillant et al. 1999; Blyth et al. 
2001). In particular, the mechanism underlying the potent synergy between Myc 
and Runx2 in lymphoma development has been studied in depth (Blyth et al. 
2006). Double transgenic animals co-expressing Myc and Runx2 uniformly 
develop tumours by 36 days on average (Blyth et al. 2001). In preneoplastic cells 
co-expression of MYC counteracts the negative effects of RUNX2 on cell growth 
and proliferation, releasing the T-cell differentiation block conferred by Runx2 
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overexpression.  At the same time, RUNX2 collaborates with MYC by inhibiting its 
ability to induce apoptosis in T-cell tumours (Blyth et al. 2006).  Additional 
evidence of an oncogenic role for RUNX2 comes from studies on a model for 
CBFβ-SMMHC (also known as inv16), a common translocation in human AML 
(Castilla et al. 2004). Retroviral infection of this model identified Runx2 as a 
target for insertional mutagenesis (Kuo et al. 2009). Moreover full-length Runx2 
cooperated with CBFβ-SMMHC in leukaemia development in transplantation 
assays and conversely, Runx2 haplo-insufficiency delayed the onset and reduced 
the incidence of acute myeloid leukaemia (Kuo et al. 2009). Focusing on the 
human disease, so far RUNX2 expression has been detected in plasmacytoid 
dendritic cell malignancy (Dijkman et al. 2007) and in multiple myeloma (Colla 
et al. 2005) so although mouse studies indicate a possible oncogenic role for 
RUNX2 in haematopoietic malignancies, little clinical evidence supporting this 
hypothesis has been found in human disease.  
Focusing on other malignancies, RUNX2 genomic locus 6p21 is amplified in 
osteosarcoma (Lau et al. 2004) and increased expression of RUNX2 in 
osteosarcoma biopsies has been associated with increased tumourigenicity, 
metastases, lower survival, and poor prognosis (Sadikovic et al. 2010; Kurek et 
al. 2010). RUNX2 is consistently upregulated in papillary carcinomas and thyroid 
carcinoma cell lines compared with normal thyroid tissue (Endo et al. 2008; 
Dalle Carbonare et al. 2012). In addition RUNX2 silencing on thyroid carcinoma 
cells caused a decrease in EMT-related molecules and angiogenic factors (Niu et 
al. 2012). In recent years several studies have also linked RUNX2 to prostate 
cancer (Pratap et al. 2006; Blyth et al. 2010). In the conditional Pten-knockout 
mouse model, a widely used mouse model of prostate cancer, Runx2 levels 
increased with growth of prostate tumour suggesting an oncogenic role for this 
transcription factor (M. Lim et al. 2010). Furthermore increased RUNX2 
expression positively correlated with Gleason scores and metastatic potential of 
human prostate cancer (Chua et al. 2009; Akech et al. 2010). Several in vitro 
studies have focused on understanding the possible oncogenic mechanism of 
Runx2 in prostate cancer. In the PC-3 cell line, RUNX2 can mediate N to E-
cadherin switch, activation of AKT and enhanced invasive capacity (Chua et al. 
2009). Conversely, knocking down of RUNX2 expression in the PC3 cell line led to 
increased adhesion to fibronectin and reduced invasion through matrigel (Akech 
66 
 
et al. 2010). In a similar way transcriptomic analysis of gene expression in 
response to RUNX2 overexpression in the C4-2B cell line, showed up-regulation 
of genes implicated in cancer progression and cellular migration (Baniwal et al. 
2010). Those results showed how RUNX2 can regulate invasive features of 
prostate cancer cell lines. In addition, RUNX2 positively regulated Survivin, an 
important inhibitor of apoptosis, thus facilitating cancer cell survival in vitro 
(Akech et al. 2010, Lim et al. 2010). 
1.4.3.3 RUNX3 
A tumour suppressor role for RUNX3 has been proposed following studies using 
transgenic knockout mouse models. In particular Runx3 deficiency in the gastric 
epithelia is associated with a preneoplastic state characterized by loss of chief 
cells (Li et al. 2002). Runx3 deleted mice, unlike wild-type mice, consistently 
develop gastric cancer after chemical-induced (N-methyl-N-nitrosourea) 
carcinogenesis (Ito et al. 2011). These results, published by Ito’s group, have 
caused some controversy on the actual role of Runx3 in stomach cancer. In fact 
a Runx3 knock-out model created by Yoram Groner’s laboratory showed no 
evidence of gastric abnormalities (Levanon et al. 2002). Moreover RUNX3 protein 
was not detectable at the protein level in the gastric epithelium by Groner’s 
group (Levanon et al. 2011), questioning the tumour suppressor role for this 
protein in this organ. Heterozygous inactivation of Runx3 has also been shown to 
induce colon adenoma at a frequency similar to ApcMin/+ mice (Ito et al. 2008), 
data again not reproducible by other laboratories. Runx3 has also been shown to 
be required in the lung during bronchiolar epithelial cell differentiation and 
Runx3 deletion leads to lung adenoma development in aging mice (Lee et al. 
2010). One recent study has analysed the role of Runx3 in neuroblastoma: high 
levels of RUNX3 expression contribute to the favourable outcome in patients 
with neuroblastoma. Furthermore Runx3 tumour suppressor role in this 
malignancy could depend on its direct repression of MYCN oncogenic activity (Yu 
et al. 2013). All the evidence presented so far suggests a causal link between 
loss of Runx3 and cancer development. However, compared to RUNX1 and 
RUNX2, point mutations in the RUNX3 gene are rarely identified. This 
phenomenon could be explained by the finding that RUNX3 inactivation in cancer 
seems to occur mainly through aberrations in DNA methylation or histone 
modification (Lee 2011). Importantly, multiple studies have shown that 
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hypermethylation and subsequent silencing of RUNX3 gene expression is 
prevalent in solid tumours of breast, colon, lung, bladder and gastric origins 
(Chuang & Ito 2010). These results suggest a strong tumour suppressive role for 
RUNX3. However evidence indicates that RUNX3 can also act as an oncogene 
(Blyth et al. 2005). In lymphomas Runx3 is targeted by viral insertions, which 
drive protein overexpression (Wotton et al. 2002). Moreover Runx3 is expressed 
in a considerable proportion of pancreatic tumours suggesting that Runx3 might 
play a role in the pathogenesis of pancreatic ductal adenocarcinoma (Li et al. 
2004). RUNX3 is also overexpressed in skin (Lee et al. 2011), head and neck 
(Kudo et al. 2011) and ovarian cancers (Nevadunsky et al. 2009) again supporting 
an oncogenic role for RUNX3 in those tumours. The evidences linking RUNX3 to 
breast cancer will be discussed in detail later in the thesis. 
1.4.3.4 RUNX genes in tumours: mechanism and pathways.  
Runx genes can regulate cell growth and proliferation through a tight control on 
the cell cycle: not surprisingly the effects of Runx genes on the cell cycle are 
highly context dependent and dose sensitive (Coffman 2009). RUNX protein 
levels oscillate throughout the cell cycle indicating that variations in RUNX 
activity influence cell cycle progression. Indeed RUNX1 has been found to 
stimulate G1 to S progression in haematopoietic cells (Strom et al. 2000) while 
overexpression of RUNX2 in MC3T3-E1 osteoblastic cells delays progression from 
G1 to S phase (Galindo et al. 2005). Another way RUNX proteins regulate the cell 
cycle is through the control of cell cycle regulators: for example RUNX1 
represses p21 transcription, inducing cell cycle progression, in hair follicle stem 
cells in vivo (Lee et al. 2013). On the other hand RUNX activity is modulated by 
cell cycle regulators such as cyclins and cyclin-dependent kinases (Cdks): for 
example RUNX protein is ubiquitinated and degraded following phosphorylation 
by Cdk–cyclin complexes such as Cdk4/cyclin D1 and Cdk1/cyclin B (Biggs et al. 
2006). Furthermore Cdk/cyclin complexes can affect RUNX function through 
other mechanisms such as disruption of RUNX-DNA interaction, displacing of co-
receptors and inhibition of RUNX transactivation ability (Chuang et al. 2012). In 
addition to their role on cell cycle, RUNX proteins can control cell growth 
through expression of genes required for protein synthesis, such as rRNA genes 
(Young et al. 2007). Beyond regulation of cell growth and proliferation, RUNX 
can influence tumour growth through control on apoptosis and senescence.  In 
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particular RUNX proteins can either activate apoptosis through induction of pro-
apoptotic proteins such as BAX and BIM (Eliseev et al. 2008) or inhibit MYC-
induced or p53-dependent cell death (Blyth et al. 2006; Ozaki et al. 2013). In 
addition Runx genes play a key role in oncogene-induced senescence, as shown 
by in vitro experiments on primary mouse embryonic fibroblasts (MEFs) where, 
after aberrant Ras expression, all RUNX proteins are necessary to induce a 
senescence-like growth arrest (Kilbey et al. 2008).  RUNX genes are also playing 
a role in the regulation of genes that are intimately associated with tumour 
progression, invasion and metastasis including osteopontin, bone sialoprotein 
and matrix metalloproteinase. Again the role of Runx is highly isoform- and 
context- dependent: RUNX2 has been shown to promote invasiveness of breast 
and prostate cancer cells (Pratap et al. 2005), whereas RUNX3 expression 
inhibits metastasis of colon cancer cells (Peng et al. 2008) and decreases cell 
migration and invasion abilities of renal cell carcinoma cells (Chen et al. 2013).   
Runx genes are intertwined with major intercellular signalling pathways 
associated with animal development, each of which is also known to be hijacked 
during neoplastic transformation.  
TGFb signalling 
Transforming growth factor-β (TGFβ) signalling is a key pathway involved in 
various developmental programmes where it regulates multiple processes such 
as differentiation, proliferation, apoptosis and adhesion (Massagué 2012). 
Interestingly like Runx, the TGF-β pathway can play opposite roles as it serves to 
both inhibit the growth of many normal cells and induce highly malignant tumour 
processes such as EMT.  Multiple lines of evidence support cooperation between 
Runx and the two major branches of TGF-β superfamily: TGF-β and bone 
morphogenetic proteins (BMPs) (Ito & Miyazono 2003). All RUNX members 
interact with the SMAD transcription factors which are key effectors of the TGF-
β pathway. RUNX proteins physically interact with Smad2/3 acting on the TGF-β 
signalling pathway and cooperatively stimulating the synthesis of IgA (Pardali et 
al. 2000). In addition, the ability of RUNX3 to augment the TGF-β pathway is 
essential for its tumour suppressor role in gastric cancer since gastric 
hyperplasia in Runx3 knockout mice occurs, in part, through defective TGF-β -
mediated apoptosis (Li et al. 2002). In another example, RUNX2 interacts with 
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SMAD5 to perform critical roles in BMP-induced bone formation (Lee et al. 2000). 
RUNX2 can also regulate the expression TGF-β type I receptor (Ji et al. 1998). 
Wnt Signalling 
Wnt signalling is a key regulator of stem cell differentiation and maintenance in 
different systems (Cadigan & Peifer 2009). Interestingly several evidences, 
coming from different experimental models, are linking RUNX and Wnt 
signalling. In particular, in sea urchin embryos, Runt-1 expression promotes the 
expression of several Wnt genes (Robertson et al. 2008). In C.Elegans, Rnt-1 
collaborates with Wnt signalling to regulate asymmetric divisions in the T-blast 
stem-cell lineage (Kagoshima et al. 2007). In osteoblasts and chondrocytes Wnt 
signalling induces differentiation and activates RUNX2 where Wnt induces 
chondrocyte hypertrophy through RUNX2 upregulation (Dong et al. 2006) while 
during osteogenesis, RUNX2 is a direct target of β-catenin/TCF1 for the 
stimulation of bone formation (Gaur et al. 2005). Finally in the skin epithelium, 
RUNX1 is an activator of Wnt signalling since in vivo loss of RUNX1 results in a 
generalized decrease in LEF1 protein and in canonical Wnt signalling (Osorio et 
al. 2011). 
Notch signalling 
The Notch signalling pathway plays a key role in modulating cell fate decisions 
throughout the development of invertebrate and vertebrate species (Fortini 
2009). Studies in Zebrafish showed that Notch signalling activates RUNX1 
expression, which in turn drives haematopoietic stem cell and progenitor 
expansion (Burns et al. 2005). In Drosophila haemocytes (blood cells), where 
Notch promotes crystal cell differentiation, the RUNX protein Lozenge (Lz) 
directs Notch to activate a combination of target genes which drives cells into 
the differentiation programme (Terriente-Felix et al. 2013). In bone 
development, Notch signalling in bone marrow acts to maintain a pool of 
mesenchymal progenitors by suppressing osteoblast differentiation through HES 
or HEY proteins, which diminish RUNX2 transcriptional activity via physical 
interaction (Hilton et al. 2008). 
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The Hippo/MST2 pathway 
The Hippo/MST2 signalling pathway is a potent regulator of organ growth, and its 
deregulation leads to tumourigenesis (Zhao et al. 2010). Several studies have 
uncovered a crosstalk between RUNX and components of the Hippo pathway. 
YAP1 (Yes-associated protein), the main downstream target of the mammalian 
Hippo pathway, interacts with the PY motif of RUNX proteins via its WW domain 
(Yagi et al. 1999). Following this interaction, RUNX proteins recruit YAP1 to 
RUNX target promoters such as Osteocalcin, to stimulate transcription (Cui et al. 
2003). In addition, RUNX3 forms a complex with two other components of the 
Hippo/MST2 pathway, scaffold protein SAV1 and tumour suppressor LATS2 kinase 
and it is necessary for Hippo-mediated cell death (Min et al. 2012). 
1.5   RUNX genes in mammary development 
The first evidence of Runx expression in mammary tissue came from a Runx2 
knock-out mouse where expression of LacZ from the targeted allele was 
detected in the embryonic mammary epithelium (Otto et al. 1997).  Later work 
showed that RUNX2 is expressed in normal mammary epithelial, and some breast 
cancer, cell lines (Selvamurugan & Partridge 2000; Inman & Shore 2003). 
Moreover RUNX2 can directly regulate several mammary specific genes such as 
Osteopontin (Inman & Shore 2003) and Beta-casein (Inman et al. 2005). All three 
Runx genes were shown to be expressed in the adult mouse mammary epithelium 
with expression fluctuating during different stages of mammary development 
(Blyth et al. 2010). At the transcript level, Runx1 is the most abundant gene and 
all three Runx transcripts follow a similar pattern of expression in whole gland 
extracts; decreasing during late pregnancy and lactation and rising again during 
involution. These stage-specific fluctuations in transcript levels suggest that 
RUNX proteins undergo a specific spatial and temporal regulation in mammary 
epithelium, underlining a possible new role for these transcription factors in the 
context of mammary development. The expression of RUNX genes has also been 
investigated in MCF10A cells, a human mammary epithelial cell line derived from 
a basal-like fibrocystic disease; RUNX1 mRNA is 15 fold higher than RUNX2 while 
RUNX3 is undetectable (Wang et al. 2011). Interestingly, RUNX2 overexpression 
in the MCF10A cell line cultured in a 3D culture model disrupts normal acini 
development resulting in increased cell proliferation and hyperplasia  (Pratap et 
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al. 2009).  On the other hand, confirming the exquisite cell context dependence 
of RUNX genes, a different study showed that loss of RUNX1 in MCF10A resulted 
in hyperplastic acini (Wang et al. 2011). These results suggest key independent 
roles for both RUNX1 and RUNX2 in regulating normal mammary epithelium 
growth and homeostasis, however direct in vivo genetic evidence, through 
conditional knock-out or knock-in transgenic models is still lacking.  A study from 
our lab is the first to address this need (McDonald et al, submitted). Using a 
transgenic mouse model in which Runx2 is placed under the transcriptional 
control of an MMTV promoter (MMTV-Runx2 mouse) we have shown that ectopic 
Runx2 expression leads to a defect in alveolar development and lack of milk 
production in post-parturient transgenic mice.  Downstream analysis showed that 
Runx2 overexpression could block lactation through its negative effects on the 
prolactin signalling pathway as shown by downregulation of prolactin receptor 
and decreased pSTAT5 activation in MMTV-Runx2 lactating glands. These results 
suggest that RUNX2 is involved in the regulation of mammary alveolar progenitor 
differentiation in vivo. Moreover MMTV-Runx2 transgenic glands are 
characterized by delayed ductal elongation during virgin development and a 
reduction in tertiary side-branching in the mature gland. These results represent 
the first evidence of an in vivo role for a member of the RUNX transcription 
family in mammary tissue. A natural extension to these studies using conditional 
knock-out models has been addressed in this thesis. 
1.6   RUNX genes in breast cancer 
A growing body of evidence has linked RUNX genes with breast cancer (Ferrari et 
al. 2013; Chimge & Frenkel 2012).  The most studied RUNX gene in the context 
of breast cancer is RUNX2 while recent studies are also indicating a possible role 
for RUNX1 and RUNX3. The most compelling evidence linking RUNX1 to breast 
cancer comes from two recent sequencing studies which identified RUNX1 
somatic mutations in a small number of human breast cancer cases (Ellis et al. 
2012; Banerji et al. 2012). In addition RUNX1 was identified as a downregulated 
gene in a 17-gene signature associated with metastasis of adenocarcinoma 
nodules of diverse origin, including breast cancer (Ramaswamy et al. 2003). 
Decreased expression of RUNX1 was also detected in BC compared to normal 
breast epithelial cells, with a more pronounced decrease with increasing tumour 
invasiveness (Kadota et al. 2010). Finally,  RUNX1 silencing in MCF10A cells led 
72 
 
to the formation of hyperplastic acinar structures in 3D cultures (Wang et al. 
2011). There is however also studies suggesting a possible oncogenic role for 
RUNX1 in breast cancer (Janes 2011) which is discussed in greater detail in 
Chapter 6.   
In human breast cancers expression of RUNX3 decreases during human BC 
progression and reduced RUNX3 expression predicts worse survival, suggesting a 
putative tumour suppressive role for RUNX3 in BC (Jiang et al. 2008; Bai et al. 
2013). Moreover in vivo studies showed that 20% of Runx3 heterozygous knockout 
mice develop spontaneous ductal carcinoma at an average age of 14.5 months 
(Huang et al. 2012). However, as work from our laboratory is unable to detect 
Runx3 gene expression in purified mammary epithelial cells from normal mice 
(see Chapter 3) we question the role of Runx3 as a tumour suppressor in this cell 
lineage. As the study by Huang and colleagues use a constitutive knockout model 
it is possible that reduced gene dosage in the non-autonomous tissue (e.g. 
stroma) may promote tumourigenesis.  This discordance is somewhat mirroring 
the unsolved controversy about the possible tumour suppressive role of Runx3 in 
gastric and colorectal cancers (Ito et al. 2008; Li et al. 2002; Levanon et al. 
2011). Interestingly all these in vivo cancer studies are based on the same Runx3 
knock-out mouse (Li et al. 2002) and these results have not been confirmed by 
other laboratories (Levanon et al. 2003). Further studies are needed to clarify 
this discrepancy.  
While RUNX1 and RUNX3 have a supposedly tumour suppressor role in the 
mammary epithelium, evidence indicates that RUNX2 could have oncogenic 
properties in breast cancer. RUNX2 is upregulated in some human breast cancer 
cell lines compared to normal mammary epithelial cells (Lau et al. 2006; Inman 
& Shore 2003). In addition RUNX2 was identified as one of the most upregulated 
genes in a comparative transcriptomic analysis of invasive versus non-invasive 
breast cancer cell lines (Nagaraja et al. 2006).  Since the metastatic cell line 
MDA-MB-231 expresses high levels of RUNX2, much of the research published to 
date to understand the role of RUNX2 in breast cancer, focus on this in vitro 
model. RUNX2 inhibition in these cells results in a less invasive phenotype in 
vitro together with reduced osteolytic disease in vivo (Javed et al. 2005). 
Conversely RUNX2-negative MCF-7 cells become more invasive after RUNX2 
overexpression (Pratap et al. 2006; Leong et al. 2010).  Inhibition of RUNX2 in a 
73 
 
3D culture model reverted the disorganized structures formed by MDA-MB-231 
cells to a more normal phenotype resulting in formation of acinar-like structures 
(Pratap et al. 2009). RUNX2 deletion was also shown to inhibit tumour growth in 
mammary fat pad transplantations of MDA-MB-231 cells (Pratap et al. 2009). In 
line with these observations, RUNX2 regulates genes that are closely associated 
with tumour invasiveness, metastasis and angiogenesis, such as BSP, OPN, MMPs 
and VEGF (Pratap et al. 2005; Inman & Shore 2003; Javed et al. 2005; Barnes et 
al. 2003). Interestingly many of these RUNX2-dependent genes, seen to be 
upregulated in breast cancer cell lines, are also the same genes which are 
required for bone development and turnover (MMPs, RANKL, OPN, BSP) (Pratap 
et al. 2006).  This observation has led to the formulation of the ‘osteomimicry’ 
theory in which RUNX2-mediated expression of bone-specific genes confers 
osteoblast-like features to breast cancer cells allowing them to home and thrive 
in the bone microenvironment, leading to bone metastasis formation (Barnes et 
al. 2003). However the in vivo proof of this theory is still lacking and only a few 
in vitro studies support this hypothesis. During bone metastasis, breast cancer 
cells must induce osteoclast activity and block osteoblast differentiation in order 
to create a vital space in which to grow (Suva et al. 2011). Interestingly the 
ability of two breast cancer cell lines to inhibit osteoblast differentiation and 
enhance osteoclast differentiation is abrogated upon deletion of RUNX2 in in 
vitro  co-culture assays (Barnes et al. 2004).  Moreover, in the MDA-MB-231 
model, the RUNX2/CBF-β complex was shown to inhibit osteoblast 
differentiation through the induction of Sclerostin, a known inhibitor of bone 
formation (Mendoza-Villanueva et al. 2011).  Taken together these data are 
indicating RUNX2 as a key regulator of the invasive and metastatic potential of a 
few breast cancer cell lines in vitro. Recent publications have also linked RUNX2 
in primary breast cancer. In particular, our work and that of others has found 
expression of RUNX2 restricted to specific subsets of breast cancer.  In a study 
from Das and co-workers, nuclear RUNX2 expression was detected in 28% of 
breast tumours and this expression was significantly associated with ER/PR 
positive, Grade 2 tumours (Das et al. 2009).  However, this study is in contrast 
with other publications (McDonald et al. submitted; Khalid et al. 2008) which 
identified a positive association between RUNX2 and ER-negative disease. Meta-
analysis of gene expression in 779 breast cancer biopsies showed a negative 
correlation between the expression of ER and RUNX2 target genes (Khalid et al. 
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2008).   In a small TMA study, high RUNX2 expression was associated with worse 
clinical outcome, and this correlation was more marked in ER negative patients 
(Onodera et al. 2010), while unpublished data from our laboratory confirm the 
correlation between RUNX2 expression and ER negative patients in human breast 
cancer. Assessment of RUNX2 expression in a large tissue microarray constituted 
by 459 primary human breast cancers showed that high RUNX2 expression 
correlates with poor overall patient survival and ER negative tumours (McDonald 
et al. submitted). Supporting evidence of a role for RUNX2 in ER negative disease 
comes from in vitro analysis where high RUNX2 expression is found specifically in  
“basal-like” (ER-negative) cell lines, and not in those of a ‘luminal-like’ subtype 
(Lau et al. 2006). Confirming the negative correlation between RUNX2 and 
oestrogen, recent in vitro experiments showed that RUNX2 expression can 
decrease oestrogen-driven colony formation of breast cancer cells in soft agar 
colony assays (Chimge et al. 2012) while estradiol treatment antagonizes RUNX2-
induced EMT and invasiveness in vitro, in part through decreased expression of 
the EMT-inducer SNAI2 (Chimge et al. 2011).  
To conclude, the picture of RUNX genes in breast cancer is still far from 
complete and their dualistic role as oncogenes and tumour suppressors (Blyth et 
al, 2005), highlight their extreme context dependency. It is likely that each of 
the Runx proteins will play different, and even opposing, roles in different 
subtypes of breast cancers. Better characterization of RUNX function in small 
subgroups of breast cancer will hopefully translate into more targeted therapies 
which could greatly benefit subsets of patients.  
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Aims of the thesis 
 
The mammary gland is a complex secretory organ that undergoes dramatic 
changes during its entire development. In order to maintain such complexity, 
mammary gland development is a tightly controlled process that involves a wide 
variety of molecular regulators. A better understanding of the regulatory system 
involved in mammary development is needed to improve our knowledge of 
breast cancer initiation and progression. This could translate in the 
identification of new therapeutic targets for the treatment of this deadly 
disease. Accumulating evidence suggests a possible role for RUNX transcription 
factors in mammary gland development and in breast cancer. However this 
evidence is mainly coming from in vitro studies and no in vivo study has been 
carried out so far.  
The aim of the first part of this thesis was to determine the physiological role of 
Runx genes in normal mammary gland development through understanding the 
expression of Runx genes in the mammary epithelium and utilising an in vivo 
conditional deletion strategy to create Runx-specific knock-out in the mouse 
gland. 
Besides being key developmental regulators, Runx genes have recently emerged 
as major players in stem cell biology, coordinating cell-fate decisions and 
lineage differentiation. It was intriguing then that results achieved in the first 
part of this thesis suggested Runx expression may correlate with mammary stem 
cells.  Therefore the involvement of RUNX proteins in mammary stem cell 
physiology was investigated in Chapter 4 through a combination of in vitro 
(mammospheres, matrigel colony-forming assay) and in vivo assays.   
Finally, considering that genes involved in normal tissue development often take 
part in cancer initiation and progression, the role of RUNX1 and RUNX2 in breast 
cancer was characterized through a combination of in vitro and in vivo 
modelling as discussed in Chapter 5 and Chapter 6.  
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2 Materials & Methods 
 
 
2.1 Animals 
All animal work was carried out under UK Home Office guidelines in line with 
Animal (Scientific Procedures) Act 1986 and the EU Directive 2010. Experimental 
cohorts and breeding stocks were maintained for defined periods of time and 
health of animals was checked at least two times weekly. Animals were 
euthanized by cervical dislocation or by carbon dioxide (CO2) asphyxiation. 
Mouse ear notching and general maintenance (food, water and housing) was 
carried out by the Biological Services Unit at the Beatson Institute. Genotyping 
was carried out by Transnetyx, Inc. (Cordova, TN, US). 
2.1.1 Characterization of the Runx2flx/flx mouse model 
The Runx2flx/flx mouse was made in the lab of Professor Mike Owen by Theresa 
Higgins and Iain Rosewell, (ICRF labs, London) and characterised here. To 
generate Runx2flx/flx mice one loxP site was inserted in the intron 5' of exon 3 and 
a ploxPneo cassette in the intron 3' of exon 3 of the Runx2 gene. Exon 3 was 
chosen because that was the one encoding for the RUNX2 DNA binding domain 
(FIGURE 2-1-A). A gPCR on DNA extracted from the tail of Runx2flx/flx mice was 
carried out to amplify each loxP site using the following primers: loxP1 (F-
GACCTCCTCCCTACAGCTTCG) and R-CCCTCGCGTTTCAAGGTGCCG), loxP2 (F-
CAGCTGACAGCAGGTTGAAA; R-TGTCTGTTGTGCCCAGTCAT) and loxP3 (F-
TCGCTAACTTGTGGCTGTTG; R-TGGATGCTCTCAAAAAGGAAA).  The PCR products 
were purified from contaminants (primers, nucleotides, enzymes, salts and other 
impurities from DNA samples) with QIAquick PCR Purification Kit (Qiagen). Then 
the location and the integrity of the loxP sequences were confirmed through 
DNA sequencing of the PCR products (FIGURE 2-1-B). To confirm the 
recombination capability of the Runx2flx/flx mouse model, mouse embryonic 
fibroblasts (MEFs) from Runx2flx/flx and Runx2WT/WT embryos, were retrovirally 
transfected with a Cre-expressing plasmid (pBABE-Puro-Cre) or a control empty-
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vector (pBABE-Puro). After 5 days of selection in Puromycin (2µg/ml) transfected 
MEFs were harvested and Runx2 expression was assessed both at the RNA and at 
the protein level (FIGURE 2-2).  
2.1.2  Other mouse strains 
Runx1flx/flx mice (Growney et al. 2005), BLG-Cre mice (Selbert et al. 1998),and 
Z/EG reporter mice (Novak et al, 2000) have all been described previously.  K14-
Cre mice (Dassule et al. 2000) were obtained from The Jackson Laboratory.  
MMTV-PyMT (Guy et al. 1992) and MMTV-Her2 (Muller et al. 1988) tumour 
samples were obtained from mouse cohorts bred in our facilities. BLG-
Cre/Brca1flx/flx/p53+/- mouse tumour samples were kindly provided by Prof. Matt 
Smalley (European Cancer Stem Cell Research Institute, Cardiff). Apc1572T mouse 
tumour samples were kindly provided by Prof. Riccardo Fodde (Erasmus Medical 
Centre, Rotterdam). BLG-Cre/Ptenflx/flx Apcflx/flx mouse tumour samples and the 
Catnb+/lox(ex3) mouse model (Harada et al. 1999)  were kindly provided by Prof. 
Owen Sansom (Beatson Institute for Cancer Research, Glasgow). 
FVB wild type, SCID and CD1-nude mice were obtained from Charles River 
Laboratories (UK). 
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Figure 2-1   Characterization of the Runx2flx/flx mouse model. 
Schematic representation of the Runx2flx/flx mouse (exon3 genomic locus), with the relative 
position of loxP sequences and Neomycin cassette (neo) (A). Sequences of the three loxP sites as 
obtained from DNA sequencing (highlighted in yellow). The expected loxP sequence of 34bp is 
shown above (B). 
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Figure 2-2  Runx2 deletion after in vitro Cre-recombination. 
RT-PCR on MEFs extracted from Runx2flx/flx and Runx2WT/WT embryos and retrovirally transfected 
with a Cre-expressing plasmid (WT-Cre, Flx-Cre) or a control empty vector (WT-Puro, Flx-Puro). 
β-Actin was used as loading control (A). Western blot on cytoplasmic (C) and nuclear (N) extracts 
extracted from MEFs derived from Runx2flx/flx and Runx2WT/WT embryos; MEFs were retrovirally 
transfected with a Cre-expressing plasmid (WT-Cre, Flx-Cre) or a control empty vector (WT-Puro, 
Flx-Puro). Lamin A/C was used as a nuclear control. β-Actin was used as a total loading control 
(B). 
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2.2   Wholemount/histological analysis of mammary glands 
For wholemount analysis, inguinal mammary glands were dissected, air dried 
onto a glass slide and fixed in Carnoy’s (300ml 70% EtOH, 150ml chloroform, 50 
ml acetic acid).  Glands were rehydrated through ethanol and stained with 
carmine alum overnight.  Glands were dehydrated in increasing concentration of 
EtOH, cleared in xylene, mounted in Permount (Thermo Fisher) and captured 
with a Zeiss stereomicroscope.  For pregnancy samples the state of pregnancy 
was determined by checking vaginal plugs (as carried out by BSU staff). For 
involution studies a 7 day forced involution strategy was used where pups were 
standardised to 6, culled 7 d after parturition to initiate involution and the dam 
was taken at the selected time points. For histological analysis, adult mammary 
glands were dissected into 10% neutral buffered formalin and processed for 
haematoxylin and eosin (H&E) staining.  For histological analysis of embryonic 
mammary glands, the age of embryos were determined by checking vaginal 
plugs. Whole embryos were taken at the different time points and fixed into 
neutral buffered formalin for at least 1 week. Embryos were then cut 
transversally at the level of the 4th and 3rd mammary gland, embedded in 
paraffin blocks and serial sections were taken to identify the embryonic 
mammary duct tree. All histopathological processing was carried out by Mr. Colin 
Nixon and staff. 
2.3  In vivo imaging 
In vivo GFP imaging was carried out on freshly dissected mammary tissue. 
Briefly, gland #4 was dissected and spread onto a glass microscope slide. The 
gland was then imaged using OV-100 Imaging System (Olympus). 
CD-1 nude mice were injected with 106 cells/mouse in the tail vein (procedure 
carried out by Derek Miller). Metastatic growth was monitored weekly by in vivo 
luciferase imaging. Mice were anaesthetized with isofluorane and 
subcutaneously injected with 150 mg/kg of D-luciferin (PerkinElmer, US) in PBS. 
Bioluminescence images were acquired 5 min after injections, to allow the 
distribution of D-luciferin in the entire body of the animal, by using the IVIS 
Spectrum Imaging System (PerkinElmer, US). 
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2.4  Fat pad transplantation 
Single cell suspensions of freshly extracted mammary epithelial cells (see below) 
were re-suspended into a solution of PBS/25% Matrigel™ Matrix Phenol Red-Free 
(BD Biosciences, CAT 356237) at the desired concentration to allow a final 
injection volume of 10µl. Cells were injected using a 10µl Hamilton syringe 
(Hamilton, CH) into the inguinal fat pads of 3-week-old SCID females cleared of 
endogenous epithelium by surgical intervention. At the point of clearing, fat 
pads were mounted on a slide and stained for wholemount analysis to confirm 
the clearing of endogenous epithelium. The outgrowths were analysed 7 weeks 
after transplantation by GFP imaging (Leica M205 FA) and wholemount analysis 
(Zeiss Semi 2000-C). 
 
2.5  Cell lines 
Mouse embryonic fibroblasts from Runx2flx/flx and Runx2WT/WT embryos (previously 
extracted by Dr. Karen Blyth) were expanded in culture using DMEM (Gibco), 10% 
Fetal Calf Serum (FCS), 1% Pen/strep (Gibco) and 1% L-Glutamine (Gibco). 3SS 
(mouse leukaemia cell line) nuclear extracts (kindly provided by Prof. Ewan 
Cameron) were used as a negative control in RUNX1 western blots. MDA-MB-231-
luc-D3H2LN cells (kind gift of Dr Dan Croft) were grown in Hyclone MEM/EBSS 
media (Thermoscientific), 10% FCS; 1% MEM/NEAA (non-essential amino acid); 1% 
of Sodium Pyruvate; 1% Pen/strep and 1% L-Glutamine. MDA-MB-468, HCC-70, 
BT-549, T47D, MDA-MB-361 and BT-474 nuclear extracts were generated by 
Susan Mason.  hMEC-TERT cell line (a kind gift of Barbara Chaneton) was grown 
in HuMEC complete media (Gibco). All cell lines were grown in a Galaxy+ 
incubator (RS Biotech) at 37oC with 5% CO2. Cells were dissociated enzymatically 
and passaged using a solution of 0.05% trypsin (Gibco). 
2.5.1  Cell line transfections 
To generate RUNX2 stable knock-out, MDA-MB-231-luc-D3H2LN cells were 
transfected with 4 different RUNX2 Sh-RNAs and 1 scrambled control (HuSHTM, 
Origene) through electroporation using Nucelofector Kit V, program X-013 
(Amaxa, Lonza).  After electroporation, cells were allowed to recover for 24h 
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and then selected in puromycin selection media (1µg/ml) for 2 weeks. Selected 
cells were then FACS-sorted for GFP expression for at least three times to 
achieve maximum population purity. 
To generate RUNX1 overexpressing cells, hMEC-TERT were transfected with p-
BABE-Puro-Runx1 or p-BABE-Puro (kindly provided by Anna Kilbey) through 
electroporation using Nucelofector Kit V, program T-013 (Amaxa, Lonza). After 
electroporation, cells were allowed to recover for 24h and then selected in 
puromycin selection media (10µg/ml) for 2 weeks. 
2.5.2  Cell line assays 
2.5.2.1 2D Growth curve  
Cells were seeded in triplicate in 12 well plates (5x104 cells/well) and harvested 
at 24, 48, 72 and 96 hours. Cells were trypsinised and counted using the Trypan 
Blue (Life Technologies) exclusion method on haemocytometer.  
2.5.2.2 Tumourspheres 
Cells were dissociated enzymatically (Trypsin) and mechanically by pipetting to 
single-cell suspension and plated on nonadherent plates (Corning) at a 
concentration of 1000 cells/ml. Cells were grown in a serum-free Hyclone 
MEM/EBSS media (Minimal Essential Medium with Earle's, Thermoscientific) with 
1% Pen/strep and 1% L-Glut (Gibco) supplemented with B27® (Gibco), 20 ng/ml 
EGF (Sigma), 20 ng/ml b-FGF (Sigma), BSA 0.4% and 4 µg/ml Heparin (Sigma). 
Tumourspheres were grown for 7 days and colonies were counted under a bright 
field microscope. 
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2.6   Primary mouse mammary cells 
Mouse mammary epithelial cells (MMECs) were extracted from mammary glands 
of adult virgin mice (more than 12 weeks of age) unless otherwise specified. At 
least 2 mice x group were used for virgin analysis, 1 per group for other 
developmental stages. Glands #4 were dissected and the lymph node excised to 
avoid contamination with non-mammary cells; glands #2-3 were dissected 
avoiding the surrounding muscular tissue. Dissected glands were placed into 
50ml falcon tubes with cold 15ml DMEM (0% FCS, + Pen/Strep) and kept on ice. 
Then glands were finely minced using a McIlwain tissue chopper (Mickle 
Laboratories, UK) at maximum speed and force until a liquid slurry with white 
fat on the top was formed. The minced tissue was then transferred into a 50ml 
falcon tube and digested for 90 mins in 15ml of Collagenase (300 U/ml, Sigma) 
plus Hyaluronidase (100 U/ml, Sigma) solution in DMEM 0% FCS at 37˚C under 
shaking. Tubes were then spun down at 300g for 5 min, pellets were 
resuspended in 5ml DMEM 0% FCS and transferred to a 15ml falcon tube. After an 
additional centrifugation (300g for 5 min), pellets were incubated for 5min at RT 
in 2ml NH4Cl solution (0.8% in H2O) to eliminate red blood cells. The reaction 
was stopped with 3ml of DMEM 0%FCS and cells were spun down (300g for 5 min). 
After eliminating the supernatant, 2ml of TEG (0.25% trypsin and 1mM EGTA in 
PBS) plus 10% DNAse (1mg/ml in PBS, Worthington) were added to the pellet 
followed by serial pipetting to allow dissociation. The digestion solution was 
then incubated for 10 min at 37˚C in a water bath. After incubation all 
remaining DNA clumps were dissolved by pipetting or by additional DNAse 
treatment. The digestion was stopped by addition of DMEM 10% FCS followed by 
filtering with a 70µm filter to eliminate remaining clumps of tissue. After an 
additional centrifugation step (250g for 5 min) pellets were resuspended in the 
required final media. The single cell suspension was checked and counted using 
the Trypan Blue exclusion method on haemocytometer. 
2.6.1  Flow cytometry/cell sorting 
For mammary population profiling virgin mammary glands were dissected (at 
least 3 groups of n≥3 for Runx2flx/flx and Runx2WT/WT cohorts); for pregnancy, 
lactation and involution stages (at last 3 groups of n=1 for Runx2flx/flx and 
Runx2WT/WT cohorts).  Tissues were processed to obtain single cell suspensions of 
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mammary epithelial cells (see above). Cells were labelled with CD24- 
Phycoerythrin (PE) (1:200, BD Bioscience), CD29-PerCP-eFluor® 710 (1:100, 
eBioscience), CD31- Allophycocyanin (APC) (1:100, BD Bioscience) and CD45-APC 
(1:200, BD Bioscience) in preparation for flow cytometry (1h incubation on ice in 
the dark). DAPI (1:250, Sigma) was added to the samples at the end of antibody 
incubation, 5 minutes before analysis. For each day of FACS analysis, single 
labelled controls were prepared to confirm the gating strategy. Live Lin- cells 
(DAPI/CD31/CD45 negative) were gated on a BD FACSAria, doublet exclusion was 
sequentially performed for FSC (FSC-A vs FSC-H plot) and single cells were 
analysed to assess GFP+ populations in CD24hiCD29lo (luminal) and CD24hiCD29hi 
populations (basal/myoepithelial) using FlowJo software (FIGURE 2-3).  For cell 
sorting, CD24hiCD29lo and CD24hiCD29hi populations were collected and processed 
for RNA extraction and quantitative RT-PCR. The efficacy of the sorting strategy 
was confirmed by RT-PCR for a basal (CK5) and a luminal (CK18) marker (FIGURE 
2-4). 
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Figure 2-3   FACS gating strategy for mammary population profiling. 
Cells were first gated based on forward and size scatter to exclude debris (SSC-A/FSC-A). Alive 
cells were selected based on DAPI staining (DAPI/FSC-A). Blood and endothelial cells were 
excluded based on CD31 and CD45 staining (Lin-/FSC-A). Doublets and triplets were excluded 
based on forward scatter height vs area (FSC-H/FSC-A). Luminal and basal population were 
resolved based on CD24 and CD29 markers (CD24/CD29). % of GFP+ cells was assessed in the 
luminal and in the basal population (GFP+ Luminal and GFP+ Basal). 
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Figure 2-4  Validation of FACS sorting strategy. 
Luminal and basal populations from 6 weeks virgin FVB mice were sorted based on CD24/CD29 
expression. RNA was extracted from those populations and qRT-PCR was performed for a luminal 
(CK18) and a basal (CK5) marker. As expected CK18 was enriched in the luminal population, 
while CK5 was enriched in the basal one. 
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2.6.2  MMECs 2D cultures. 
Single cells extracted from 12 week old virgin mice were plated onto 6-well 
plates (3x105 cells seeded per well) and cultured in DMEM/F12 10% FCS with 
Pen/strep and L-Glut, supplemented with 10 ng/ml EGF (Sigma), 5 μg/ml Insulin 
(Roche) and 10 ng/ml Cholera Toxin (Sigma). For quantitative RT-PCR analysis, 
2D MMECs were dissociated enzymatically after 7 days and processed for RNA 
extraction. 
2.6.3  Mammospheres 
Single cells extracted from 12 week old virgin mice, were plated in ultra-low 
adherent 24-wells plates (Corning) at a density of 20,000 viable cells/ml for 
primary passage and 1000 cells/ml for second passage. Cells were grown in a 
serum-free medium DMEM/F12 with Pen/Strep and L-Glut (Gibco), supplemented 
with B27® (Gibco), 20 ng/ml EGF (Sigma), 20 ng/ml bFGF (Sigma), 0.4% BSA and 
4 μg/ml Heparin (Sigma). Growth factors were re-added fresh to the culture 
every 3-4 days. Plates were left untouched in the incubator to avoid cell 
clumping due to excessive manipulation. After 7 days, mammospheres were 
counted under a bright field microscope, collected by gentle centrifugation (200 
g for 5 minutes) and dissociated enzymatically (10 min in TEG at 37˚C in water 
bath) and mechanically, by pipetting. The cells obtained from dissociation were 
checked for single-cellularity, counted using the Trypan Blue exclusion method 
on haemocytometer and seeded again to generate secondary mammospheres. 
For quantitative RT-PCR analysis, mammospheres were processed for RNA 
extraction after 7 days. For histologic analysis, mammospheres were fixed on 
day 7 with 500 µl of 2% paraformaldehyde for 15 minutes. After centrifugation 
pellets were resuspendend in 150 µl of 3% UltrPureTM low-melting agarose 
(Invitrogen) and left for 20 minutes at room temperature to solidify. The agarose 
plug was then put into 70% EtOH and embedded in paraffin blocks. RUNX2 
staining (1:500 45 min at RT, Sigma) was carried out on mammosphere blank 
sections using citrate buffer antigen retrieval and standard IHC protocols (see 
below). For size measurement, primary and secondary mammospheres colonies 
were photographed with a bright field microscope (Olympus CKX41) after 7 days 
in culture and colony size was assessed using Axiovision software (Zeiss). 
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For adenoviral infection of mammospheres, MMECs single cell suspensions from 
Runx2flx/flx and Runx2WT/WT 12 week old virgin mice, were spin-infected with 
Ad5CMVCre-eGFP (Iowa University) (3.30 hours at 300g, RT; MOI=100) in 200 µl 
DMEM/F12 with 2% FCS, 20 ng/ml EGF (Sigma) and 20 ng/ml bFGF (Sigma). After 
infection, cells were seeded at 20,000 cells/ml in ultra-low adherent 24-well 
plates (Corning). After 7 days mammospheres were counted under a bright field 
microscope and processed for RNA extraction and quantitative RT-PCR.  
2.6.4  WNT3a treatments on mammospheres and 2D-MMECs 
For long-term WNT3a treatment, primary mammospheres (from 12 week old FVB 
virgin mice) were grown for 1 week in mammosphere media supplemented with 
50 ng/µl of recombinant  WNT3a (Sigma, SRP3259) or vehicle (H2O). After 7 days 
mammospheres were counted under a bright field microscope and processed for 
RNA extraction and quantitative RT-PCR. For size measurement, mammospheres 
colonies were photographed with a bright field microscope (Olympus CKX41) and 
colony size was assessed using Axiovision software (Zeiss) after 7 days in culture.  
For short-term WNT3a treatment, mammospheres and 2D-MMECs were grown for 
3 days in normal conditions. At day 4, 100ng/µl of recombinant WNT3a or vehicle 
(H2O) was added to the media and cells were processed for RNA extraction 24h 
after. 
2.6.5  Matrigel Colony forming assay 
Single cells extracted from 12 week old virgin mice were re-suspended in ice-
cold Growth-factor-reduced Matrigel (BD Biosciences, CAT 356237). 8000 
cells/well were seeded for primary Matrigel colony formation. 5000 cells/well 
were seeded for secondary Matrigel colony formation. A drop of 20 µl of 
Matrigel/cells was added in the centre of each well of a 24 well plate and the 
plate was returned to the incubator for 5 minutes to allow the Matrigel to 
solidify. 1 ml of DMEM/F12 with Pen/Strep and L-Glut supplemented with 20 
ng/ml EGF (Sigma) was added to each well. Fresh EGF was re-added to the 
culture every 3-4 days. After 7 days, Matrigel colonies were counted under a 
bright field microscope and dissociated enzymatically (10 min in TEG at 37˚C in 
water bath) and mechanically, by pipetting. The cells obtained from dissociation 
were checked for single-cellularity, counted using the Trypan Blue exclusion 
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method on haemocytometer and seeded again to generate secondary Matrigel 
colonies. For quantitative RT-PCR analysis, Matrigel colonies were processed for 
RNA extraction after 7 days. For histologic analysis, Matrigel colonies were fixed 
with 500 µl of 2% paraformaldehyde for 15 minutes on day 7. After 
centrifugation pellets were resuspendend in 150 µl of 3% UltrPureTM low-melting 
agarose (Invitrogen) and left for 20 minutes at room temperature to solidify. The 
agarose plug was then put into 70% EtOH and embedded in paraffin blocks. For 
size measurement, primary and secondary Matrigel colonies were photographed 
after 7 days in culture with a bright field microscope (Olympus CKX41) and 
colony size was assessed using Axiovision software (Zeiss). 
 
2.7  Immunohistochemistry 
Paraffin-embedded tissue sections were rehydrated before antigen retrieval 
using pH6 sodium citrate buffer (or 1mM EDTA pH8 for RUNX2).  After washing 
with Tris buffered saline and blocking endogenous peroxidase (Peroxidase 
blocking solution, DAKO), sections were incubated with the following HRP-
conjugated primary antibodies:  RUNX1 (Sigma HPA004176; 1/200 1h RT), RUNX2 
(Sigma HPA022040; 1/100 overnight at 4°C), β-Catenin (BD Bioscience, 610154; 
1/1000 1h RT), GFP (Abcam ab6556; 1/2000 overnight at 4°C). Anti-rabbit 
secondary (Dako EnVision) was used for all antibodies except for β-Catenin (anti-
mouse; Dako EnVision).  Sections were incubated with secondary antibodies for 1 
hour at RT, treated with DAB (Dako) and counterstained with haematoxylin. 
Images were captured using a Zeiss AX10 or an Olympus BX51 microscope. 
 
2.8  Immunofluorescence 
Paraffin-embedded tissue sections were rehydrated before antigen retrieval 
using pH6 sodium citrate buffer and permeabilized with incubation in 1% Triton® 
X-100 (T8787, Sigma) in PBS for 10 minutes. Slides were then blocked with a 
solution of 0.5% Triton® X-100 and 5% Goat Serum (DAKO, X0907) in PBS for 1h at 
RT. Primary antibodies were diluted in Dako REALTM Antibody Dilutent and 
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incubated on sections overnight at 4°C. Primary antibodies used were anti-
cytokeratin 8/18 (Fitzgerald 20R-CP004; 1/400), anti-GFP (Abcam ab6556; 
1/250), anti-CK14 (Abcam ab7800; 1/250). After washing with Tris buffered 
saline sections were incubated with Alexa 488 (goat-anti-rabbit-IgG), Alexa 594 
(goat-anti-mouse-IgG) and Alexa 647 (goat-anti-guinea pig-IgG) secondary 
antibodies (1:250 in PBS, Invitrogen) for 1 hr at room temperature. Slides were 
mounted using Vectashield mounting media with DAPI (Vector, H-1200). Confocal 
images were captured using a Zeiss 710 confocal microscope. 
 
2.9  Non quantitative PCR  
2.9.1 PCR determination of Runx2 status. 
To test the presence of the recombined Runx2 allele, genomic DNA was 
extracted using isopropanol precipitation. Samples were resuspended in 500 µl of 
chilled isopropanol to precipitate DNA. After centrifugation (16 rcf for 10 min at 
4˚C) the supernatant was poured off and 500 µl of 70% EtOH added to wash the 
DNA pellet. After an additional centrifugation (16 rcf for 5 min at 4˚C), the 
supernatant was poured off and samples were left to dry for 20 min. The final 
DNA pellet was resuspended in 100 µl of dH2O and dissolved at 37˚C for 15 min. 
A set of primers was then used to check for the recombination of the Runx2 
genomic locus; Flx probes: F-TCAGCTTTAGCGTCGTCAGA, R-CAAGCTAACGGG 
ACTTGGAA. WT probe: R-TGTCCGCCACCGCCAAG. PCR was performed in a 25 μl 
reaction mixture containing 12.5 μl of 2 x Reddymix  ThermoPrime Taq DNA 
Polymerase master mix (Thermo),  0.4 μM of each of the primers and 1 μl of 
DNA. The reaction mixture with added water instead of the DNA template was 
run as a negative control. The cycling conditions were as follows: 95°C for 3 
min, followed by 34 cycles of three steps consisting of denaturation at 95°C for 
30 s, primer annealing at 60°C for 30 s and extension at 72°C for 60s plus a final 
step of extension at 72°C for 10 min. PCR reactions were loaded onto a 2% 
agarose gel and bands visualized under a GelDoc-IT TS Imaging System (UVP, US). 
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2.9.2  PCR detection of Runx2 mRNA. 
RNA was isolated using a Qiagen RNeasy Mini Kit (Qiagen, UK) according to the 
manufacturer’s instructions and quantified using a Nanovue spectrophotometer.  
RNA was cleared from any DNA contamination with DNAse treatment and reverse 
transcribed to cDNA using Quantitect® Reverse Transcription Kit (Qiagen, 
205311). A PCR for genomic DNA was performed to confirm the purity of the 
cDNA obtained. RT-PCR was performed in a 25 μl reaction mixture containing 
12.5 μl of 2 x Reddymix  ThermoPrime Taq DNA Polymerase master mix 
(Thermo),  1 μM of each of the primers and 1 μl of cDNA. Primers used were 
Runx2 (F- AGAGGGCACAAGTTCTATCTG; R-GCTGTTGCTGTTGTTGCT) and β-Actin 
(F-     AGAGGGAAATCGTGCGTGAC; R-CAATAGTGATGACCTGGCCGT). The reaction 
mixture with added water instead of the cDNA template was run as a negative 
control. The cycling conditions were as follows: 95°C for 3 min, followed by 34 
cycles of three steps consisting of denaturation at 95°C for 30 s, primer 
annealing at 60°C for 30 s and extension at 72°C for 60s plus a final step of 
extension at 72°C for 10 min. PCR reactions were loaded onto a 2% agarose gel 
and bands visualized under a GelDoc-IT TS Imaging System (UVP, US). 
 
2.10   Quantitative RT-PCR 
RNA was isolated using a Qiagen RNeasy Mini Kit (Qiagen, UK) according to the 
manufacturer’s instructions and quantified using a Nanovue spectrophotometer.  
RNA was cleared from any DNA contamination with DNAse treatment and reverse 
transcribed to cDNA using Quantitect® Reverse Transcription Kit (Qiagen, 
205311).  SYBR Green based quantitative PCR was performed in triplicate in a 20 
μl reaction mixture containing 10 μl of 2 x SYBR®Green JumpstartTM Taq (Sigma, 
S4438) master mix,  0.5 μM of each of the primers and 5 μl of 10x diluted cDNA. 
The reaction mixture with water instead of the template was run as a control. 
The cycling conditions were as follows: 94°C for 2 min, followed by 40 cycles of 
two steps consisting of denaturation at 94°C for 15 s and primer 
annealing/extension at 60°C for 60s plus a final step of extension at 72°C for 5 
min. A melting curve analysis was performed from 70°C to 95°C in 0.3°C 
intervals to demonstrate the specificity of each amplicon and to identify the 
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formation of primer dimers. Data were acquired using an MJ Chromo4 (BioRad) 
and analysed using MJ Opticon Monitor 3 software (BioRad). The following 
primers were used: Runx1 (Qiagen Quantitect Assay QT0010000380), Runx2 
(Qiagen Quantitect assay QT00102193), Runx3 (F-GCA CCG GCA GAA GAT AGA 
AGAC; R-GGTTTAAGAAGCCTTGGATTGG), Axin2 (F-GCTCCAGAAGATCACAAAGAG; 
R-AGCTTTGAGCCTTCAGCATC), Hes1 (F-CAGGAGGGAAAGGTTATTTTGACG; R-TAG 
TTGTTGAGATGGGAGACCAGGCG), Slug (F-CTCACCTCGGGAGCATACA; R-GACTTAC 
ACGCCCCAAGGATG), p21 (F-CAAGAGGCCCAGTACTTCC; R-TGGAGTGATAGAA 
ATCTGTCAGG) and GAPDH (PrimerDesign kit).  All reactions were performed in 
triplicate, and expression was normalised to GAPDH.   
 
2.11  Western blot 
Nuclear extracts were prepared from mammary cell lines using NE-PER Nuclear 
and Cytoplasmic Extraction Reagents (Thermo Scientific, Cat No 78833) as per 
kit instructions. Briefly, addition of the first two reagents of the kit (CER1, 
CER2) to a cell pellet causes cell membrane disruption and release of 
cytoplasmic contents. After recovering the intact nuclei from the cytoplasmic 
extract by centrifugation, the nuclei are lysed with a third reagent (NER) to 
yield the nuclear extract. At least 15 micrograms of protein extract were 
resolved on 10% NuPAGE Novex Bis-Tris gels (Life Technologies) and transferred 
to Hybond-ECL nitrocellulose membranes (Amersham).  Membranes were probed 
with antibodies to RUNX1 (HPA004176, Sigma), RUNX2 (HPA022040, Sigma and 
R&D Systems, AF2006), GAPDH (Cell Signalling), β-Actin (Cell signalling), Lamin 
A/C (Cell Signalling), E-Cadherin (Cell Signalling), Vimentin (Sigma). 
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2.12  Human breast samples/tissue microarray 
All expression studies in human tissues were ethically approved (REC Ref: 
Project Number 02/SG007(10), R and D project: RN07PA001).  
Tissue microarrays used in the current study were kindly provided by Dr. Joanne 
Edwards who has given a brief outline of the procedure. 0.6 mm2 cores of breast 
cancer tissue, identified by the pathologist, were removed from representative 
areas of the tumour taken from breast cancer patients at the time of surgical 
resection.  All tissue microarray blocks were constructed in triplicate.  All 
patients were diagnosed with operable invasive breast carcinoma between 1980 
and 1999 in the Greater Glasgow and Clyde area.  These patients received 
standard adjuvant treatment according to protocols at the time of diagnosis.  
Patient follow-up details included information on clinical attendances, 
recurrence and metastasis, date and cause of death as well as adjuvant therapy 
details.  ER, PR (Mohammed et al. 2012), HER2 status (Mohammed et al. 2012), 
immune and inflammatory infiltrate (Mohammed et al. 2012) were already 
available for this cohort. The tissue microarrays were stained for RUNX1 protein 
by immunohistochemistry and quantified using the weighted histoscore method 
[(0 x % negative staining) + (1 x % weak staining) + (2 x % moderate staining) + (3 
x % strong staining)] to give a value of 0 – 300 (Kirkegaard et al. 2006). 
 
2.13  Statistical analysis 
Statistical significance (p<0.05) of differential findings between experimental 
groups was determined by a Student’s t test (unless otherwise specified) using 
Minitab or GraphPad software.  For the human studies SPPS-19 software was 
employed and disease-specific survival rates were generated using the Kaplan-
Meier method.  The log-rank test was used to compare significant differences 
between subgroups using univariate analysis.  Interrelationships between RUNX1 
expression and clinical parameters, hormonal status and inflammatory features 
were calculated using Cox-regression and chi square test. 
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3 Characterization of the RUNX genes in the 
mammary gland. 
 
 
3.1 INTRODUCTION 
 
3.1.1 RUNX proteins in mammary gland development.  
Given its first discovery as the “bone-master regulator” gene, most of the 
research on RUNX2 has been focused on its role in osteoblast lineage 
specification and regulation of bone development (Long 2011). Similarly most 
research on RUNX1 has been focused on its role in the haematopoietic system 
while RUNX3 has been mostly studied in the context of its role as a putative 
tumour suppressor in epithelial lineages and in neuronal development (Blyth et 
al. 2005).  However RUNX genes are expressed in a wide variety of tissues and 
cell types indicating possible new roles for these transcription factors in 
different systems (Blyth et al. 2010; Scheitz & Tumbar 2012). In particular 
several evidences coming from in vitro and in vivo studies are suggesting a new 
role for RUNX genes in mammary gland development (see Chapter 1). Briefly, all 
three RUNX transcripts have been shown to fluctuate during the different phases 
of mammary development, decreasing during pregnancy and lactation to rise 
again in involution (Blyth et al. 2010). In addition, RUNX2 regulates genes 
characteristic of mammary epithelial cells such as β-Casein and Osteopontin in 
the HC11 mammary cell line (Inman et al. 2005; Inman & Shore 2003). Moreover 
RUNX2 is likely to be expressed in normal murine mammary cells in the 
embryonic mammary gland (Otto et al. 1997) and it is enriched in the terminal 
end buds (TEB) of young pubertal mammary glands (Kouros-Mehr & Werb 2006). 
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3.1.2  Experimental Aims. 
So far the early lethality of RUNX knock-out animals has hindered the study of 
the role of those transcription factors in the mammary gland, an organ which 
mainly develops after birth. The aim of this study was to characterize the 
function of RUNX genes in mammary gland development through a combination 
of in vitro and in vivo loss of function approaches based on the use of RUNX-
specific conditional knock-out models.  
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3.2  RESULTS 
 
3.2.1  Characterization of RUNX expression in the normal 
mammary gland. 
To better understand the role of RUNX proteins in mammary gland development 
it is important to improve our knowledge of their normal physiological 
expression pattern in mammary epithelial tissue. The mammary epithelium is 
composed of two main lineages: luminal (ductal and alveolar) and basal cells 
(myoepithelial) (Richert et al. 2000). Recent advances in cell surface marker 
analysis through FACS allow the isolation of specific cell lineages from mouse 
mammary epithelium. In particular specific enrichment for the 
basal/myoepithelial or luminal compartment can be achieved by using a 
combination of cell surface markers (CD31, TER119 and CD45 to exclude 
haematopoietic and endothelial cells together with the epithelial markers CD24 
and CD29) (Shackleton et al. 2006). To investigate RUNX expression in the two 
main mammary lineages FACS sorting for luminal and basal populations was 
performed (see Material and Methods) on fresh-extracted mouse mammary 
epithelial cells (MMECs) from 6 week old mice. qRT-PCR on the sorted 
populations showed that Runx1 represents the more expressed isoform while 
Runx3 transcripts are expressed at very low levels or undetectable in both 
compartments (FIGURE 3-1-A). Moreover both Runx1 and Runx2 transcripts are 
enriched in the basal population which interestingly has been showed to be 
enriched in mammary stem cells (Shackleton et al. 2006). Since the pubertal 
virgin mammary gland at 6 weeks is an actively growing and expanding organ 
characterized by high numbers of TEBs, expression in the mature virgin 
mammary gland was also assessed.  qRT-PCR on FACS-sorted MMECs extracted 
from 12 week old mature virgin mice confirmed the expression pattern for all 
Runx isoforms as observed in the younger mice (FIGURE 3-1-B). From these 
results it was decided to concentrate future analysis on RUNX1 and RUNX2 
proteins, since they are the major RUNX proteins expressed in mammary tissue. 
To confirm RUNX1 and RUNX2 expression at the protein level, 
immunohistochemistry (IHC) was performed showing that both RUNX1 and RUNX2 
are indeed expressed in discrete subpopulations of mouse and human mammary 
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epithelium (FIGURE 3-2). RUNX1 and RUNX2 expression was then characterized 
during different phases of embryonic and adult mammary development. 
Interestingly RUNX1 and RUNX2 have the opposite pattern of expression during 
embryonic development, with RUNX2 being expressed specifically at embryonic 
day E12 while RUNX1 was apparent from E16 onwards (FIGURE 3-3). However, in 
adult mouse mammary development both RUNX1 and RUNX2 show a similar 
expression pattern, decreasing during pregnancy and lactation to rise again 
during involution (FIGURE 3-4) which confirms with what has been shown at the 
RNA level (Blyth et al. 2010). 
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Figure 3-3-1  Expression of Runx genes in mammary luminal and basal populations. 
The relative levels of Runx1, Runx2 and Runx3 mRNA measured by real-time RT-PCR on mouse 
mammary luminal and basal populations as sorted by FACS, based on expression of CD29 and 
CD24 surface markers. MMECs were extracted from 6 weeks (A) and 12 weeks (B) virgin FVB 
female mice. Data are expressed as mean relative expression (±SD). Runx1 is plotted on a 
different Y-axis due to the higher levels of expression.  Expression normalised to Gapdh is 
relative to luminal Runx2; each bar represents at least 3 separate experiments (3 independent 
groups of 3 mice each). 
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Figure 3-3-2    Expression of RUNX1 and RUNX2 in human and murine mammary gland. 
Immunohistochemistry for RUNX1 and RUNX2 on mouse and human virgin mammary epithelium. 
Sections were counterstained with haematoxylin. Scale bars represent 10 μm. 
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Figure 3-3   RUNX1 and RUNX2 expression in murine embryonic development. 
Immunohistochemistry for RUNX1 and RUNX2 on mouse embryonic mammary epithelium, taken 
at the selected timepoints (e.g. E12 is 12 days post-coitus). Sections were counterstained with 
haematoxylin. Scale bars represent 20 μm.  
  
101 
 
  
Figure 3-4  RUNX1 and RUNX2 expression in adult mammary development. 
Immunohistochemistry for RUNX1 and RUNX2 on adult mouse mammary epithelium, taken at the 
selected timepoints (12 week old virgin, d17 pregnancy, d1 lactation, d7 involution). Sections 
were counterstained with haematoxylin. Scale bars represent 30 μm. 
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3.2.2  Mammary specific deletion of RUNX1 and RUNX2 
To understand the functional role of Runx genes in mouse mammary gland 
biology in vivo and given the early lethality of RUNX knock-out animals, 
conditional knock-out mouse models for Runx1flx/flx (Growney et al. 2005) and 
Runx2flx/flx (unpublished, see Material and Methods for characterization) in 
combination with a mammary specific Cre recombinase (BLG-Cre) were used.  In 
those mice Cre DNA-recombinase is under the control of the mammary gland 
specific promoter of the ovine beta-lactoglobulin (BLG) gene. BLG-Cre is mainly 
activated during pregnancy and lactation and is commonly used as a specific Cre 
for targeting the mammary luminal lineage (Selbert et al. 1998). First BLG-Cre 
expression in the mammary gland was characterized using the Z/EG reporter 
mouse which utilises a lox-stop-lox GFP reporter cassette (Novak et al., 2000).  
In vivo GFP imaging on BLG-Cre:Z/EG+ mice showed consistent GFP expression in 
the mammary epithelium indicating that the transgenic models were working 
(FIGURE 3-5-A). To identify the mammary lineages which are targeted by BLG-
Cre expression, FACS mammary lineage profiling was performed using GFP 
expression as a tracker for BLG-Cre activation. Confirming published data 
(Molyneux et al. 2010), we found that BLG-Cre is mainly expressed in the virgin 
luminal population. However, a small but detectable percentage of the basal 
population in which BLG-Cre is active was also detected (FIGURE 3-5-B). 
Immunofluorescence was used to confirm this data showing double positive 
GFP+/CK14+ cells in BLG-Cre:Z/EG+ mice (FIGURE 3-5-C). This discrepancy with 
published data could be due to differences in mouse strains or the use of a more 
sensitive reporter gene compared to β-gal as used previously (Molyneux et al. 
2010). BLG-Cre expression was then characterized at different stages of 
mammary development confirming that Cre expression is activated during 
pregnancy and lactation and decreases during involution (FIGURE 3-5-D).  
  
103 
 
 
Figure 3-5  Characterization of BLG-Cre expression through the use of a GFP reporter. 
In vivo GFP expression as a surrogate for Cre expression in 12 week virgin BLG-Cre:Z/EG negative 
(a) and BLG-Cre:Z/EG+ (b) mice.  Scale bars represent 5 mm (A). Reporter GFP expression as 
analysed by FACS, gated on CD24+/CD29low luminal population (green) and CD24+/CD29high 
basal population (red) from 12 week BLG-Cre+:Z/EG+ mice. Data are expressed as % of GFP+ 
cells over total (±SD). 8 groups of 2 mice each analysed (B).  CK14 (red) and GFP (green) co-
immunofluorescence on mammary gland tissue from BLG-Cre+:Z/EG+ mice. Red arrow indicates 
a GFP+ (green) CK14+ (red) basal cell. Glands were counterstained with DAPI (blue). Scale bar 
represents 10 μm (C). Reporter GFP expression, as analysed by FACS, on total cells extracted 
from mammary glands of BLG-Cre+:Z/EG+ mice at different developmental stages (n=3 for each 
stage). Data are expressed as % of GFP+ cells over total (±SD) (D).  
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Using the RUNX conditional knock-out mice two mouse cohorts were generated: 
BLG-Cre:Z/EG:Runx1flx/flx and BLG-Cre:Z/EG:Runx2flx/flx (FIGURE 3-6-A). IHC on 
BLG-Cre Runx1flx/flx mice showed a reduction of RUNX1 protein expression in the 
adult virgin epithelium (FIGURE 3-6-B). Moreover PCR for Runx2 genomic locus 
on MMECs extracted from BLG-Cre Runx2flx/flx mice showed the presence of a 
recombinant band, indicating that an in vivo Cre-mediated deletion of the Runx2 
gene was occurring (FIGURE 3-6-C). These results confirm that the conditional 
knock-out strategy is working in vivo. 
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Figure 3-6   Characterization of Runx1 and Runx2 conditional knock-out mice. 
Schematic representation of the conditional knock-out strategy used to create a mammary-
specific deletion of Runx1 and Runx2 combined with a GFP reporter. The BLG promoter will drive 
Cre expression specifically in the mammary gland. In the target tissue Cre recombinase will drive 
recombination at the LoxP sites resulting in Runx1 or Runx2 loss. In addition Cre recombinase 
activity will cause loss of the LacZ cassette and activation of eGFP expression (A). 
Immunohistochemistry for RUNX1 on 12 weeks old virgin mammary epithelium from BLG-Cre 
Runx1WT/WT and BLG-Cre Runx1flx/flx mice. Scale bar represents 30 μm (B). PCR on gDNA extracted 
from BLG-Cre Runx2flx/flx MMECs and tail. In the BLG-Cre Runx2flx/flx MMECs (Flx Cre+) the 2 bands 
correspond to the recombined Runx2 locus (lower band) and the unrecombined cells (upper 
band). The size of the band in Runx2flx/flx cells is larger than the one from Runx2WT/WT because of 
the presence of LoxP sites (C). 
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No obvious phenotype was detectable in mature virgin mice (>12 weeks of age) 
from the two cohorts as assessed by whole gland analysis and histological 
analysis (FIGURE 3-7). However, the lack of phenotype in Runx deleted mice 
could be due to loss of recombined cells and re-population of the gland by wild 
type (unrecombined) cells. Furthermore, since BLG-Cre is only expressed in a 
small percentage of the virgin mammary epithelium (around 15% of mammary 
epithelial cells, Figure 1-5-D) the phenotype may be too mild to be observed at 
the histological level. To better analyse the recombinant glands, the fate of 
Runx-deleted cells was tracked in the mammary epithelium using the lox-stop-
lox GFP reporter cassette. FACS analysis of GFP expression levels in MMECs 
extracted from mature virgins of BLG-Cre Runx1flx/flx and BLG-Cre Runx2flx/flx 
females was performed. Interestingly both RUNX1 and RUNX2 loss caused a 
significant decrease in overall GFP levels compared to BLG-Cre+ Runx1WT/WT 
Runx2WT/WT (FIGURE 3-8).  Thus, RUNX1 and RUNX2 loss is impairing mammary 
epithelial cell maintenance in vivo. To determine if RUNX1 and RUNX2 are 
playing diverse roles in different mammary cell types, mammary population 
profiling through FACS using CD24 and CD29 cell surface markers, was performed 
to separate basal and luminal lineages. The GFP+ in each of the gated basal and 
luminal population is then used to specifically ascertain levels of RUNX-deleted 
cells. Interestingly loss of RUNX1 caused a reduction in GFP+ cells in the luminal 
compartment but did not affect the basal population (FIGURE 3-9-A, 3-9-B). In 
contrast BLG-Cre Runx2flx/flx mice showed a reduction in both basal and luminal 
GFP+ cells compared to BLG-Cre Runx2WT/WT mice (FIGURE 3-9-C, 3-9-D). These 
results suggest that RUNX1 and RUNX2 expression is important for maintenance 
of specific subpopulations of the virgin mammary epithelium in vivo.  
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Figure 3-7   Effects of loss of RUNX1 and RUNX2 in the virgin mammary gland. 
Wholemounts (A) and histological sections (B) of mammary gland from BLG-Cre RunxWT/WT, 
Runx1Flx/Flx and Runx2Flx/Flx mice extracted from 12 week virgin mice (n>7 for each genotype). No 
differences were detected between the three genotypes. Scale bars in (A) represent 1 mm. Scale 
bars in (B) represent 50 μm. 
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Figure 3-8   Effects of RUNX1 and RUNX2 loss in mammary epithelium in vivo. 
Reporter GFP expression as analysed by FACS, on cells extracted from whole mammary glands of 
12 week BLG-Cre RunxWT/WT, BLG-Cre Runx1Flx/Flx and BLG-Cre Runx2Flx/Flx mice. Data are 
expressed as % of GFP+ cells over total (±SD). n≥4 for each genotype. *p<0.05, Mann Whitney 
test. 
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Figure 3-9    Effects of RUNX1 and RUNX2 loss on luminal and basal populations in vivo. 
Reporter GFP expression as analysed by FACS, gated on CD24+/CD29low luminal population 
(green) and CD24+/CD29high basal population (red). MMECs were extracted from 12 week BLG-Cre 
Runx1Flx/Flx (A, B) and BLG-Cre Runx2Flx/Flx (C,D) mice and compared to the BLG-Cre RunxWT/WT 
cohort . Data are expressed as % of GFP+ cells over total in the selected population (±SD). n≥4 
for each stage. *p<0.01, Mann Whitney test. 
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To investigate if Runx2 is involved at different stages of mammary development 
the BLG-Cre Runx2flx/flx cohort was analysed during the lactation cycle. 
Conditional Runx2 knock-out mice do not have any obvious defect during 
pregnancy and lactation and they can lactate and nurse their pups as normal. 
FACS analysis of GFP expression levels in MMECs extracted from different phases 
of the lactation cycle of the BLG-Cre Runx2flx/flx mice showed no difference in 
GFP levels compared to BLG-Cre Runx2WT/WT mice (FIGURE 3-10). This result 
shows that RUNX2 is not necessary for the process of alveolar differentiation and 
milk production in vivo. Further work is currently focusing on the 
characterization of the effects of RUNX2 loss on the involution process and on 
the analysis of RUNX1 during the different phases of the lactation cycle.  
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Figure 3-10  Effects of in vivo Runx2 deletion during the lactation cycle. 
Reporter GFP expression, as analysed by FACS, on total mammary gland cells extracted from 
BLG-Cre Runx2WT/WT (green) and BLG-Cre Runx2Flx/Flx (blue) mice at different developmental 
stages. Data are expressed as % of GFP+ cells over total (±SD). n≥3 for each stage. *p<0.05, Mann 
Whitney test. 
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3.2.3  Effects of combined deletion of Runx1 and Runx2 on virgin 
mammary development. 
All three RUNX transcription factors bind to the same DNA sequence and some 
cross-regulation between different RUNX family members has been found in the 
haematopoietic system (Spender et al. 2005). Hence some redundancy could also 
occur in the mammary gland where RUNX1 and RUNX2 follow a similar pattern of 
expression. To avoid any compensatory effect of single RUNX deficiency in vivo, 
a double knockout mouse BLG-Cre:Runx1flx/flx:Runx2flx/flx was generated. No 
obvious phenotype was detectable in young virgin females from this cohort 
(FIGURE 3-11). FACS analysis of GFP expression levels was then performed in 
MMECs extracted from mature virgins from BLG-Cre:Runx1flx/flx:Runx2flx/flx mice. 
Interestingly combined loss of both Runx1 and Runx2 rescued the significant 
decrease in overall GFP levels caused by the single knock-outs (FIGURE 3-12). To 
understand the cellular dynamics underlying this rescue mammary population 
profiling through FACS was performed using GFP+ cells as a marker for deleted 
cells. The percentage of GFP+ cells in the luminal compartment was reduced in 
the double knock-out gland compared to BLG-Cre RunxWT/WT mice, a similar 
phenotype to the single Runx1 and Runx2 knock-outs (FIGURE 3-13-A). However, 
the basal population was significantly affected in the double knock-out gland 
with a 5-fold increase in the GFP+ basal population (FIGURE 3-13-B). GFP and 
CK14 co-immunofluorescence confirmed the increase in basal GFP expression in 
the BLG-Cre:Runx1flx/flx:Runx2flx/flx glands (FIGURE 3-14-A). Interestingly the 
overall pattern of GFP expression in the double knock-out mice showed a drastic 
change with appearance of many ducts with high basal GFP positivity and ducts 
showing GFP expression only in the basal layer (FIGURE 3-14-B). This result 
shows that combined loss of RUNX1 and RUNX2 is causing a deregulation in 
normal homeostasis of mammary lineages driving an expansion of the basal 
population.  
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Figure 3-11   Effects of combined loss of RUNX1 and RUNX2 in the virgin mammary gland. 
Representative wholemounts (A) and histological sections (B) of mammary gland from BLG-Cre 
RunxWT/WT and BLG-Cre:Runx1Flx/Flx:Runx2Flx/Flx mice extracted from 12 week virgin mice (n>7 for 
each stage). No differences were detected between the two genotypes. Scale bars in (A) 
represent 1 mm. Scale bars in (B) represent 50 μm. 
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Figure 3-12  Effects of combined loss of RUNX1 and RUNX2 in mammary epithelium in vivo. 
Reporter GFP expression as analysed by FACS, on total mammary gland extracted from 12 week 
BLG-Cre Runx1Flx/Flx, BLG-Cre Runx2Flx/Flx, BLG-Cre:Runx1Flx/Flx:Runx2Flx/Flx mice, compared to the 
BLG-Cre RunxWT/WT cohort. Data are expressed as % of GFP+ cells over total (±SD). n≥4 for each 
stage. *p<0.05, Mann Whitney test. No significance was found comparing the double knock-out 
with the single knock-out cohorts. 
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Figure 3-13   Combined loss of RUNX1 and RUNX2 on luminal and basal populations in vivo. 
Reporter GFP expression as analysed by FACS, on CD24+/CD29low luminal population (A) and 
CD24+/CD29high basal population (B). MMECs were extracted from 12 week BLG-Cre Runx1Flx/Flx, 
BLG-Cre Runx2Flx/Flx, BLG-Cre:Runx1Flx/Flx:Runx2Flx/Flx mice and compared to the BLG-Cre 
RunxWT/WT cohort. Data are expressed as % of GFP+ cells over total in the selected population 
(±SD). n≥4 for each stage. In graph A, *=p<0.05, **=p<0.01 when compared to the WT/WT. In 
graph B, *=p<0.005 when compared to the WT/WT, Mann Whitney test. No significance was found 
comparing the double knock-out with the single knock-out cohorts in the luminal compartment. 
The double knock-out was statistically different from the single knock-out cohorts in the basal 
compartment. p<0.02, Mann Whitney test.  
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Figure 3-14  Changes in GFP reporter expression in RUNX1-RUNX2 double knock-out glands. 
CK14 (red) and GFP (green) co-immunofluorescence on mammary glands extracted from BLG-
Cre+ RunxWT/WT and BLG-Cre+Runx1Flx/FlxRunx2Flx/Flx mice. Glands were counterstained with DAPI 
(blue). Representative images shown. Scale bars represent 50 μm (A). Bar chart showing the 
distribution of GFP+ cells in BLG-Cre+ RunxWT/WT and BLG-Cre+ Runx1Flx/Flx Runx2Flx/Flx mice as 
determined by GFP IHC (n=4 per each genotype) (B). 
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To determine the long term effects of the population imbalance caused by 
Runx1 and Runx2 single and double deletion, cohorts of BLG-Cre Runx1flx/flx, 
BLG-Cre Runx2flx/flx  and BLG-Cre:Runx1flx/flx:Runx2flx/flx mice were aged to 6 
months and compared to a BLG-Cre wild-type cohort. Histological analysis 
showed an increase in alveolar structures in the double knock-out glands 
compared to wild-type and single knock-outs (FIGURE 3-15). Moreover 33% of 
double knock-out mice develop rare lesions in the mammary gland compared to 
none of the controls or the single Runx-deleted models (Chi square test 
p=0.0089) (Figure 3-16-A). Histological analysis showed that all lesions are 
hyperplastic intraductal preneoplastic lesions, characterized by nuclear atypia, 
squamous metaplasia or necrosis in the middle combined with an abundant 
immune reaction (Figure 1-16-B).  
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Figure 3-15  Double deletion of RUNX1 and RUNX2 causes alveolar hyperplasia in virgin mice. 
Representative examples of alveolar structures detected in wholemounts (A) and histological 
sections (B) of mammary glands extracted from 6 month virgin mice from the BLG-Cre:Runx1 
Flx/Flx:Runx2Flx/Flx  cohort. Scale bar in (A) represents 200 μm. Scale bar in (B) represents 25 μm. 
Scatter plot showing the number of alveolar clusters per gland detected in 6 month old BLG-Cre  
Runx1Flx/Flx, BLG-Cre Runx2Flx/Flx, BLG-Cre:Runx1Flx/Flx:Runx2Flx/Flx mice, compared to the BLG-Cre 
RunxWT/WT controls. Mice (n≥6 per group) were oestrous matched (metestrous-diestrous) through 
vaginal smear (C). Alveolar clusters per gland were counted under a bright-field microscope on 
an H&E section. * = p<0.05. t-test with Welch’s correction. 
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Figure 3-16   Double deletion of Runx1 and Runx2 causes pre-neoplastic lesions in virgin 
mice. 
Table showing the incidence of preneoplastic lesions found in the 6 month aging cohort (number 
of mice with detectable preneoplastic lesions, total number assessed in brackets). Chi square 
test p=0.0089 (A). H&E stained examples of lesions developed by BLG-Cre:Runx1Flx/Flx:Runx2Flx/Flx 
mice (B). 
 
 
 
 
120 
 
3.3 DISCUSSION 
The results presented in this chapter represent an answer to the unmet need of 
better characterization of RUNX expression in normal mammary development. 
Increasing the basic understanding of the role of Runx genes in the regulation of 
normal mammary epithelial homeostasis will expand the knowledge of the 
molecular controls acting in this tissue and would hopefully translate into new 
possible biomarkers or targeted therapies for breast cancer treatment.  
Studies on FACS purified mammary epithelial cells investigate for the first time 
expression of Runx genes in enriched populations of mammary epithelial cells. 
These findings demonstrate that Runx1 is the main expressed Runx transcript 
while Runx2 levels are around 50 fold lower. Moreover Runx3 transcript is not 
detectable in the purified mammary populations. Supporting this pattern of 
expression, IHC on mouse and human mammary epithelium showed high 
widespread levels of RUNX1 staining, while RUNX2 was expressed at lower levels 
in discrete subpopulations of luminal and basal cells. RUNX3 expression could not 
be assessed due to the lack of good specific antibodies for IHC.  However given 
the absence of detectable Runx3 RNA in the mammary epithelium it seems 
unlikely that any protein can be translated. Interestingly, confirmation of this 
pattern of expression comes from another study of qRT-PCR on MCF10A cells, a 
human mammary epithelial cell line derived from a basal-like fibrocystic 
disease, where a similar pattern of Runx expression with RUNX1 mRNA being 15 
fold higher than RUNX2 and undetectable levels of RUNX3 was found (Wang et 
al. 2011). However, the lack of detectable Runx3 expression in normal mammary 
epithelial cells is conflicting with some published observations. Firstly this 
differs with the expression pattern published by Blyth and colleagues (Blyth et 
al. 2010) which indicates that all three Runx genes are expressed in the adult 
mouse mammary gland. However this study was based on qRT-PCR analysis on 
whole mammary extracts where contamination with non-epithelial cells, like 
stromal, immune and endothelial cells would be expected.  Secondly, some 
reports have indicated Runx3 as a tumour suppressor in breast cancer. In 
particular one study shows that about 20% of female Runx3(+/-) heterozygous 
mice spontaneously developed ductal carcinoma at an average age of 14.5 
months (Huang et al. 2012). However the authors failed to provide convincing 
evidence of Runx3 expression in normal mammary epithelium. Thus the 
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phenotype observed could be caused by the effects of Runx3 haploinsufficiency 
on non-epithelial stromal components of the mammary gland.  
Another interesting data coming from our analysis of FACS purified mammary 
populations is the finding that both Runx1 and Runx2 are enriched in the 
mammary basal population: a lineage which has been shown to be enriched in 
mammary stem cells (Shackleton et al. 2006). Moreover several proteins which 
have been found enriched in the basal population (such as SLUG, β1-Integrin, 
LGR5) have also been found to play a role in the regulation of mammary stem 
cells (Plaks et al. 2013; Guo et al. 2012; Taddei et al. 2008). So it is tempting to 
speculate an involvement for Runx1 and Runx2 in the mammary stem cell 
population. The characterization of Runx1 and Runx2 in mammary stem cells will 
be discussed in the next chapter. 
Our studies characterize for the first time RUNX1 and RUNX2 protein expression 
during mouse mammary gland development. Focusing on embryonic mammary 
development, expression of RUNX1 and RUNX2 seems to follow an opposite 
pattern of expression. Mouse embryonic mammary development starts around 
embryonic day 10 (E10) with the formation of the milk line, a slight thickening of 
the ectoderm which at E11.5 develops into individual placodes which sink deeper 
into the dermis (Robinson 2007). This phase of mammary embryonic 
development, between E10 and E13, is when the growing epithelium acquires its 
identity as mammary tissue (Wansbury et al. 2011). Interestingly RUNX2 
epithelial expression is detectable specifically at E12 and is then turned off. This 
result indicates that RUNX2 could play a role in the early specification of the 
mammary lineage. Between E13 to E15, the bud undergo a period of relative 
quiescence, to then start proliferating again at E15.5 when the primary sprout 
starts invading the mammary mesenchyme towards the fat pad. At E18.5 the 
elongating duct has grown into a small rudimental ductal system (Cowin & 
Wysolmerski 2010). These last stages of mammary embryonic development, 
going from E16 to E18.5, are the ones characterized by RUNX1 expression. This 
pattern would suggest that RUNX1 is not involved in early mammary epithelium 
specification. Hence its expression could mark an embryonic population of 
mammary epithelial cells which have already acquired their lineage 
specifications. Further investigations are needed to investigate the functional 
role of RUNX1 and RUNX2 in mammary embryonic development.  
122 
 
Focusing on RUNX1 and RUNX2 protein expression in the adult mammary gland, 
RUNX1 IHC showed that this protein is widely expressed at high levels in the 
adult mammary epithelium. On the other hand, RUNX2 expression is confined to 
specific subpopulations of luminal and basal cells which are scattered in 
mammary epithelium. Moreover the RUNX2 positive population greatly varies 
between different areas of the same mammary gland and between mammary 
glands extracted from different mice, suggesting waves of expansion and 
contraction of RUNX2 positive cells. This dynamic pattern of expression is 
reminiscent of the cycling changes which characterize the mammary gland tissue 
during the oestrous cycle. Thus it is tempting to speculate that the spatial and 
temporal regulation of RUNX2 in adult mammary epithelium could be linked to 
the oestrous cycle: interestingly preliminary results from our laboratory seem to 
indicate an increase in RUNX2 expression during metestrous and diestrous (data 
not shown). This phase of the oestrous cycle is characterized by an increase in 
progesterone levels together with WNT-4 which are driving the branching 
expansion characteristic of that stage (Brisken et al. 2000).  So RUNX2 
expression could mark a highly dynamic progenitor subpopulation of the adult 
mammary epithelium which could undergo expansion in the second phase of the 
oestrous cycle and could participate in the formation of secondary and tertiary 
branching. Further experiments using ovariectomized mice treated with single 
injections of oestrogen and progesterone to induce a controlled oestrous cycle 
are needed to investigate the possible link between RUNX2 expression and 
oestrous cycle. Focusing on RUNX1 and RUNX2 expression during the lactational 
cycle, both genes were found to follow a similar pattern of expression, dropping 
during pregnancy and lactation to rise again in involution. Interestingly RUNX1 
and RUNX2 expression are at the lowest during the highest differentiated phases 
of mammary gland development (pregnancy and lactation) where the majority of 
the mammary gland is comprised of alveolar cells. This data suggests that RUNX 
genes need to be turned off to allow a complete alveolar differentiation 
program. The in vivo proof of this concept can be found in the phenotype 
observed in transgenic mice overexpressing RUNX2 under a luminal promoter 
(MMTV-Runx2). These mice showed impaired lactation capability due to a block 
in alveolar differentiation as showed by lack of functional alveolar structures 
and terminal differentiation markers such as WAP and β-Casein (McDonald et al, 
submitted).  
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To study the role of RUNX1 and RUNX2 in the mammary epithelium we adopted a 
combination of conditional RUNX knock-out models targeted to the mammary 
epithelium. No overall effects after deletion of both RUNX1 and RUNX2 were 
observed in the mammary epithelium. The lack of a gross detectable phenotype 
is not surprising considering that BLG-Cre is only acting in a small percentage of 
mammary epithelial cells at the virgin stage. Moreover Cre expression in this 
model peaks during pregnancy and lactation, stages where the maximum amount 
of recombination is achieved, but which are both characterized by lack of 
expression of RUNX proteins. To achieve a better recombination in the virgin 
mammary gland, our lab is currently generating conditional knock-out models 
using a different mammary specific Cre (MMTV-Cre) (Wagner et al. 2001). This 
model will help identify any possible gross defects after RUNX loss in the virgin 
stage. The use of a genetic marker (GFP expression) to trace the fate of RUNX-
deleted cells in vivo allowed us to show for the first time the requirement for 
both RUNX1 and RUNX2 in normal mammary epithelial maintenance. In fact both 
loss of RUNX1 and RUNX2 caused a reduction of overall GFP levels in the virgin 
mammary gland. Moreover focusing on mammary populations, individual loss of 
either RUNX1 or RUNX2 caused a decrease in GFP positivity in the luminal 
compartment. However, only RUNX2 deletion caused a reduction in GFP+ cells in 
the basal layer, suggesting a possible specific role for RUNX2 in this population. 
The mechanism underlying the loss of RUNX-deleted cells is still unknown. 
However the most likely explanation could be induction of quiescence and block 
of the cell cycle after loss of Runx genes. RUNX proteins are well known 
regulators of the cell cycle in different systems: for example, in vitro studies 
showed that RUNX1 stimulates the G1 to S phase transition in haematopoietic 
cells (Strom et al. 2000) and RUNX2 acts as transcriptional repressor of the 
p21Cip1/Waf1 cyclin-dependent kinase inhibitor (Westendorf et al. 2002). In 
vivo studies also showed evidence of a link between RUNX and quiescence where 
in the adult skin RUNX1 promotes hair follicle stem cell proliferation through 
repression of negative cell cycle regulators such as p21, p27, p57, and p15 (Lee 
et al. 2013).  In our model, a block in the cell cycle would be sufficient to cause 
a decrease of GFP populations in long term maintenance. In particular while the 
RUNX wild-type cells will keep dividing and growing in number, the RUNX-
deleted quiescent population will be slowly diluted down and the mammary 
gland will be repopulated by non-recombined cells. Transcriptional profiling of 
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sorted GFP+ populations from the Runx knock-out mice would help to clarify the 
molecular mechanisms underlying loss of RUNX-deleted cells in the virgin 
mammary gland. It should be acknowledged that the use of reporter mice to 
track the fate of conditional-deleted cells may bring some intrinsic flaws as 
shown by work from Anton Berns’ lab. Here the existence of marked differences 
in the recombination frequencies of different loci within the same cell was 
demonstrated (Vooijs et al. 2001). A different frequency of recombination at the 
GFP locus compared to the Runx locus cannot be ruled out in the models 
presented in this chapter. To prove the efficiency of GFP reporter expression as 
direct readout for in vivo RUNX deletion, freshly sorted GFP+ populations could 
be tested for recombination at the RUNX locus by genomic PCR.  
To avoid any compensatory effect of single Runx gene deficiency in vivo, a 
double Runx1-Runx2 knockout mouse was generated. This model is characterized 
by the appearance of gross phenotypes detectable both in mature virgins and 
aging cohorts indicating that compensation between RUNX isoforms is happening 
in the single knock-out models.  The first striking phenotype of the double 
Runx1-Runx2 knockout mouse is the rescue of overall GFP positivity in Runx1-
Runx2 knock-out glands: this is not caused by a rescue in the luminal population 
but it is caused by a 5 fold specific expansion of the basal population.  
Immunofluorescence showed that GFP+ basal cells maintain their normal 
localization as a single layer surrounding the duct suggesting that those cells are 
not transformed. This result indicates Runx genes as new key regulators of the 
basal population.  However, the overall picture of the role of Runx1 and Runx2 
in the mammary basal population is not clear: in fact both Runx1 and Runx2 are 
enriched in the basal lineage but only loss of Runx2 leads to a decrease in the 
basal population. Moreover combined loss of Runx1 and Runx2 causes basal cell 
expansion. Those results could be explained taking in account the vast array of 
isoform specific cofactors which are required for RUNX-mediated transcriptional 
control. In speculation RUNX2, but not RUNX1, may be a key regulator of 
proliferation of a mammary basal subpopulation and it does so cooperating with 
an unknown transcriptional cofactor which we can call cofactor-X. In a normal 
gland RUNX2 and cofactor-X cooperate and control the growth of a basal 
subpopulation.  After loss of RUNX1, as a compensatory effect, RUNX2, which is 
usually expressed at lower levels than RUNX1, is upregulated together with 
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cofactor-X. Then the complex RUNX2-cofactor-X compensates for RUNX1 loss 
keeping basal cell growth under control. In the scenario of loss of RUNX2 
instead, cofactor-X will not be transcribed in basal cells. RUNX1 will then try to 
compensate RUNX2 loss but, since cofactor-X is not translated, RUNX1 will not 
be able to maintain normal basal cell homeostasis and it will drive a different 
transcriptional program resulting in a block of proliferation or induction of 
quiescence. In the case of combined loss of RUNX1 and RUNX2 instead, basal 
cells lose all key controllers of cell proliferation (RUNX2, cofactor-X and RUNX1) 
leading to an expansion and uncontrolled growth of that subpopulation. In 
another scenario, the luminal lineage could be the one responsible for the 
expanded basal subpopulation: combined loss of RUNX1 and RUNX2 could start a 
dedifferentiation program pushing luminal cells into the basal lineage. It will be 
interesting to investigate the actual mechanism for this phenotype further. 
At 12 weeks of age double Runx1-Runx2 knockout mice showed no gross 
abnormality. However more severe phenotypes started to appear when mice 
were aged for 6 months.  The first detectable phenotype was an increased 
alveolar hyperplasia. Alveolar hyperplasia is the most common preneoplastic 
lesion in mouse mammary glands (Medina 2002), characterized by appearance of 
foci of hyperplastic lobuloalveolar development in a virgin mammary gland. 
Activation of several oncogenes such as CyclD1, Wnt1 and Tnf, have been found 
to cause alveolar hyperplasia in the mouse mammary gland. Moreover Runx1-
Runx2 knockout mice also develop rare preneoplastic lesions characterized by 
elements of necrosis, squamous metaplasia and extensive inflammation and 
stromal cell recruitment. The rarity of these lesions is not surprising considering 
the low amount of recombination achieved by BLG-Cre in the virgin mammary 
gland. The downstream molecular causes underlying alveolar hyperplasia and 
preneoplastic lesions development are currently under investigation. However 
the squamous metaplastic appearance of some of the lesions would suggest an 
involvement of Wnt signalling, whose activation has already been shown to cause 
extensive squamous metaplasia in the mammary gland (Miyoshi, Shillingford, et 
al. 2002). Further experiments will help to clarify the underlying mechanism of 
preneoplastic lesion formation after Runx1 & Runx2 loss. In particular fat pad 
transplantation of FACS sorted basal GFP+ cells from the double Runx1-Runx2 
knockout mice will test the ability of Runx-deleted cells to regenerate an entire 
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mammary epithelium and will clarify the oncogenic potential of this population. 
Moreover double Runx1-Runx2 knockout mice will be crossed with transgenic 
lines carrying oncogenes (Myc, Wnt) targeted specifically to the mammary gland. 
These models will test the tumour suppressor/oncogenic role of Runx isoforms in 
the context of breast cancer and how different oncogenic signalling pathways 
can affect this behaviour. 
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4 A new role for RUNX2 in mammary stem 
cells 
 
 
4.1  INTRODUCTION 
 
4.1.1  Runx genes and stem cells. 
An exciting role for RUNX proteins in stem cell biology has emerged recently 
from different studies using diverse animal models, from sea urchins to 
mammals (Braun, 2009). In invertebrate systems, which represent a good 
simplified model for the study of basic developmental processes, Runx genes are 
involved in several processes linked to stem cell regulation and homeostasis;  in 
particular RUNX proteins have been found to play key roles in stem cell 
maintenance, lineage differentiation and organ regeneration in Planarians, 
C.elegans and Drosophila (Kagoshima et al. 2007; Braun & Woollard 2009; 
Wenemoser et al. 2012).  Additional studies are unveiling a role for RUNX 
transcription factors in stem cell biology in different mammalian systems such as 
haematopoietic stem cells, hair follicle stem cells and mesenchymal stem cells 
(Wang et al. 2010). Several features make Runx genes an ideal hub for the 
control of stem cell homeostasis; Runx genes regulate transcription through 
interaction with a wide variety of co-repressors and co-activators which bring to 
this transcriptional network high flexibility and context dependency, features 
necessary for the regulation of dynamic entities such as stem cells (Chuang et al. 
2012). Moreover RUNX transcription factors can control different signalling 
pathways such as Wnt, Notch and Hedgehog, which are all fundamental in stem 
cell biology (Coffman 2009).  RUNX proteins can also interact with several 
chromatin-modifying proteins, such as acetyltransferases, helping to shape the 
stem cell epigenetic landscape (Lunyak & Rosenfeld 2008). Finally RUNX proteins 
can function as potent cell cycle regulators, activating and/or repressing cell 
proliferation and quiescence (Coffman 2003).  
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Mammary gland stem cells represent a poorly characterized population of the 
adult mammary gland characterized by the ability to differentiate into the 
multiple cell lineages which make up the mammary epithelium, and the capacity 
to self-renew in order to maintain a stable pool of tissue stem cells (Rosen 
2012).  Improving our knowledge of mammary stem cell biology is of pivotal 
importance for a deeper understanding of mammary gland and breast cancer 
development. Recently some evidence has emerged in the literature, suggesting 
a possible role for RUNX transcription factors in mammary stem cell biology.  
Runx2 transcript is enriched in the mammary basal population, a compartment 
characterized by high stem cell content.  In particular, microarray analysis on 
FACS sorted murine mammary cells showed that Runx2 is enriched in the 
CD24+/Low Sca1- basal population (Kendrick et al. 2008).  Interestingly, Runx2 
expression is also upregulated in the luminal ER negative population (CD24+/high 
SCA1-) where the luminal-restricted progenitors are thought to reside (Kendrick 
et al. 2008).  Moreover, qRT-PCR on the same populations confirmed that Runx2 
transcript is upregulated in the basal/myoepithelial and in the stem-cell 
enriched mammary population (Molyneux et al. 2010).  Embryonic mammary 
development is characterized by actively proliferating stem cells which will 
generate all the different cell types and structures of the mature ductal 
epithelium.  Intriguingly, work from the Howard lab identified Runx1 as a key 
node of the transcriptional network which guides mammary embryonic 
development (Wansbury et al. 2011).  Moreover, gene expression analysis on 
microdissected adult mammary tissue revealed that both Runx1 and Runx2 RNA 
are enriched in the terminal end buds, virgin-specific mammary structures which 
are thought to contain a high number of activated mammary stem cells (Kouros-
Mehr & Werb 2006).   In vitro experiments using HC11 cells, a murine mammary 
epithelial cell line, added some evidence to a possible involvement of Runx 
genes in mammary stem cell biology.  HC11 cells have been widely used as a 
model to study changes in gene expression during the mammary stem cell 
differentiation process (Ball et al. 1988). Runx2 transcript decreases during in 
vitro mammary differentiation in HC11 cells, suggestive of a possible role in 
stem cell maintenance (Williams, 2009). Several observations from our previous 
experiments also point to a role for RUNX proteins in mammary stem cells 
(previous chapter). First, we confirmed that not only Runx2 but also Runx1 is 
enriched in the mammary basal population. Second, both RUNX1 and RUNX2 are 
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expressed during embryonic mammary development, a stage characterized by a 
high degree of stemness and epithelial plasticity. Finally our conditional knock-
out mouse model shows that loss of RUNX2 dramatically affects the basal cell 
population in vivo, indicating a possible key role for this transcription factor in 
this lineage. 
 
4.1.2  RUNX, mammary stem cells and Wnt signalling. 
Wnt signalling is a key regulator of stem cell differentiation and maintenance in 
different systems (Cadigan & Peifer 2009). Moreover the Wnt pathway has been 
shown to play a role in mammary gland development and in mammary stem cell 
regulation and maintenance (Zeng & Nusse 2010). Interestingly evidence coming 
from different experimental models links RUNX2 and Wnt signalling (see 
Introduction). Studies show that Wnt and RUNX2 follow similar expression 
patterns in the mammary gland while Wnt signalling pathway is enriched in the 
mammary basal population (E. Lim et al. 2010; van Amerongen et al. 2012), the 
same population which we have shown to be enriched in Runx2. Also, similar to 
RUNX2 expression, Wnt signalling is active until E15.5 in mammary embryonic 
epithelial cells and then is switched off (Chu et al. 2004).   
 
4.1.3  Experimental Aims. 
The aim of this study was to characterize RUNX1 and RUNX2 in mammary stem 
cell biology. In addition the interaction between Wnt signalling and RUNX2 in 
mammary stem cells has been investigated. 
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4.2  RESULTS 
 
4.2.1  Expression of Runx1 and Runx2 in mammospheres. 
To investigate a possible role for Runx genes in mammary stem cells, 
mammospheres were used as a tool for the generation of mammary stem cell-
enriched cultures (see Introduction and Material and Methods for details). As a 
control, primary mammary cells were grown in differentiating conditions (from 
now on called 2D MMECs) as adherent 2D-culture on plastic with foetal calf 
serum (FCS) and a cocktail of growth factors (Insulin, EGF and Cholera toxin). 
Fresh-extracted MMECs, after one week in mammosphere-culturing conditions 
form floating spherical colonies as expected (FIGURE 4-1-A & B). First the 
pattern of expression of all three Runx genes was analysed by qRT-PCR to check 
if in vitro culture was affecting their normal pattern of expression. Again Runx1 
transcript represented the main isoform while Runx3 levels were very low, close 
to the limit of detectability (FIGURE 4-1-C).  This data confirmed our previous 
results on fresh sorted MMECs and showed that in vitro culturing conditions are 
not causing drastic changes in the pattern of expression of Runx genes. Runx 
expression was then assessed in primary cells grown in differentiating conditions 
and those grown as primary and secondary mammospheres. Since mammosphere 
passaging has been shown to enrich for mammary cells with stem cell features 
(Dontu et al. 2003), this experiment allowed to test a possible involvement of 
Runx genes in the MaSC population. Interestingly Runx2 was enriched in primary 
and secondary mammospheres when compared to 2D MMECs (FIGURE 4-1-D). On 
the other hand Runx1 showed no enrichment in primary mammospheres and a 
decrease in secondary mammospheres (FIGURE 4-1-E). Western blot analysis 
confirmed RUNX2 enrichment in primary mammospheres at the protein level 
(FIGURE 4-2-A). IHC analysis was used to characterize the pattern of RUNX2 
expression in mammospheres. High RUNX2 expression in primary and secondary 
mammospheres was detectable in a subgroup of cells, usually located at the 
centre of the spheres (FIGURE 4-2-B & C).  Together these results indicate a 
correlation between elevated RUNX2 expression and stem cell-enriched cultures.  
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Figure 4-1   Characterization of Runx expression in mammospheres. 
Bright field (A) and H&E (B) of primary mammospheres after 1 week of culture. qRT-PCR for 
Runx1, Runx2 and Runx3 on MMECs grown in 2D (2D MMECs), primary and secondary 
mammospheres  (C-E). RNA levels were normalized to GAPDH. Data are expressed as mean 
relative expression (±SD). n≥5 for each group. Expression in primary and secondary 
mammospheres was compared to 2D MMECs; in (E), *=p<0.001. **=p<0.0005. Expression in 
primary mammospheres was also compared to secondary mammospheres; in (D), p<0.02. In (E), 
p<0.05. 
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Figure 4-2   RUNX2 protein is enriched in mammospheres. 
Western blot on MMECs grown in 2D from two separate experiments (2D MMEC1, 2D MMEC2) and 
primary mammospheres nuclear and cytoplasmic extract (1stMammo N, 1stMammo Cyt). Two 
different antibodies against RUNX2 were used as specified in the figure (A). RUNX2 IHC on 
primary (B) and secondary mammospheres (C). Scale bars represent 30 μm. 
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To test if RUNX2 is necessary for mammospheres formation a loss of function 
experiment was performed whereby MMECs extracted from Cre-negative 
Runx2WT/WT and Runx2Flx/Flx mice were infected with adenoviral Cre-GFP and 
grown as mammospheres. There was no difference in total number of primary 
and secondary mammospheres generated from Runx2WT/WT and Runx2Flx/Flx cells 
(FIGURE 4-3-A & B). However RT-PCR on RNA extracted from mammospheres 
derived from Runx2Flx/Flx cells showed that the partial Runx2 knock-down induced 
by Cre expression in vitro is rescued in secondary mammospheres (FIGURE 4-3-C 
& D). This result indicates that Runx2-deleted cells are selected against in this 
assay suggesting a functional role for Runx2 in mammosphere formation. 
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Figure 4-3   Effects of Runx2 loss on mammospheres formation. 
Quantification of primary (A) and secondary (B) mammospheres on MMECs extracted from 
Runx2WT/WT and Runx2Flx/Flx mice and infected with Adenoviral Cre. MMECs were spin-infected 
with adenoviral Cre-GFP and grown in non-adherent conditions as mammospheres. Primary and 
secondary mammospheres were counted after 7 days in culture under a bright field microscope. 
Runx2 mRNA expression from primary and secondary mammospheres (C) Runx2 expression is 
shown as fold change compared to the WT control. Data are expressed as mean fold expression 
(±SD), average of 4 independent experiments. Chart showing rescue of Runx2 expression in 4 
independent experiments (D).   
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4.2.2  In vivo deletion of Runx2 in the mammary basal 
compartment does not affect normal mammary 
development. 
To investigate the role of Runx2 in mammary stem cells in vivo, a loss of 
function mouse model targeted to the mammary basal population was created. 
Here K14-Cre mice, which express the Cre recombinase under the control of the 
human keratin 14 promoter, were used. Under this promoter, specific deletion 
of loxP flanked target sequences can be achieved in the basal layer of different 
epithelial tissues such as skin, tongue and mammary gland (Dassule et al. 2000). 
To achieve a targeted deletion of Runx2 in the basal population of the mammary 
epithelium the K14-Cre mouse was combined together with the Runx2flx/flx 
mouse. No obvious phenotype was detectable in K14-Cre+/Runx2flx/flx glands at 
the histological level in mature virgin, lactating and involuting stages when 
compared to K14-Cre+/Runx2WT/WT controls (FIGURE 4-4-A). The lactating 
capability of K14-Cre+/Runx2flx/flx mice was also tested by weighing litters at 7 
days of age. No difference in weight was found between pups nursed by K14-
Cre+/Runx2WT/WT and K14-Cre+/Runx2flx/flx females indicating that loss of Runx2 
in the basal layer of the mammary gland is not affecting milk production 
(FIGURE 4-4-B).  The fate of K14-Cre/Runx2 deleted cells in the mammary 
epithelium was then tracked using the GFP reporter as previously described 
(Chapter 3). FACS analysis on MMECs extracted from mature virgins showed no 
difference in total GFP expression levels between K14-Cre+/Runx2WT/WT and K14-
Cre+/Runx2flx/flx mice (FIGURE 4-5-A). Interestingly the levels of GFP expression 
driven by K14-Cre (~40% of total MMECs) are much higher compared to BLG-Cre 
(~16% of total MMECs, see figure 3-8) indicating that K14-Cre is highly active in 
the mature virgin state. To identify possible aberrations in mammary lineages 
induced by loss of Runx2 in the basal population, mammary population profiling 
through FACS looking at GFP expression specifically in basal and luminal lineages 
was carried out. Loss of Runx2 causes no effects on GFP levels in either the basal 
or luminal population (FIGURE 4-5-B & C). FACS analysis confirmed that K14-Cre 
is expressed at high levels in the basal layer of the mammary gland: however a 
considerable amount of GFP+ cells were also detected in the luminal 
compartment (FIGURE 4-5-B). GFP expression in luminal cells was confirmed 
through immunofluorescence showing double positive GFP+/CK18+ cells in K14-
Cre Z/EG+ mice (FIGURE 4-6). 
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Figure 4-4   Effects of loss of Runx2 in the basal layer of the virgin mammary gland. 
Representative histological sections of mammary glands from K14-Cre+/RunxWT/WT and K14-
Cre+/Runx2Flx/Flx mice extracted from mice at 12 week old virgin, lactation  day 3 and involution 
day7 (n>4 for each stage). Scale bar represents 50 μm (A). Bar chart showing the weight of pups 
from K14-Cre+/RunxWT/WT and K14-Cre+/Runx2Flx/Flx litters expressed in grams. Litters (n≥5) were 
normalized to 6 and pups were weighed after 7 days from the start of lactation (B). 
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Figure 4-5  Analysis of Runx2 loss in the basal lineage using a GFP reporter. 
Reporter GFP expression as analysed by FACS, on  whole mammary gland extraction (A), and 
gated on CD24+/CD29low luminal population (B) and CD24+/CD29high basal population (C). MMECs 
were isolated from 12 week K14-Cre+/Runx2WT/WT and K14-Cre+/Runx2Flx/Flx mice. Data are 
expressed as % of GFP+ cells over total in the selected population (±SD). n≥5 for each stage. 
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Figure 4-6   K14-Cre is expressed in the luminal population of the virgin mammary gland.  
Immunofluorescence of CK14 (red), CK18 (yellow) and GFP (green) on mammary glands extracted 
from K14-Cre+/Runx2WT/WT mice. Red arrows indicate GFP+ luminal cells on the merge image. 
Glands were counterstained with DAPI (blue). Scale bar represents 20 μm. 
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4.2.3  In vivo deletion of Runx2 in the K14+ population impairs in 
vitro MMECs regenerative potential. 
Overall Runx2 loss with a K14-Cre driven promoter, and high recombination in 
the basal lineage, causes no detectable phenotypes in the mammary gland. 
However loss of genes involved in stem cells and regeneration can often result in 
no overall phenotype during normal development, with the defect becoming 
apparent only after challenging the recombinant tissue through regenerative 
assays (Taddei et al. 2008).  To test the regenerative potential of Runx2 deleted 
mammary epithelial cells in vitro stem cell assays were carried out. In fresh 
extracted MMECs from K14-Cre+/Runx2flx/flx and K14-Cre+/Runx2WT/WT mice, loss 
of Runx2 caused a significant reduction in number and size of primary 
mammospheres (FIGURE 4-7-A-C). In addition secondary mammosphere growth 
was also affected (FIGURE 4-7-D & E). qRT-PCR on RNA extracted from primary 
and secondary mammospheres confirmed Runx2 deletion in K14-Cre+/Runx2flx/flx 
derived spheres while Runx1 levels were not affected (FIGURE 4-8-A & B). 
Considering that Runx genes are key regulators of cell cycle progression 
(Coffman 2009), RNA levels of p21, a cyclin-dependent kinase inhibitor, were 
checked to test if loss of Runx2 was affecting mammospheres proliferation 
status. qRT-PCR for p21 on RNA extracted from primary mammospheres from 
K14-Cre+/Runx2flx/flx and K14-Cre+/Runx2WT/WT mice showed that p21 levels are 
reduced after Runx2 deletion (FIGURE 4-8-C). 
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Figure 4-7  In vivo loss of Runx2 in the basal lineage impairs mammosphere formation. 
Bright field images of mammosphere cultures derived from K14-Cre+/Runx2WT/WT and K14-
Cre+/Runx2Flx/Flx mice. Scale bars represent 100 μm (A). Quantification and size of primary (B-C) 
and secondary (D-E) mammospheres on MMECs extracted from K14-Cre+/Runx2WT/WT and K14-
Cre+/Runx2Flx/Flx mice. Primary and secondary mammospheres were counted and measured after 
7 days in culture. Data are expressed as mean (±SD). Four independent experiments for each 
group. *= p<0.001; **=p<0.01. 
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Figure 4-8  Runx1, Runx2 and p21 expression on mammospheres derived from K14-
Cre+/Runx2flx/flx mice. 
qRT-PCR for Runx2 (A) and Runx1 (B) mRNA expression in primary and secondary mammospheres 
derived from K14-Cre+/Runx2WT/WT and K14-Cre+/Runx2Flx/Flx mice. p21 mRNA expression on 
primary mammospheres derived from K14-Cre+/Runx2WT/WT and K14-Cre+/Runx2Flx/Flx mice (C). 
RNA levels were normalized to GAPDH. Data are expressed as mean relative expression (±SD). 
n=4 for each group. *=p<0.05. **=p<0.01. 
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In vitro clonogenic assays are widely used in the stem cell field as a surrogate to 
identify putative stem/progenitor cells (Grompe 2012). To further characterize 
the role of Runx2 in mammary stem cells, the self-renewal potential of Runx2 
deleted cells in vitro using colony-forming assays in Matrigel (Guo et al. 2012) 
was performed. Specifically, fresh MMECs were extracted and seeded as single 
cells in Matrigel with serum-free medium supplemented with epidermal growth 
factor (EGF) (Zeng & Nusse 2010). In this assay, after one week in culture, 
MMECs form 3D colonies which develop into a ring of cells surrounding a hollow 
lumen, a structure resembling a mammary duct tree (FIGURE 4-9-A & B). These 
colonies can be further dissociated into single cells and plated again to form 
secondary colonies. Runx1 and Runx2 expression was assessed in this system. RT-
PCR on primary and secondary colonies grown from wild type mice confirmed 
that Runx1 is the most expressed of the Runx genes while Runx3 transcripts are 
undetectable (FIGURE 4-9-C). Moreover, in a nice parallel with findings in the 
mammospheres system, Runx2 is enriched in secondary colonies while Runx1 
expression is not (FIGURE 4-9-D & E).    
Fresh extracted MMECs from K14-Cre+/Runx2flx/flx and K14-Cre+/Runx2WT/WT mice 
were then assessed in matrigel colony-forming assays. Interestingly MMECs 
extracted from K14-Cre+/Runx2flx/flx mice formed less primary and secondary 
colonies when compared to controls (FIGURE 4-10-A-C). No difference was 
detectable in the size of matrigel colonies between the two groups (FIGURE 4-
10-D,E).  Runx2 deletion was confirmed by RT-PCR on RNA extracted from 
primary matrigel cultures (FIGURE 4-11-A-B). Again Runx1 levels were not 
affected indicating the specificity of the targeted deletion approach. These 
results indicate that Runx2 expression in the K14+ cells of the mammary 
epithelium is required for sustaining MMECs growth in matrigel colony-forming 
assays. 
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Figure 4-9   Runx expression in matrigel colony-forming assays. 
Bright field (A) and H&E (B) of primary colonies after 1 week in culture. qRT-PCR for Runx1, 
Runx2 and Runx3 on primary and secondary matrigel colonies (C). qRT-PCR for Runx2 (D) and 
Runx1 (E) on primary and secondary matrigel colonies. RNA levels were normalized to GAPDH.  
Data are expressed as mean relative expression (±SD). n=4 for each group. *=p<0.001. 
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Figure 4-10  In vivo loss of Runx2 in the K14+ cells impairs matrigel colony formation. 
Bright field images of primary matrigel colonies derived from K14-Cre+/Runx2WT/WT and K14-
Cre+/Runx2Flx/Flx mice. Scale bars represent 100 μm (A). Quantification and size of primary (B&D) 
and secondary (C&E) matrigel colonies from K14-Cre+/Runx2 WT/WT and K14-Cre+/Runx2Flx/Flx 
MMECs. Primary and secondary matrigel colonies were counted and measured after 7 days in 
culture. Data are expressed as mean number of colonies (% over the WT) and mean colony 
diameter (±SD). Four independent experiments for each group.   
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Figure 4-11   Runx1 and Runx2 expression on K14-Cre+/Runx2flx/flx matrigel colonies. 
qRT-PCR of Runx1 (A) and Runx2 (B) expression on primary matrigel colonies derived from K14-
Cre+/Runx2WT/WT and K14-Cre+/Runx2Flx/Flx mice after 7 days in culture. RNA levels were 
normalized to GAPDH. Data are expressed as mean relative expression (±SD). n=4 for each group. 
*=p<0.005. 
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To determine if these in vitro findings were transferable to an in vivo setting 
and to test if Runx2 is indeed involved in the regulation of mammary stem cell 
regenerative potential, the cleared fat pad transplantation assay was 
performed. MMECs were extracted from K14-Cre+/Runx2flx/flx and K14-
Cre+/Runx2WT/WT mice bearing the Z/EG transgene. Two different concentrations 
of cells (1x104 and 1x105 MMECs) were injected into the cleared fat pad of 3 
week old SCID female mice. After 7 weeks epithelial duct trees were detectable 
at the same frequency in both control and Runx2 knock-out groups (FIGURE 4-12-
A). Moreover in vivo GFP analysis indicated that Runx2 deleted cells contributed 
to the ductal outgrowth in a similar manner to the WT (FIGURE 4-12-B). This 
data indicates that Runx2 deleted cells can contribute to mammary epithelial 
regeneration when injected together with WT cells.  
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Figure 4-12   In vivo regeneration activity of Runx2 deleted mammary cells. 
Table showing the results obtained from cleared fat pad transplantation of total MMECs 
extracted from K14-Cre+/Runx2flx/flx and K14-Cre+/Runx2WT/WT mice bearing the Z/EG transgene. 
Freshly isolated total MMECs were transplanted at the two concentrations specified above (A). 
Examples of reconstituted glands from the two cohorts: whole mounts (left) and in vivo GFP 
imaging of glands extracted from K14-Cre+/Runx2WT/WT (top) and K14-Cre+/Runx2flx/flx (bottom) 
mice. Scale bars represent 1mm (B).  
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4.2.4   Runx2 is a downstream target of Wnt signalling in 
mammary stem cells. 
The evidence showed so far suggests that RUNX2 is important for the 
regenerative potential of a mammary stem/progenitor population. Since Wnt 
signalling has been shown to regulate mammary stem cells and evidence links 
Runx and Wnt signalling pathways (see Introduction) the role of Runx2 as a 
possible mediator or regulator of Wnt signalling in mammary stem cells was 
investigated. Wnt signalling status was checked in mammosphere culture using 
Axin2 expression, one of the main downstream targets of Wnt signalling (Jho et 
al. 2002), as a readout for Wnt pathway activation. RT-PCR showed increased 
levels of Axin2 in mammospheres culture compared to MMECs grown in 
differentiating conditions (FIGURE 4-13-A). This result indicates that Wnt 
signalling is more active in a population enriched in mammary stem cells. The 
effects of Wnt signalling activation on the mammosphere-forming capacity of 
MMECs was then tested. Treatment of fresh extracted MMECs grown as 
mammospheres with recombinant WNT3A caused an increase in mammosphere 
number and size (FIGURE 4-13-B-D). These data suggest a growth promoting 
effect of Wnt pathway on mammary stem cells. Runx2 as a downstream target of 
Wnt signalling in MMECs was tested by performing a 24h treatment with 
recombinant WNT3A on MMECs grown in 2D differentiating conditions and on 
MMECs grown as mammospheres. After incubation with the recombinant protein, 
qRT-PCR for Axin2 was used as a readout to confirm activation of Wnt pathway 
in both systems (FIGURE 4-14-A,B). Interestingly WNT3A treatment did not affect 
Runx2 transcript levels in MMECs grown in differentiating conditions (FIGURE 4-
14-C). However WNT3A treatment caused a significant up-regulation of Runx2 
expression in mammospheres (FIGURE 4-14-D). To confirm the specificity of that 
up-regulation levels of Slug, another transcription factor involved in mammary 
stem cells, were unchanged (FIGURE 4-14-E). Moreover RT-PCR for Hes1, one of 
the main transcriptional targets of Notch pathway, showed no difference, 
confirming the specific activation of Wnt signalling (FIGURE 4-14-F). These 
results are indicating Runx2 as a potential downstream target of Wnt signalling 
specifically in mammary stem cell-enriched cultures. 
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Figure 4-13   Effects of Wnt signalling on mammosphere cultures. 
qRT-PCR for Axin2 of MMECs grown in 2D (2D MMECs) and primary mammospheres. RNA levels 
were normalized to GAPDH. Data are expressed as mean relative expression (±SD). n≥5 for each 
group (A). Bright field images of mammosphere cultures treated for 1 week, with either vehicle 
(Vh) or WNT3A (B).  Quantification (C) and size (D) of primary mammospheres extracted from 12 
week old virgin FVB mice and treated for 1 week, with either vehicle (Vh) or WNT3A. Data are 
expressed as mean (±SD). 3 independent MMECs extractions for each group. *=p<0.005. 
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Figure 4-14  Effects of Wnt signalling activation on Runx2 expression in mammospheres.  
qRT-PCR for Axin2 (A,B) and Runx2 (C,D) on MMECs grown in 2D (2D MMECs) and primary 
mammospheres treated for  24h, with either vehicle (Vh) or WNT3A. qRT-PCR for Slug (E) and 
Hes1 (F) on primary mammospheres treated for  24h, with either vehicle (Vh) or WNT3A. RNA 
levels were normalized to GAPDH. Data are expressed as mean relative expression (±SD). 3 
independent MMECs extractions for each group.*=p<0.05. **=p<0.0005. 
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4.3  DISCUSSION 
 
In this study mammosphere culture was used as a tool to study the role of Runx 
genes in the mammary stem cell population. Several studies have shown a link 
between mammospheres and MaSC: in particular cleared fat pad injection of a 
single sphere is able to generate mammary outgrowth in 11 out of 18 
transplantations, indicating that enrichment for cells with high regenerative 
capability is achievable in this assay (Cicalese et al. 2009). Moreover, the 
progenitor/stem cell content of mammospheres has been shown to increase with 
passage.  Indeed whereas freshly isolated mammary cells contain less than 10% 
multi-lineage progenitors when cultured under differentiating conditions, these 
are enriched to 70% in primary mammospheres, and virtually 100% in secondary 
mammospheres (Dontu et al. 2003). Results presented here showed that Runx2 
expression is enriched in primary and further enriched in secondary 
mammosphere cultures. This data indicates that Runx2 expression increases 
together with the stem cell content of mammospheres. Characterization of 
RUNX2 expression through immunohistochemistry showed that RUNX2 is 
expressed at high levels in a few cells usually located at the centre of the 
sphere. Intriguingly work from Wicha’s lab showed that cytokeratin 5 (CK5) and 
CD49f, two known markers for the basal stem cell population,  followed a similar 
pattern of expression (Dontu et al. 2003). Confirming these observations in a 
different in vitro system, Runx2 is also upregulated in secondary matrigel 
colonies. These results unveiled a correlation between cells characterized by a 
certain degree of self-renewal in vitro and upregulation of Runx2 expression. 
Interestingly this upregulation is specific for Runx2 since Runx1 showed no sign 
of enrichment in either mammosphere or matrigel cultures. Rather, Runx1 was 
significantly downregulated in secondary mammospheres suggesting a possible 
role for this transcription factor in a more differentiated population of the 
mammary epithelium. The specific enrichment for Runx2 but not Runx1 in 
mammosphere cultures is also fitting with the data coming from the BLG-
Cre/Runx2flx/flx cohorts indicating that only loss of Runx2 (and not Runx1) 
perturbs the basal compartment.  Taken together, the experiments above show 
a correlation between high Runx2 expression and stem cell enriched cultures. To 
investigate the functional role of Runx2 in mammospheres in vitro, Runx2 knock-
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out experiments, using adenoviral infection were performed. These experiments 
showed that Runx2 is required for mammospheres formation since Runx2-deleted 
cells undergo a negative selection in the mammosphere assay.  
Given the correlative and functional link discovered between Runx2 and stem 
cells and since stem cells are enriched in the basal population we decided to 
create an in vivo deletion of Runx2 specific for the basal lineage using the K14-
Cre system. K14-Cre/Runx2flx/flx mice didn’t show any phenotype at the 
histological level in all the tested developmental stages. This lack of phenotype 
could be due to a sufficient number of wild-type cells still present in the Runx2-
deleted gland which can compensate for Runx2 loss of function. Moreover 
lineage profiling with GFP marker showed no alterations in the mammary 
populations after Runx2 deletion indicating that loss of Runx2 per se in the basal 
compartment is not deleterious. This is in apparent contrast with the reduction 
of GFP+ basal cells seen after Runx2 loss in the BLG-Cre model. However this 
could be explained by the fact that Runx2 is expressed only in a small 
subpopulation of basal cells while K14-Cre is expressed in the majority of them. 
Hence the lack of a detectable reduction in the number of basal cells in the K14-
Cre/Runx2flx/flx mouse could be due to the inherent lack of sensitivity of this 
system; in other words the reduction in GFP+ cells which may be caused by loss 
of Runx2 in the basal layer would be smaller than the biological variation of K14-
Cre expression. In the BLG-Cre model instead, the small percentage of basal 
cells that are targeted and which could represent the RUNX2 positive basal 
population, allows us to detect their loss after RUNX2 deletion.  
Although no gross phenotype was detectable in normal mammary development 
of K14-Cre/Runx2flx/flx mice, interesting results started to appear when those 
cells were challenged in in vitro stem cell assays. MMECs extracted from K14-
Cre/Runx2flx/flx mice generated fewer colonies in the mammosphere assay. This 
is showing that Runx2 expression in the mammary basal compartment is required 
for the mammosphere generating potential of the virgin mammary gland. 
Moreover a reduction in colony size suggests that Runx2 deleted colonies are 
somewhat arrested in development. Two possible scenarios could explain the 
reduced size and number of colonies observed; firstly, Runx2 loss forces MaSC 
into quiescence hindering mammosphere formation. Or in fact Runx2 deleted 
stem cells may be unable to enter quiescence; this would cause stem cell 
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exhaustion in vivo in the K14-Cre+/Runx2flx/flx mammary epithelium. Hence 
MMECs extracted from the Runx2 deleted glands will be depleted of stem cells 
and this will cause the defective mammospheres forming capability. Preliminary 
results showing reduced levels of p21, a key regulator of quiescence (Cheng et 
al. 2000), in Runx2 deleted mammospheres cultures support the second 
scenario. Furthermore, evidence in the literature suggests a role for Runx2 in 
the induction of quiescence. For example Runx2 is upregulated during 
quiescence in osteoblasts and Runx2 can induce quiescence in prostate cancer 
cells (Galindo et al. 2005; Baniwal et al. 2010). Further experiments such as cell 
cycle profiling through FACS of primary mammospheres from K14-
Cre+/Runx2flx/flx and K14-Cre+/Runx2WT/WT mice will help to confirm if loss of 
Runx2 is affecting MaSC cell cycle.  
To further test if Runx2 could affect the regenerative potential of mammary 
cells in a different in vitro culture model, 3D matrigel colony forming assay was 
performed. This assay is commonly used in mammary stem cell research by 
several labs for the study of MaSC regenerative potential in vitro (Guo et al. 
2012; Zeng & Nusse 2010; Bai & Rohrschneider 2010). Interestingly results from 
these experiments confirmed that loss of Runx2 impairs in vitro mammary 
regenerative potential causing a reduction in the number of colonies formed 
after one week in culture. How can loss of Runx2 cause a reduction of 
regenerative potential in in vitro experiments without affecting normal 
mammary development? Looking into the literature this situation appears to be a 
common theme of different studies focusing on the role of stem cell genes in 
mammary gland and skin: no obvious gross defects are detectable during normal 
development with a phenotype becoming apparent only when cells are tested in 
regenerative assays in vitro and in vivo (Taddei et al. 2008; Jensen et al. 2009). 
This behaviour would suggest that, at least in some tissues, normal epithelial 
adult homeostasis does not require activation of the stem cell population, whose 
regenerative potential is instead necessary in more extreme conditions which 
can be physiological, such as tissue repair after wounding, or experimentally 
induced, such as stem cell assays. Besides forcing stem cell regenerative 
potential, in vitro assays also serve as a good tool to eliminate confounding and 
redundant effects of the tissue microenvironment on the targeted population 
which could result in the rescue of the phenotype. Overall in vitro assays 
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represent a way to simplify in vivo systems, unmasking phenotypes which would 
be otherwise hidden by the complexity of tissue compensatory systems.  
However in vitro assays also come with flaws; cells are grown in artificial 
conditions, no microenvironment is present and the structures formed are only 
reminiscent of the real complex architecture of a mature mammary epithelium. 
To prove if Runx2 is really needed for the generation of a functional mammary 
duct tree in vivo, a cleared fat pad transplantation experiment was required. 
Epithelial duct trees were detectable at the same frequency in both control and 
Runx2 knock-out groups showing that Runx2-deleted cells can take part in the 
regeneration process and be incorporated in the newly formed duct tree. 
However this experiment does not definitively prove that Runx2 is not essential 
for mammary regenerative potential as the cells injected were not FACS purified 
so they represented a mixed population of Runx2 wild-type and Runx2 deleted 
cells. Thus the duct tree reconstitution capability of the Runx2 deleted group 
could be due to the regenerative potential of the non-recombined population 
with Runx2-deleted cells being passively incorporated in the duct tree. Serial fat 
pad transplantation experiments using a pure population of FACS sorted GFP+ 
basal cells extracted from K14-Cre+/Runx2flx/flx and K14-Cre+/Runx2WT/WT mice 
will clarify if Runx2 is absolutely required for the regenerative potential of 
mammary stem cells.  
The fat pad transplantation technique also comes with limitations: in this assay 
MMECs undergo several stresses (tissue dissociation, enzymatic digestion, FACS 
sorting) which could affect the MaSC population. Moreover recent lineage tracing 
studies showed that fat pad transplantation can force cells to acquire stem cell 
behaviours which they do not normally have in physiological conditions (Van 
Keymeulen et al. 2011; van Amerongen et al. 2012).  The final experiment which 
would show if Runx2 is really involved in a mammary stem population would be 
lineage tracing using a tetracycline-inducible GFP, driven by the endogenous 
Runx2 promoter. This would allow a precise localization and characterization of 
RUNX2 positive cells in the mammary epithelium. Using pulse and chase 
experiments at different stages of development (embryonic, virgin, pregnancy) 
would allow the clarification of the actual contribution of RUNX2 positive cells 
to mammary development and homeostasis (van Amerongen et al. 2012; Van 
Keymeulen et al. 2011). 
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 The signalling mechanism by which Runx2 can exert its effects on stem cell 
regulation has also been investigated. With evidence linking Runx2 with Wnt 
signalling (Dong et al. 2006; Gaur et al. 2005) this seemed to be a promising area 
to investigate. First it was shown that Wnt signalling is activated in 
mammospheres compared to 2D-MMECs and that Wnt treatment stimulates the 
growth of mammospheres. These results are in line with the published evidence 
indicating Wnt signalling as a key regulator of MaSC (Zeng & Nusse 2010). 
Moreover, treating mammospheres for 24h with recombinant WNT3A induces 
Runx2 transcription indicating that Runx2 is a downstream target of Wnt 
signalling. The specificity of Runx2 activation was confirmed by looking at Slug, 
another gene involved in MaSC which did not show any change after Wnt 
treatment. Furthermore no effects on Runx2 expression were seen on 
differentiating 2D MMECs suggesting that Runx2 is downstream to Wnt signalling 
only in MaSC enriched cultures. Probably MaSC cells are characterized by a 
different epigenetic conformation or a specific set of coactivators which allows 
the increase of Runx2 expression in response to Wnt signalling. 
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5 The role of RUNX2 in metaplastic squamous 
breast cancer. 
 
 
5.1 INTRODUCTION 
 
5.1.1  Runx2 in breast cancer 
An oncogenic role for RUNX2 was first reported in the haematopoietic lineage, 
where RUNX2 overexpression was shown to promote lymphoma development in 
mice (Stewart et al. 1997; Vaillant et al. 1999). In addition several studies have 
also suggested a possible role for RUNX2 as an oncogene in metastatic breast and 
prostate cancer (Pratap et al. 2006; Blyth et al. 2010). In particular some human 
breast cancer cell lines overexpress RUNX2 and its inhibition leads to less 
invasive potential in vitro and to decreased osteolytic metastatic activity in vivo 
(Barnes et al. 2003).  Furthermore RUNX2 regulates several genes that are 
involved in breast cancer metastasis such as collagenase3, bone sialoprotein, 
osteopontin and MMP-9 (Pratap et al. 2005; Barnes et al. 2003). More hints 
regarding a role for RUNX transcription factors in the mammary gland are 
emerging from studies using three-dimensional epithelial culture systems. 
Interestingly RUNX2 overexpression in a 3D culture model using the MCF10A cell 
line disrupts normal acini development resulting in increased cell proliferation 
and hyperplasia (Pratap et al. 2009). However all the published studies to date 
have analysed the effects of RUNX2 in an in vitro context, using a limited 
number of cell lines. Hence in vivo evidence of the pro-tumourigenic role of 
RUNX2 in breast cancer is still lacking. A study from our laboratory is the first to 
provide in vivo confirmation of an oncogenic role for RUNX2 in breast cancer. 
McDonald et al showed that in vivo overexpression of Runx2 caused hyperplasia 
and induces DCIS in old virgin mice (McDonald, Ferrari et al, submitted). Only a 
few studies have looked at RUNX2 in human breast cancer with contrasting 
results (Onodera et al. 2010; Das et al. 2009; Khalid et al. 2008). Unpublished 
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data from our laboratory show that RUNX2 is highly expressed in a small 
percentage of human breast cancers and interestingly its expression correlates 
with triple negative disease. Triple negative breast cancers, which account for 
around 15% of all BCs, are a mixed group of tumours defined by lack of 
expression of oestrogen, progesterone, and ERBB2 receptors. This subgroup is 
associated with poor outcome and lack of specific targeted therapy (Foulkes et 
al. 2010).  
5.1.2  Experimental Aims 
A few previous reports (our lab included) have indicated RUNX2 as a new 
oncogene in a specific subgroup of human breast cancer, the triple negative 
subtype. The aim of this study was to better characterize the role of RUNX2 in 
triple negative breast cancer through a combination of in vitro and in vivo 
modelling.  
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5.2  RESULTS 
 
5.2.1  Runx2 expression in mouse models of breast cancer 
RUNX2 is highly expressed in a small percentage of human breast cancers and 
interestingly its expression correlates with triple negative tumours (McDonald et 
al, unpublished). These results indicate that the role of RUNX2 in breast cancer 
could be restricted to a particular subgroup of the triple negative subtype. To 
better identify the breast cancer subgroup in which RUNX2 may play a role, six 
mouse models representing different breast cancer subtypes (Herschkowitz et al. 
2007) were stained for RUNX2. Luminal-like models (MMTV-PyMT and MMTV-
Her2) as well as a basal-like BRCA1 tumour model (BLG-Cre/Brca1flx/flx/p53+/-) 
showed low or negative RUNX2 staining (FIGURE 5-1). Conversely,  Apc1572T and 
BLG-Cre/Ptenflx/flxApcflx/flx mice, two mouse models of metaplastic breast 
cancer, a rare subtype of triple negative BC (Gaspar et al. 2009), showed high 
RUNX2 positivity, especially in correlation with squamous metaplastic lesions 
(FIGURE 5-1). In addition, in the Apc1572T model, RUNX2 expression is very high in 
the basal layer of the squamous metaplastic lesions which has been shown to 
contain a high percentage of the Ki67+ cells (Kuraguchi,  2009) (FIGURE 5-2). 
Intriguingly, both Apc1572T and BLG-Cre/Ptenflx/flxApcflx/flx models, are 
characterized by truncating mutations or deletions in the Apc tumour suppressor 
gene, the main negative regulator of the Wnt/β-catenin pathway (Cadigan & 
Peifer 2009). Thus both models are characterized by the constitutive activation 
of canonical Wnt signalling, suggesting a link between Runx2 and this pathway. 
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Figure 5-1  RUNX2 expression in mouse models of breast cancer. 
RUNX2 IHC on five mouse models of breast cancer. MMTV-PyMT and MMTV-Her2 are luminal-like 
BC while BLG-Cre/Brca1flx/flx/p53+/-, Apc1572T and BLG-Cre/Apcflx/flxPtenflx/flx are basal-like 
models. Three to five independent tumours have been stained from each genotype. Scale bars 
represent 50µM. 
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Figure 5-2      Examples of RUNX2 basal pattern of expression in squamous lesions. 
RUNX2 expression on Apc1572T tumours as assessed by IHC. Scale bars represent 50µM. 
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5.2.2  Runx2 in a mouse model of mammary squamous metaplasia. 
These data suggested a link between RUNX2 expression, squamous metaplastic 
breast cancer (SMBC) and activated Wnt signalling in mouse models of breast 
cancer. To further investigate a possible involvement of RUNX2 in metaplastic 
breast cancer, a mouse model of Wnt-induced squamous metaplasia was chosen 
(Miyoshi, Shillingford, et al. 2002), where endogenous β-catenin is stabilized 
through the deletion of exon 3 (amino acids 5-80) of the β-catenin gene 
(Catnb+/lox(ex3) mice). This model has been reported to give rise to extensive 
squamous metaplasia, but not adenocarcinomas, upon β-catenin activation 
during pregnancy (Miyoshi, Shillingford, et al. 2002). As the Cre recombinase 
used here was different from the ones published previously, it was important to 
first characterize the model, choosing to look at virgin, lactating and involuting 
stages. Activation of β-catenin driven by BLG-Cre was confirmed to induce 
squamous metaplastic lesions at all stages tested (FIGURE 5-3). These lesions are 
characterized by the presence of asymmetrical keratinized structures usually 
with a thicker layer of squamous cells at one edge (FIGURE 5-4-A). Like in 
normal epidermis (Blanpain & Fuchs 2009), the squamous cells located in the 
basal region undergo a constant process of maturation. Actively cycling basal 
cells continuously produce progenitors which are pushed upwards towards the 
centre of the cysts, while undergoing a terminal differentiation program. As they 
mature, cells acquire a flatten morphology and start to produce large amounts 
of epidermal keratins such as CK1 (FIGURE 5-4-B). At the end of the process 
these cells will become embedded in a very dense keratin structure, similar to 
hair matrix and will die, as shown by the presence of ghost cells in the middle of 
the lesions (FIGURE 5-4-C).  To investigate if Wnt signalling activation in the 
virgin epithelium induces Runx2 expression, qRT-PCR was performed on RNA 
extracted from virgin glands of BLG-Cre/Catnb+/lox(ex3) and BLG-Cre/Catnb+/+ 
mice. Interestingly a significant upregulation of Runx2 transcript was found in 
the mammary epithelium expressing the activated form of β-catenin, 
corroborating the idea of Runx2 as a downstream target of Wnt signalling in the 
mammary gland (FIGURE 5-5-A). RUNX2 activation at the protein level was then 
confirmed through immunohistochemistry showing that β-catenin stabilization 
induces RUNX2 expression during the lactation phase, a stage of development 
which is normally devoid of RUNX2 (FIGURE 5-5-B). RUNX2 expression was usually 
located in the basal layer of the squamous lesions (FIGURE 5-5-C). Interestingly 
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β-catenin expression was restricted to this compartment and not expressed in 
the terminal differentiating cells (FIGURE 5-5-D).  
To investigate how RUNX2 loss could affect development of mammary squamous 
metaplasia three cohorts, BLG-Cre/Catnb+/lox(ex3)/Runx2WT/WT, BLG-Cre/ 
Catnb+/lox(ex3)/Runx2WT/flx and BLG-Cre/Catnb+/lox(ex3)/Runx2flx/flx, were generated. 
Since BLG-Cre is mainly activated during pregnancy, and to achieve high levels 
of Wnt activation in the majority of the mammary epithelium, mice were taken 
through one round of pregnancy and then sacrificed at involution day 7. Loss of 
RUNX2 caused a significant increase in the number of squamous lesions 
compared to the wild-type and heterozygous cohort (FIGURE 5-6). This data 
could suggest that RUNX2 is activated by Wnt signalling and acts to repress the 
formation of squamous lesions. In this situation, RUNX2 would restrict the 
mammary to epidermal trans-differentiation signal mediated by aberrant Wnt 
signalling in the mammary epithelium. 
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Figure 5-3  Effects of β-catenin stabilization at different stages of mammary development. 
H&E examples of 12 weeks virgin, lactating d1 and involuting day 7, BLG-Cre/Catnb+/lox(ex3) mice. 
Red arrows indicate keratinized squamous lesions. Scale bars represent 100µM. n≥2 per group. 
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Figure 5-4  Histological analysis of β-catenin-induced squamous lesions. 
H&E examples of squamous lesions developed by BLG-Cre/Catnb+/lox(ex3) mice. Red arrows 
indicate layers of differentiating squamous cells. Black arrows indicate the keratin deposit in the 
middle of the lesion (A). H&E of a squamous lesion. Red arrow indicates the layer of 
differentiating cells which have acquired a flatten morphology. Black arrow indicates completely 
keratinized, terminally differentiated layers, which are released into the lesion (B). H&E of a 
mature squamous lesion. Red arrows indicate ghost cells as white traces left on the keratin 
matrix by dead cells (C). Scale bar in (A) represents 50µM. Scale bars in (B-C) represent 25µM.  
165 
 
 
 
Figure 5-5  Effects of β-catenin stabilization on RUNX2 expression. 
qRT-PCR for Runx2 on RNA extracted from BLG-Cre/Catnb+/+ and BLG-Cre/Catnb+/lox(ex3) virgin 
glands. RNA levels were normalized to GAPDH. Data are expressed as mean relative expression 
(±SD). n≥3 for each group. p<0.05, Mann-Whitney test (A). RUNX2 immunohistochemistry on 
lactating day 1 BLG-Cre/Catnb+/+ and BLG-Cre/Catnb+/lox(ex3) glands (B). RUNX2 (C) and β-catenin 
(D) IHC on BLG-Cre/Catnb+/lox(ex3) squamous lesions. Scale bar in (B) represents 50µM. Scale bars 
in (C-D) represent 20µM.  
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Figure 5-6   Effects of RUNX2 loss on squamous metaplasia. 
Representative H&E images of BLG-Cre/Catnb+/lox(ex3)/Runx2WT/WT and BLG-Cre/Catnb+/lox(ex3)/ 
Runx2flx/flx glands taken at involution day 7. Black arrows indicate squamous lesions. Scale bars 
represent 100µM (A). Bar-chart showing the number of squamous lesions/cm2, developed by BLG-
Cre/Catnb+/lox(ex3)/Runx2WT/WT (Runx2 WT/WT), BLG-Cre/Catnb+/lox(ex3)/Runx2WT/flx (Runx2 WT/Flx) 
and BLG-Cre/Catnb+/lox(ex3)/ Runx2flx/flx (Runx2 Flx/Flx) cohorts. n≥4 for each group. p<0.05, 
Mann-Whitney test (A). 
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5.2.3  RUNX2 deletion in an in vitro model of triple negative 
metastatic breast cancer 
The human breast cancer cell line MDA-MB-231 is a commonly used in vitro 
model representative of the triple-negative subtype as it lacks expression of the 
ER, PR and HER2 markers (Holliday & Speirs 2011).  This cell line expresses high 
levels of RUNX2 (Nagaraja et al. 2006) and was used to investigate the role of 
RUNX2 in triple-negative cells.  The subline MDA-MB-231-luc-D3H2LN, a highly 
metastatic variant of MDA-MB-231 which has been derived from a spontaneous 
lymph node metastasis of a MDA-MB-231 mammary fat pad tumour (Jenkins, 
2005) was utilised due to its high metastatic potential.  Furthermore, the 
presence of a luciferase reporter in this cell line is advantageous for in vivo 
imaging in experimental metastasis models (intravenous and intracardiac) and 
orthotopic mammary fat pad models (Jenkins et al. 2005). RUNX2 has been 
shown to be an important regulator of invasive and tumourigenic features of 
MDA-MB-231 (Pratap et al. 2009), however no study so far has looked at its role 
in the metastatic seeding process. Using short-hairpin RNA technology, stable 
MDA-MB-231 RUNX2 knock-out cell lines were generated, one carrying a scramble 
sh-RNA as a control (shSCR) and two with different RUNX2-shRNAs (shRUNX2-1, 
shRUNX2-2). The RUNX2 knock-down was confirmed through western blot 
(FIGURE 5-7-A).  No difference in 2D growth was detected between the control 
and the two knock-down (FIGURE 5-7-B).  
Previous data (Chapter 4) indicated that RUNX2 is a regulator of stemness in the 
mammary epithelium. To test if loss of RUNX2 was affecting the cancer stem cell 
properties of MDA-MB-231-luc-D3H2LN cells, a tumoursphere assay was used as 
an marker of stemness (Ponti et al. 2005). In this assay cells are grown in non-
adherent conditions and in absence of serum; conditions which allow enrichment 
in cancer stem cells. Interestingly loss of RUNX2 caused a drastic reduction in 
tumoursphere-forming capacity of MDA-MB-231 cells (FIGURE 5-8). This data is 
suggesting that RUNX2 loss could hinder cancer stem cell properties of MDA-MB-
231-luc-D3H2LN cells. Several studies have indicated a strong link between 
cancer stem cells and metastasis formation (Gao et al. 2012; Malanchi et al. 
2011). To asses if loss of RUNX2 was affecting the metastatic behaviour of MDA-
MB-231 cells, in vivo experimental metastasis experiments (tail vein injections) 
were performed taking advantage of MDA-MB-231 luciferase expression to follow 
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the metastatic disease through in vivo imaging. Interestingly, in a pilot 
experiment (3 mice per cohort), tail-vein injection of shSCR and shRUNX2-1 cells 
showed a potential decrease of lung metastasis formation after Runx2 knock-
down (FIGURE 5-8). 
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Figure 5-7  Creation of a stable RUNX2 knockdown in MDA-MB-231 cells. 
RUNX2 western blot on MDA-MB-231 cells, transfected with sh-scrambled (shSCR) or 2 
independent sh-RNAs targeting RUNX2 (shRUNX2-1, sh-RUNX2-2) (A).  2D Growth curve of MDA-
MB-231 cells transfected with shSCR, or sh-RUNX2 1 and sh-RUNX2-2 (B).  Cell numbers were 
counted daily in quadruplicate for each time point, for each cell line. Graph representative of 
two independent experiments. 
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Figure 5-8  Effects of RUNX2 knockdown in MDA-MB-231 cells. 
Tumoursphere quantification from shSCR, and sh-RUNX2 cells grown in non-adherent conditions 
for 7 days. Tumourspheres were counted under a bright field microscope. Data are expressed as 
mean +/- SD. Graph representative of four independent experiments. p<0.05 (A). Bright field 
images of tumourspheres. Scale bars represent 150µM (B). In vivo luciferase imaging of nude 
mice (n=3 per group), 12 weeks after being tail vein injected with MDA-MB-231 cells transfected 
with shSCR or shRUNX2-1 (C). 
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5.3  DISCUSSION 
 
Unpublished data from our laboratory indicate that RUNX2 expression correlates 
with triple negative samples in human breast cancer. Metaplastic breast cancer 
(MBC) is a heterogeneous subtype of triple negative breast carcinoma 
characterized by poor outcome, and few therapeutic options (Lee et al. 2012). 
One feature of MBC is the co-existence of both carcinoma and non-epithelial 
components which can include fibrosarcomatous, cartilaginous, osseus, 
muscular, or squamous differentiation (Cooper et al. 2013). MBC is rare relative 
to invasive ductal carcinoma, representing less than 1% of all breast cancers. 
However, since the total number of BC diagnosed in 2011, in the US alone 
(http://www.cancer.org) was 288130, more than 2000 women were expected to 
be affected by metaplastic breast cancer. Moreover the 5-year survival rate for 
MBC is approximately 65% compared to 89% for invasive ductal cancer, indicating 
the need of new treatment options (Verma 2012). Therefore, a better 
understanding of the molecular alterations underlying the distinctive 
morphological and clinical characteristics of this aggressive subtype is needed in 
order to identify potential new targets for treatment.    
RUNX2 immunohistochemistry on a panel of mouse breast cancer models showed 
that BRCA1-deleted triple negative breast cancers lack RUNX2 expression while a 
strong staining was detected in two different models of Wnt-induced squamous 
metaplastic breast cancer (Apc1572T and BLG-Cre/Ptenflx/flx Apcflx/flx). Moreover in 
a nice confirmation of our unpublished human data, RUNX2 expression was 
negligible in two luminal-like breast cancer models (Herschkowitz et al. 2007). 
The development of squamous metaplasia in the mouse mammary gland is 
induced by aberrant Wnt signalling (Miyoshi, Rosner, et al. 2002; Miyoshi, 
Shillingford, et al. 2002; Gaspar et al. 2009), which activates a process of trans-
differentiation of the mammary epithelium resulting in epidermal-like structures 
with extensive keratinization and basosquamous/pilar histological structures 
(Kuraguchi et al. 2009). Interestingly RUNX2 expression in both squamous 
metaplastic breast cancer (SMBC) models was limited to the tumour cells 
positioned in the basal layer of the lesions. This compartment is characterized 
by cells in a high proliferative state when compared with the other squamous 
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part of the tumour which are mainly quiescent (Kuraguchi et al. 2009). Moreover 
in the normal epidermis this is the compartment were the stem cell population 
resides (Blanpain & Fuchs 2009). These results suggest a link between RUNX2 
expression and a highly proliferative population of SMBC, which could be 
endowed with cancer stem cell features. 
To understand the possible role of RUNX2 expression in squamous metaplasia a 
published mouse model was chosen, where expression of an active form of β-
catenin (Catnb+/lox(ex3)) in the mammary gland causes constitutive Wnt signalling 
activation and widespread squamous metaplasia (Miyoshi, et al. 2002). 
Intriguingly, aberrant β-catenin activation driven by BLG-Cre expression induced 
RUNX2 expression in vivo in the mammary gland. This result is supporting 
previous in vitro data obtained from WNT3A treatment on mammospheres 
(Chapter 4), suggesting that Runx2 is a direct downstream target of Wnt 
signalling in the mammary epithelium. Moreover these data are also in line with 
various findings from other systems which link RUNX proteins to Wnt signalling 
(Gaur et al. 2005; Osorio et al. 2011). The Wnt-induced trans-differentiation 
process of the mammary epithelium is fascinating: activation of a single 
molecule, such as β-catenin, in a mature gland is able to reprogram mammary 
epithelial cells into a different lineage characterized by a completely different 
structure and function (i.e. epidermis). This could be explained by the fact that 
β-catenin is a key specifier of hair follicle fate (Gat, 1998; Huelsken, 2001); 
hence its over-activation is sufficient to induce aberrant epidermal/follicular 
trans-differentiation in the mammary epithelium. However the underlying 
molecular mechanism for this mammary to epidermal trans-differentiation has 
not been investigated.  A better understanding of this process could help 
identify new regulators of mammary epithelial identity and expand our basic 
knowledge of mammary epithelium plasticity.  Furthermore, since squamous 
metaplasia is a key feature of a subgroup of TN breast cancers (Weigelt et al. 
2009), these studies could identify new potential targets for this type of tumour.  
The experiments described in this chapter unveil a potential role for RUNX2 in 
Wnt-induced squamous metaplasia development. Conditional deletion of RUNX2 
combined with β-catenin activation led to an increase of squamous lesions 
compared to controls. This result could suggest that RUNX2 is counteracting the 
β-catenin-induced epidermal trans-differentiation process. When RUNX2 is lost 
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however, its repressor function is missing and the trans-differentiation process 
can proceed uncontrolled, leading to increased squamous metaplasia. A possible 
mechanism for RUNX2’s repressor role in this system could be through a block of 
terminal differentiation of β-catenin-activated cells, via induction of 
quiescence. Interestingly previous experiments, where loss of Runx2 in vivo 
caused a decrease in mammosphere size and number followed by a decrease in 
p21 (Chapter 4) are suggesting RUNX2 as a possible positive regulator of 
quiescence in mammary cells. A way to test if RUNX2 deletion could cause exit 
from quiescence after β-catenin  activation, would be the analysis of cell cycle 
regulators such as p21 and Cyclin D1 via qRT-PCR and western blot on BLG-
Cre/Catnb+/lox(ex3)/Runx2WT/WT and BLG-Cre/Catnb+/lox(ex3)/Runx2flx/flx glands.  
Overall these experiments suggest a new role for RUNX2 in the mammary gland 
as a downstream target of Wnt signalling and as an essential repressor of 
squamous metaplasia development. Further studies to characterize the exact 
molecular mechanism of increased trans-differentiation after RUNX2 loss are 
currently underway. Preliminary data on multiparous experiments, where 
females from control and RUNX2-deleted cohorts have been taken through 
multiple rounds of pregnancies to achieve maximum levels of recombination 
confirm the involution data, showing a dramatic increase in squamous 
metaplasia in RUNX2-deleted glands. Moreover the almost complete absence of 
proliferation (as assessed by ki67 staining) in RUNX2-deleted glands support the 
view that loss of RUNX2 is pushing cells towards terminal differentiation. 
Molecular analysis of the involuting and multiparous glands through qRT-PCR and 
western blot will help to clarify the mechanism of the observed phenotype.  To 
better investigate the role of RUNX2 in squamous metaplastic breast cancer, 
future experiments could use the Apc1572T mouse model, which develops 
squamous metaplastic breast cancer, in combination with the K14-
Cre/Runx2flx/flx mouse. If the same mechanism observed in the Catnb+/lox(ex3) 
model, where loss of RUNX2 induces differentiation, is conserved, we could 
speculate that less aggressive and more differentiated tumours will develop 
after RUNX2 deletion. The correlation between high RUNX2 expression, Wnt 
pathway activation and metaplastic breast cancer seems to be conserved also in 
human disease; transcriptomic analysis on human metaplastic breast cancer 
listed RUNX2 among the upregulated gene signature (Hennessy et al. 2009) while 
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Wnt signalling was found to be activated in 95% of metaplastic breast cancer 
(Hayes et al. 2008). As a future priority, RUNX2 expression needs to be 
confirmed at the protein level on human SMBCs samples through 
immunohistochemistry. 
In an attempt to understand the functional role of RUNX2 in human triple 
negative disease we performed in vitro experiments using a well-established 
model of the MDA-MB-231 cell line (Holliday & Speirs 2011). Interestingly, in a 
nice parallel with previous data on mammospheres, RUNX2 inhibition caused 
decreased tumoursphere capacity without affecting MDA-MB-231 growth in 2D. 
This result indicates that RUNX2 could be a widespread regulator of regenerative 
potential in both normal and breast cancer cells. Cancer stemness and 
metastatic potential are strongly linked (Malanchi et al. 2011; Gao et al. 2012). 
In fact only cancer cells characterized by a certain degree of regenerative 
potential will be able to seed and form new tumour colonies in a foreign tissue. 
RUNX2’s role in metastatic cancer cell seeding has not been investigated since 
the only “metastatic” assays used were orthotopic injections which do not 
involve seeding (Javed et al. 2005). RUNX2 has been shown to be important for 
the osteolytic potential of MDA-MB-231 cells when injected directly into the 
intramedullary space of the tibia (Barnes et al. 2004; Pratap et al. 2008). In 
addition MDA-MB-231 cells stably expressing shRNA-Runx2, when injected in the 
mammary fat pad, showed a significant reduction in tumour growth when 
compared with a control group (Pratap et al. 2009). Our pilot experiment 
showed that RUNX2 inhibition impairs lung colonization in an experimental 
metastasis experiment suggesting that RUNX2 is also required for the ability of 
MDA-MB-231 cells to seed and grow in the lung.  Further experiments 
transplanting MDA-MB-231 cells into the fat pad with stable RUNX2 knockdown,  
and thereafter removal of primary tumour will allow the assessment of 
metastatic growth and clarify the role of RUNX2 in breast cancer metastatic 
disease. Furthermore, since the majority of the research conducted so far has 
always been limited to the use of a single cell line (MDA-MB-231) which cannot 
recapitulate the disease complexity, there is a need for new and better in vitro 
and in vivo models for the study of RUNX2 role in breast cancer.   
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6 A role for RUNX1 in breast cancer 
 
 
6.1 INTRODUCTION 
 
6.1.1  RUNX1 in epithelial cancer. 
RUNX1 has been extensively studied in the haematopoietic system where it is 
essential for the establishment of definitive haematopoiesis and the generation 
of haematopoietic stem cells during embryonic development (Swiers et al. 
2010). Moreover RUNX1 is the most frequently mutated gene in human 
leukaemia, usually through chromosomal translocations which interfere with 
RUNX1 transcriptional activity (Lam & Zhang 2012). Hence, the mainstream of 
RUNX1 research has been focused on its tumour suppressive function in 
haematopoietic malignancies (Lam & Zhang 2012). However, in recent years, a 
new role for RUNX1 outside the haematopoietic system has started to emerge 
with several studies indicating how this transcription factor could be more 
broadly implicated in cancer than previously thought (Scheitz & Tumbar 2012; 
Taniuchi et al. 2012). In particular RUNX1 has been identified as a key regulator 
of tumourigenesis in various epithelial cancers. RUNX1 is expressed at high levels 
in mouse skin papilloma and squamous cell carcinoma, and Runx1 deficiency 
impairs mouse skin tumourigenesis (Hoi et al. 2010). Moreover deletion of Runx1 
in a mouse model of head and neck cancer caused a significant delay in tumour 
formation (Scheitz et al. 2012). RUNX1 is also highly expressed in primary and 
metastatic epithelial ovarian cancer compared to normal tissue (Keita et al. 
2013) while in prostate cancer, RUNX1 expression increases with pathological 
stage (Yeh et al. 2009). These data are indicating an oncogenic role for RUNX1 in 
different epithelial cancers. In contrast, RUNX1 seems to have a tumour 
suppressor role in the intestine since both wild-type and ApcMin mice develop 
significantly more colon and small intestine tumours after Runx1 deletion 
(Fijneman et al. 2011). These studies serve to highlight the context dependence 
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of Runx genes (Blyth et al. 2005), being able to orchestrate both an oncogenic 
and a tumour suppressive program probably through collaboration with different 
combinations of tissue-specific transcriptional co-regulators.  
6.1.2  RUNX1 in breast cancer 
A role for RUNX1 in breast cancer is also starting to emerge. However the 
evidences published so far are discordant. Wang et al using 3D culture models 
showed that RUNX1 deletion in MCF10A resulted in increased cell proliferation 
and abnormal morphogenesis (Wang et al. 2011). Furthermore two independent 
whole-exome sequencing studies on human breast cancers discovered recurrent 
RUNX1 mutations and deletions in a small subgroup of human tumours (Ellis et 
al. 2012; Banerji et al. 2012) while Kadota et al showed that RUNX1 deletion is 
associated with high-grade primary breast tumours (Kadota et al. 2010). These 
studies indicate a possible tumour suppressor role for RUNX1 in breast cancer. 
On the other hand, work from Tumbar’s laboratory, found RUNX1 among the top 
1% highly expressed genes in tumour versus normal tissue in a meta-analysis of 
microarray studies of various cancers, including breast (Scheitz et al. 2012). 
RUNX1 was also identified among the upregulated transcripts in breast tumours 
and short term tumour cultures when compared with established breast cancer 
cell lines (Dairkee et al. 2004). This study suggests that RUNX1 could be lost in 
established cell lines and poses a word of caution on the use of in vitro models 
for the study of RUNX1 involvement in BC. Other transcriptomic studies on 
human breast cancer support an oncogenic role for RUNX1 in this malignancy. In 
human breast cancer oestrogen receptor (ER), progesterone receptor (PR), and 
epidermal growth factor receptor 2 (HER2) are well-established prognostic and 
predictive markers and testing for them is now considered standard of care 
(Taneja et al. 2010). Based on the receptor status, human breast cancer can be 
subdivided into three main groups: oestrogen receptor positive (ER+), epidermal 
growth factor receptor 2 positive (HER2+) and triple negative (ER-/PR-/HER2-).  
ER+ and HER2+ patients benefit of targeted treatments such as Tamoxifen 
and/or Trastuzumab which have consistently improved disease outcome (Higgins 
& Baselga 2011). On the other hand, the triple negative subtype lacks any 
specific targeted therapy and is associated with worse overall prognosis in 
comparison with the other subtypes (Foulkes et al. 2010). Interestingly RUNX1 is 
among a 264 gene signature which correlates with bad prognosis in triple 
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negative breast cancer (Karn et al. 2011) and indeed was seen to specifically 
correlate with bad prognosis in the claudin-low subtype of triple negative breast 
cancers (Rody et al. 2011). Finally, RUNX1 is among the top 20% differentially 
expressed genes in two triple negative subtypes: the mesenchymal stem-like 
(MSL), and a luminal androgen receptor (LAR) (Lehmann et al. 2011). 
Interestingly the MSL subtype also displays low expression of claudins 3, 4, and 
7, confirming a possible link between RUNX1 expression and the claudin-low 
subtype. Overall these transcriptomic studies suggest a possible oncogenic role 
for RUNX1.  
 
6.1.3  Experimental Aims. 
The role of RUNX1 in breast cancer is still unresolved with different studies 
suggesting a possible oncogenic role while others point towards a tumour 
suppressive function. Since breast cancer is a very heterogeneous disease, 
constituted by different subtypes, each characterized by specific molecular 
alterations (Sorlie et al. 2003; Prat & Perou 2011), it is tempting to speculate 
that the discordant data on RUNX1 in this malignancy could reflect different 
subtype-specific roles for this transcription factor. The aim of this study was to 
better characterize RUNX1 in human breast cancer with a particular focus on the 
different tumour subtypes. 
  
178 
 
6.2  RESULTS 
 
6.2.1  Expression of RUNX1 in human breast cancer. 
To get a preliminary overview of RUNX1 expression in human breast cancer, 
data-mining in an online cancer gene microarray database 
(https://www.oncomine.org/ ) was performed. Two multi-cancer gene 
expression profiling studies showed an upregulation of RUNX1 in breast cancer 
tissue (Yu et al. 2008; Su et al. 2001). RUNX1 is amongst the top 2% upregulated 
genes in breast cancer compared to other tumours (FIGURE 6-1-A) and in the top 
3% upregulated genes in breast cancer when tumours were compared to 
adjacent normal mammary tissue (FIGURE 6-1-B). RUNX1 is also in the top 4% 
upregulated genes in invasive breast carcinoma when compared to normal tissue 
(FIGURE 6-2) (Cancer Genome Atlas Network 2012). These analyses are 
suggesting that RUNX1 could be upregulated in breast cancer. However the 
association of RUNX1 expression with clinical outcome and its significance as a 
prognostic factor in human breast cancer is still unclear. To investigate if RUNX1 
expression influenced clinical outcome in primary breast tumours, a tissue 
microarray (TMA) containing 449 patients with operable invasive ductal breast 
cancer (Mohammed et al., 2012) was stained for RUNX1. RUNX1 antibody was 
first validated by western blot and immunohistochemistry, confirming its 
specificity (data not shown). The invasive cancers showed different degrees of 
RUNX1 expression predominantly localised to the nucleus (FIGURE 6-3). RUNX1 
expression was determined by histoscore (as described in material and methods) 
and patients were divided into two groups: RUNX1 negative (histoscore = 0, 
n=109) and RUNX1 positive (histoscore > 0, n=340). The relationship between 
RUNX1 expression and clinical outcome was then assessed by looking at overall 
survival (OS) in the cohort. Survival analyses showed no difference between 
RUNX1 negative (154.9 months - 95% confidence interval, 142–164 months) and 
RUNX1 positive tumours (148.7 months - 95% confidence interval, 142.6–153.8 
months) in the full cohort (FIGURE 6-4-A). The distribution of RUNX1 positive and 
negative samples in relation to hormonal status (ER/PR/HER2) of the full cohort 
is showed in FIGURE 6-4-B. 
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Figure 6-1   RUNX1 expression on multi-cancer gene expression profiling studies. 
RUNX1 gene expression on a panel of 162 tumours. RUNX1 is overexpressed (2.24 fold-change) in 
breast cancer compared to RUNX1 median expression across the database. p = 5.94E-7 (A). 
RUNX1 gene expression on a panel of 270 tumour samples as shown in legend, compared to 
correspondent adjacent normal tissues from breast (n=13), colon (n=9), oesophagus (n=13), liver 
(n=8), lung (n=12), and thyroid gland (n=16). RUNX1 is overexpressed (3.01 fold-change) in breast 
cancer compared to RUNX1 median expression (cancer vs non-malignant tissue) across the 
database. p = 4.58E-13 (B). Information taken from www.oncomine.org. 
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Figure 6-2  RUNX1 expression in normal versus invasive breast carcinoma. 
RUNX1 gene expression on a panel of normal breast (61) and invasive breast carcinoma (76) 
samples. RUNX1 is overexpressed (2.1 fold-change) in invasive breast carcinoma compared to 
normal tissue. p = 2.03E-17. Information taken from www.oncomine.org. 
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Figure 6-3  Examples of RUNX1 expression in a breast cancer cohort. 
Invasive breast carcinomas from a tumour tissue microarray (TMA) were stained for expression of 
RUNX1.  Examples of tumours with positive RUNX1 staining are shown on the left column. 
Examples of tumours with negative RUNX1 staining are shown on the right column. Scale bar 
represents 100µM. 
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Figure 6-4   Correlation of RUNX1 expression and survival in a breast cancer cohort. 
Kaplan Meier of patient survival in a cohort of 449 breast cancers. Survival is plotted for patients 
with cancers scored positive for RUNX1 (green), or negative for RUNX1 expression (blue). p>0.1. 
p-value calculated using Log Rank (Mantel-Cox) test (A). Table showing the distribution of RUNX1 
positive and negative patients in relation to their hormonal status (B). 
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To define the prognostic impact of RUNX1 expression in different breast cancer 
subtypes, the patient cohort was divided into 4 subgroups accordingly to their 
receptor status (ER+, PR+, HER2+ and ER-/PR-/HER2-). The relationship between 
RUNX1 expression and clinical outcome was then assessed by looking at overall 
survival in each breast cancer subtype. Survival analyses showed no difference 
between the RUNX1 positive and negative groups in the ER+, PR+ and HER2+ 
patients (FIGURE 6-5). However RUNX1 positivity significantly correlated with 
poorer prognosis in the receptor negative patients (RUNX1+, 127.3 months - 95% 
CI, 111.7–143 months vs RUNX1-, 162 months - 95% CI, 145.3–178.8 months - 
p=0.017) (FIGURE 6-5-D).  
To test if RUNX1 was an independent prognostic factor in the triple negative 
cohort we performed a correlation analysis using the Cox regression model. 
Interestingly RUNX1 was an independent prognostic factor (p=0.009) together 
with size (p=0.005) and lymph node status (p=0.003) in the triple negative (TN) 
cohort. A bivariate analysis (Pearson’s chi-square) was then performed to 
determine the presence of an association between clinicopathological history 
and RUNX1 expression in TN samples. RUNX1 expression was not significantly 
associated with age (p=0.564), tumour type (p=0.442), tumour size (p=0.456), 
grade (p=0.352), nodal status (p=0.348), necrosis (p=0.736), Ki67 (p=0.225) and 
TUNEL (p=0.257) (FIGURE 6-6). This data indicates that RUNX1 is an independent 
prognostic factor specific for the triple negative subgroup of breast cancers.  
Besides being influenced by well recognised host and tumour related factors 
such as patient age, histological type and grade, tumour size, lymph node and 
hormonal status, the prognosis of breast cancer is also dependent on other 
factors such as lymphocytic infiltrate and blood vascular invasion (Z M A 
Mohammed, Going, et al. 2012). To determine any association between 
inflammatory reaction/blood vascular invasion and RUNX1 expression in the 
triple negative subgroup a new bivariate analysis (Pearson’s chi-square) was 
performed on a set of markers previously published (Z M A Mohammed, Going, et 
al. 2012; Klintrup et al. 2005; Mohammed et al. 2013). The inflammatory 
reaction in this cohort  had been previously assessed in Joanne Edwards 
laboratory by Klintrup-Makinen scoring (Z M A Mohammed, Going, et al. 2012), a 
measure of inflammation at the invasive margin of the tumours, together with 
scoring for lymphocytes (CD4+ and CD8+), plasma cells (CD138+) and 
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macrophages (CD68+). Vascular invasion was also determined by endothelial cell 
scoring (CD34+). RUNX1 expression was not significantly associated with 
Klintrup-Maninen scoring (p=0.081), CD8 (p=0.675), CD138 (p=0.251), CD68 
(p=0.710), or CD34 (p=0.928). Interestingly RUNX1 expression was correlated 
with lymphocytic CD4 staining (p=0.016) (FIGURE 6-7).  
6.2.2  Effects of RUNX1 overexpression in vitro. 
RUNX1 expression was tested on a panel of breast cancer cell lines by western 
blot analysis. The chosen cell lines included normal human mammary epithelial 
cells derived from primary tissue and immortalized with TERT expression (hMEC-
TERT), 4 basal-like (MDA-MB-468, HCC-70, MDA-MB-231, BT-549) and 3 luminal-
like (T47D, MDA-MB-361, BT-474) breast cancer cell lines. Significantly, RUNX1 
expression was not detectable in normal hMEC-TERT but was overexpressed in all 
basal-like cancer cell lines and in 1 out of 3 of the luminal cell lines (FIGURE 6-
8).  These results suggest an oncogenic role for RUNX1 in human breast cancer, 
with a particular association with the basal like subgroup of cancers.   
To further investigate the putative oncogenic role for RUNX1 in breast cancer, 
the effects of overexpressing RUNX1 in immortalized mammary epithelial cells 
(hMEC-TERT) was assessed. hMEC-TERT were transfected with a plasmid 
encoding the mouse RUNX1 protein (pBABE-puro-Runx1) and vector alone as 
control (pBABE-puro). Initially both hMEC-TERT control (hMEC-Puro) and hMEC-
TERT overexpressing Runx1 (hMEC-Runx1) showed the same morphology. 
However with passaging, cells with an elongated shape and a fibroblastic 
appearance started to appear in hMEC-Runx1 cultures. The control hMEC-Puro 
instead, maintained the same flat and rounded epithelial morphology (FIGURE 6-
9-A). RUNX1 overexpression was confirmed by western blot (FIGURE 6-9-B). This 
result suggests that RUNX1 overexpression is activating an EMT program in a 
subpopulation of hMEC-TERT. To confirm that RUNX1 overexpression elicits EMT 
changes in hMEC-TERT cells, two classical EMT markers were analysed by 
western blot. Vimentin was strongly upregulated while E-Cadherin levels were 
decreased in hMEC-Runx1 compared to hMEC-Puro (FIGURE 6-9-C).  
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Figure 6-5   RUNX1 expression in different subtypes of breast cancer. 
Kaplan Meier of patient survival in the ER+ (A), PR+ (B), HER2+ (C) and triple negative (TN) 
cohort (D). Survival is plotted for patients with cancers positive for RUNX1 (green), or those with no 
RUNX1 expression (blue).  ER+ cohort, p=0.721. PR+ cohort, p=0.378. HER2+ cohort, p=0.551. 
TN cohort, p=0.017. p-value calculated using Log Rank (Mantel-Cox) test. 
 
 
  
186 
 
 
 
Figure 6-6   Relationship between RUNX1 status and standard clinical, pathological, and 
biological features of triple-negative breast cancer. 
p-value calculated using Chi-squared test (linear by linear association). NS, not significant. 
Where information is not available on the full cohort (n=115), the number of patients with 
information is specified in brackets: Invasive grade (113), Tumour size (114), Ki67 (113), TUNEL 
(87). 
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Figure 6-7   Relationship between RUNX1 status and inflammatory infiltrate/blood vessel 
invasion in triple-negative breast cancer. 
p-value calculated using Chi-squared test (linear by linear association). NS, not significant. 
Where information is not available on the full cohort (n=115), the number of patients with 
information is specified in brackets:  CD34 (114). 
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Figure 6-8   Expression of RUNX1 in a panel of human breast cancer cell lines. 
RUNX1 western blot on a panel of human breast cell lines: hMEC-TERT (immortalized human 
mammary epithelial cells), basal-like (red) and luminal-like (green) breast cancer cell lines. 3SS 
(a leukaemia cell line deleted for RUNX1) was used as a negative control. Human GAPDH was 
used as a loading control. 
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Figure 6-9   In vitro effects of RUNX1 overexpression in hMEC-TERT. 
Bright field images of hMEC-TERT transfected with pBABE-puro (hMEC-puro) or pBABE-puro-
Runx1 (hMEC-Runx1) vector, after 4 passages in culture (A). RUNX1 western blot on hMEC-puro 
and hMEC-puro-Runx1. GAPDH was used as a loading control (B). Western blot for Vimentin and 
E-Cadherin on hMEC-puro and hMEC-puro-Runx1 cells. Actin was used as loading control (C). 
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6.3  DISCUSSION 
 
Triple-negative breast cancer (TNBC), which accounts for 15% to 20% of breast 
cancers, is an aggressive disease, associated with a significantly higher 
probability of relapse and poorer overall survival when compared with other 
breast cancer subtypes (Arnedos et al. 2012). Moreover, the lack of identified 
molecular targets in the majority of TNBCs implies that chemotherapy remains 
the treatment of choice for patients with TNBC. However early relapse after 
chemotherapy is common in patients with TNBC (Gluz et al. 2009). Hence there 
is an urgent need for identification of new prognostic markers which could 
translate into novel druggable targets specific for this lethal subgroup (Foulkes 
et al. 2010).  
Recently a number of studies indicated RUNX1 as a possible tumour suppressor 
gene in the mammary epithelium while others suggested a putative oncogenic 
role (see Chapter 1).  To clarify the role for RUNX1 in human breast cancer, 
invasive breast carcinomas from a tumour tissue microarray were stained for 
expression of RUNX1. No difference in overall survival was detectable in the full 
cohort or in ER+, PR+ and HER2+ subgroups. However RUNX1 expression was 
significantly associated with poorer overall survival in the triple negative (ER-
/PR-/HER2-) group of patients. Interestingly this data is supported by several 
transcriptomic studies which have identified RUNX1 as a possible oncogene in 
TNBC (Karn et al. 2011; Rody et al. 2011; Lehmann et al. 2011). Moreover in 
vitro analysis showed that all basal-like cell lines tested overexpressed RUNX1 
compared to only 1 out 3 luminal-like. Correlation analysis using the Cox 
regression model, confirmed that RUNX1 is an independent prognostic factor 
together with size and lymph node status in the TNBC subgroup. Moreover 
bivariate analysis (Pearson’s chi-square) did not find any association between 
clinicopathological history and RUNX1 expression in TNBC samples confirming the 
independent prognostic value of RUNX1 expression. Inflammation has been 
shown to represent a critical component of tumour progression (Grivennikov et 
al. 2010). Interestingly, RUNX1 expression correlates with the presence of 
lymphocytic CD4+ infiltrate in TNBC. RUNX1 is one of the key factors that drives 
various aspects of T-cell differentiation including regulation of cytokine 
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production (Wong et al. 2012). We could speculate that in TNBC highly positive 
for RUNX1 that RUNX1 would drive a transcriptional program in breast cancer 
cells resulting in production and secretion of high levels of cytokines which 
would then lead to recruitment of lymphocytic cells at the tumour site. Further 
studies will clarify the significance of the correlation between RUNX1 and CD4 
lymphocytes in TNBC.  Overall the results indicate that RUNX1 could be a new 
prognostic biomarker in triple negative breast cancers. The usefulness of RUNX1 
as a new prognostic marker is reinforced by the fact that RUNX1 positive samples 
represent the majority (73%) of the triple negative cohort. Interestingly, no 
reliable markers have been identified as having a predictive role for the 
prognosis of TNBC patients so far (Arnedos et al. 2012). So RUNX1 could 
represent one of the first prognostic factors specific for triple negative breast 
cancers. Follow-up studies looking at RUNX1 expression in different cohorts of 
breast cancer patients from different institutions, will help to confirm the 
prognostic value of RUNX1. RUNX1 overexpression induced EMT in immortalized 
normal mammary cells suggesting that the worse prognosis in TN patients could 
be due to increased invasiveness of RUNX1 expressing tumours. These data are in 
line with reports correlating RUNX1 expression to the claudin-low tumours, a TN 
subtype characterized by mesenchymal features (Lehmann et al. 2011; Rody et 
al. 2011). Moreover RUNX2 expression has been shown to induce EMT in a breast 
cancer cell line (Chimge et al. 2011) suggesting a possible broad role of Runx 
transcription factors as EMT inducers.  
The widespread expression of RUNX1 in TNBC suggests new therapeutic avenues 
for the treatment of TNBCs. In particular, work from Tumbar’s laboratory 
showed that Runx1 overexpression leads to Stat3 activation and is necessary for 
skin and oral cancer growth (Scheitz et al. 2012). Interestingly STAT3 is involved 
In human breast cancer with high STAT3 levels correlating with poorer survival 
(Diaz et al. 2006). It would be interesting to ascertain if RUNX1 overexpression 
and STAT3 activation was also conserved in human breast cancer and in TNBC in 
particular. Further studies are needed to investigate this correlation between 
STAT3 and RUNX1 expression in TNBC which could pave the way for new 
treatment options, based on the use of STAT3 inhibitors (Fagard et al. 2013). 
Moreover the development of small-molecule inhibitors which bind to CBFβ and 
inhibit RUNX1 activity opens the possibility of a RUNX1-specific targeted therapy 
192 
 
for the treatment of TNBC (Gorczynski et al. 2007; Cunningham et al. 2012). 
Taken together these results are indicating RUNX1 as a new prognostic 
biomarker in TNBC and are opening exciting possibilities for the development of 
new targeted therapies for this lethal subgroup.  
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7 Conclusions and Future Directions 
 
The mammary gland is a very dynamic tissue composed of different mammary 
epithelial cell populations with different specialized functions (Visvader & Smith 
2010).  In order to maintain lineage heterogeneity, various transcription factors 
are used to determine the correct specification of different mammary 
subpopulations (Siegel & Muller, 2010).  Our current understanding of mammary 
lineage determination is far from complete; thus the identification of new 
transcription factors with a role in mammary lineage specification is required to 
improve our knowledge of normal mammary epithelial development and 
homeostasis.    
This study identifies for the first time RUNX1 and RUNX2, two transcription 
factors previously linked to haematopoiesis and bone development (Blyth et al. 
2005), as new regulators of the mammary epithelium. RUNX1 and RUNX2 follow a 
similar pattern of expression during mammary development, decreasing during 
pregnancy and lactation to rise again during involution. In addition, mammary 
population profiling showed that both RUNX1 and RUNX2 are enriched in the 
basal compartment. However, only loss of RUNX2 in vivo is detrimental for the 
basal compartment while both genes affect the luminal population. These 
results suggest a possible independent role for RUNX1 and RUNX2 in the 
maintenance of specific mammary lineages. The mechanisms driving the loss of 
RUNX-deleted cells are still not clear and, given the extreme context 
dependency of Runx genes (Blyth et al. 2005), they are likely to be different in 
divergent compartments of the mammary gland. For example RUNX1 loss in a 
subpopulation of luminal cells could cause apoptosis while RUNX2 loss in basal 
cells could cause induction of differentiation. Both in vivo and in vitro 
approaches to unravel the role of RUNX1 and RUNX2 in the mammary gland will 
be informative. Here combined infection of FACS sorted basal and luminal 
MMECs with lentivirus carrying sh-RNA targeting Runx1 or Runx2 could be used to 
create luminal and basal RUNX knock-out cells. These cells could then be grown 
in different culture conditions (2D, Matrigel) and analysed for any growth defect 
when compared to sh-scrambled controls. In addition, transcriptional profiling of 
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early time points cultures will help to show the main transcriptional changes 
occurring after RUNX loss in luminal and basal mammary cells.  
However the ultimate experiment which will clarify the role of RUNX1 and 
RUNX2 in the mammary epithelium will be the generation of lineage tracing 
models. As an example of this technique, Van Amerongen et al., performed 
lineage tracing to characterize the contribution of Wnt-activated cells to 
different stages of mammary development, using an Axin2CreERT2 mouse combined 
with fluorescent reporters (van Amerongen et al. 2012). In the same way the 
construction of transgenic mice carrying the Runx1CreERT2 and Runx2CreERT2 
constructs (which will drive an inducible Cre from the endogenous Runx1 and 
Runx2 promoters) combined with GFP and RFP fluorescent reporters will allow us 
to mark any RUNX1 or RUNX2 positive cell in the entire mammary gland. This will 
allow a precise localization of RUNX positive cells at different stages of 
mammary development through a combination of in vivo imaging, IHC and FACS 
population profiling. In addition transcriptional profiling of pure RUNX positive 
populations, FACS sorted based on fluorescent marker expression, will help to 
characterize those populations at the molecular level. Overall this in vivo 
approach will help to characterize the role and the dynamics of RUNX positive 
lineages in the mammary epithelium, with the possibility to further extend 
lineage tracing analysis to other organs in which RUNX proteins could be 
implicated, such as prostate (Blyth et al. 2010). 
One of the most interesting phenotypes observed in this thesis is the dramatic 
expansion of the basal population when both Runx1 and Runx2 are deleted in the 
BLG-Cre driven model, especially given that Runx2 loss alone diminishes this 
pool. These results suggest the existence of compensatory mechanisms between 
RUNX proteins in the mammary gland and they are supporting a role for Runx 
genes as lineage regulators in mammary epithelium. Since BLG-Cre is expressed 
in both luminal and basal compartments, this effect could be due to an 
expansion of the basal population or a dedifferentiation of luminal cells into the 
basal lineage. The creation of conditional Runx1-Runx2 mouse models specific 
for the basal and the luminal population would address this point. A luminal 
specific K8-Cre (Van Keymeulen et al. 2011) combined with the 
Runx1flx/flxRunx2flx/flx mouse and a fluorescent reporter would prove if loss of 
RUNX1 and RUNX2 is sufficient to drive luminal to basal dedifferentiation in vivo. 
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Conversely, the creation of a double Runx1 and Runx2 knock-out in the basal 
layer of the mammary gland using a K14-Cre would show if combined loss of 
RUNX1 and RUNX2 can drive an expansion of the basal population in vivo. 
However, the creation of K14-Cre/Runx1flx/flx mice was found to be problematic 
since all animals displayed severe growth defects (data not shown), an 
interesting phenotype which we have not characterized further. This problem 
could be avoided by using a Tamoxifen or doxycycline-inducible K14-Cre in 
combination with the Runx1flx/flxRunx2flx/flx mouse.  
Another interesting phenotype was the appearance of preneoplastic lesions in 
double Runx1 and Runx2 knock-out mice. The frequency of lesions (33%) is quite 
high, taking into consideration the low amount of recombination driven by BLG-
Cre in the virgin gland (~15% of recombined MMECs over total). This result is 
pointing to a tumour suppressive role for RUNX1 and RUNX2 in mammary 
epithelium which, however, only becomes apparent when both genes are 
deleted. Importantly, this study is the first to adopt a double conditional knock-
out strategy for the combined deletion of two Runx genes in vivo.  The 
interesting phenotypes observed in this model suggest that the extent to which 
different Runx genes compensate for each other during development of different 
organs in single knock-out mice remains largely unknown; in the future we can 
envisage that the use of combined double or triple Runx conditional knock-out 
models will likely identify new compensatory mechanisms between RUNX 
proteins in the regulation of multiple tissues. Further experiments are needed to 
characterize the mechanism underlying the formation of neoplastic lesions in 
aged mice after combined loss of RUNX1 and RUNX2. Fat pad transplants of FACS 
sorted luminal or basal RUNX1-RUNX2 deleted cells will show if the oncogenic 
potential lies in the basal or in the luminal compartment. Molecular 
characterisation of these lesions will also help to identify the signalling pathways 
which are perturbed (for example Wnt).  For this a candidate pathway approach 
could be done using IHC which has the advantage that spatial information can be 
made apparent.  Alternatively by laser microdissecting the lesions a microarray 
could be carried out to get a broader overview of the genetic features of the 
hyperplastic areas. 
In Chapter 4 the possible role for RUNX1 and RUNX2 in the mammary stem cell 
population was examined. Widespread expression of RUNX1 in the mammary 
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epithelium, and the fact that its expression decreases in mammosphere culture, 
suggests that this transcription factor could be expressed in a more 
differentiated population of the virgin mammary gland. Future experiments will 
need to investigate if RUNX1 expression is necessary for the differentiation of 
mammary cells. The COMMA-1D cell line could be used to clarify this point. 
COMMA-1D cell line exhibits several characteristics distinctive of normal 
mammary epithelial cells, including induction of casein synthesis in vitro and 
normal duct morphogenesis in the cleared mammary fat pads of syngeneic mice 
(Danielson et al. 1984). The creation of stable RUNX1 deleted and RUNX1 
overexpressing COMMA-1D cells, followed by differentiation assays will address if 
RUNX1 is involved in mammary differentiation in vitro. These studies will then 
be expanded in vivo through the use of RUNX1 mammary conditional knock-out 
models. 
In vitro assays indicate that RUNX2 has a role in the regenerative potential of 
mammary epithelial cells. This is in line with several reports from different 
systems which indicate RUNX proteins as key regulators of stem cell biology 
(Appleford & Woollard 2009). However the final proof for a role of RUNX2 in the 
regulation of mammary regenerative potential in vivo is still lacking. Fat pad 
experiments using pure FACS sorted populations of RUNX2-deleted cells will 
clarify this point. In particular GFP+ basal cells will be extracted from K14-Cre 
Runx2flx/flx mice and implanted at limiting dilutions in cleared fat pads 
(Shackleton et al. 2006). This will prove if RUNX2 has a role in mammary 
regenerative potential in vivo. In addition lineage tracing experiments (see 
above) will help to unveil the real behaviour of the RUNX2 positive mammary 
population in vivo.  Single induction of mice carrying the Runx2CreERT2 allele in 
combination with a fluorescent reporter at different developmental time points 
will result in the permanent labelling of RUNX2 positive population in the 
mammary epithelium. The behaviour of labelled RUNX2 positive cells will then 
be followed in vivo to investigate if they are maintained over time and after 
several rounds of involution, two classic features of stem cell populations (Van 
Keymeulen et al. 2011).  
The functional role for RUNX2 in a MaSC population is still unknown, but some 
pieces of evidence indicate that RUNX2 could be linked to regulation of 
quiescence and Wnt signalling in those cells. HC11, a murine mammary 
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epithelial stem-like cell line, could be used as an in vitro model to test RUNX2’s 
molecular regulation of stem cells. In fact Runx2 transcript has been shown to 
decrease during the in vitro differentiation process of HC11 cells (Williams et al. 
2009). The creation of stable HC11 RUNX2 knock-out cells using sh-RNAs, 
followed by growth analysis, differentiation assays and transcriptional profiling 
will address possible molecular mechanisms of RUNX2-mediated regulation of 
mammary stem cells. The actual relevance of RUNX2-dependent pathways 
identified in HC11 cells could then be confirmed in primary cells, using RUNX2 
deleted mammosphere cultures. 
Focusing on the link to Wnt, RUNX2 could contribute to the regulation of the 
MaSC population acting as a downstream mediator of Wnt signalling, as shown by 
RUNX2 induction after WNT3A treatments on mammospheres. Future work is 
needed to understand the role of RUNX2 on the Wnt pathway in this cell type. 
For example, is RUNX2 acting as a repressor or as a co-activator of the Wnt 
signal and what is the outcome of Wnt-induced RUNX2 expression in MaSC? 
Possible answers to those questions come from the in vivo studies of aberrant 
Wnt signalling activation in the mammary gland performed in Chapter 5. In vivo 
β-Catenin stabilization in the mammary gland induces RUNX2 expression and loss 
of RUNX2 correlates with increased trans-differentiation of the mammary 
epithelium into squamous metaplastic lesions. This result could suggest that 
RUNX2 acts as a repressor of Wnt-induced squamous differentiation.   
In the context of normal mammary development Wnt signalling is finely tuned to 
guarantee the correct balance between MaSC maintenance, luminal progenitor 
expansion and alveolar differentiation (Brisken et al. 2000; Joshi et al. 2010). 
During pregnancy, progesterone induces WNT4 production from PR+ cells which 
then signal in a paracrine fashion to the MaSC compartment stimulating their 
expansion (Joshi et al., 2010). MaSC expansion during the first phases of 
pregnancy is probably linked to their differentiation and creation of a large pool 
of luminal progenitors which will differentiate into alveolar cells (Asselin-Labat 
et al. 2010). One hypothesis from our results could be that RUNX2 is expressed in 
a subpopulation of mammary stem cells/progenitors where it is required to 
maintain their regenerative potential. In this scenario RUNX2 is activated during 
the waves of progesterone-induced WNT4 which characterize oestrous cycle and 
act as a gatekeeper of stemness restricting MaSC expansion and differentiation. 
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During pregnancy instead RUNX2 expression is downregulated and progesterone-
induced WNT4 can stimulate MaSC expansion and differentiation in luminal 
progenitors which will drive the subsequent phases of alveolar differentiation. 
This scenario is in line with the lactational defects observed after ectopic RUNX2 
expression in transgenic MMTV-Runx2 animals (McDonald, Ferrari et al. 
submitted) where RUNX2 overexpression in the pregnant mammary gland blocks 
alveolar development. Intriguingly, such a hypothetical role for RUNX2 in 
mammary lineage specification has a nice parallel in the osteoblast maturation 
process where during skeletal development RUNX2 activates a differentiation 
pathway in bone marrow-derived mesenchymal stem cells which is necessary for 
osteoblast differentiation (Long 2011). Interestingly, RUNX2 expression needs to 
be downregulated to guarantee a correct osteoblast terminal differentiation (Liu 
et al. 2001). If this is indeed paralleled in the mammary lineage then the role of 
RUNX2 as a key lineage specifier, regulating the fine balance of proliferation, 
quiescence and differentiation in different organs and tissues is highly relevant. 
The role of RUNX1 and RUNX2 in breast cancer was discussed in Chapter 5 and 6. 
Interestingly both RUNX1 and RUNX2 have been linked to the TN subtype. RUNX1 
is expressed in the majority of TNBC (~80%) while RUNX2 is detectable in a 
smaller group of the same cohort (15%, McDonald et al, submitted). In addition, 
no overlap or exclusiveness between the two RUNX genes has been detected in 
the patient cohort analysed (data not shown). 
Triple negative breast cancer is an highly heterogeneous group (Metzger-Filho et 
al. 2012). Metaplastic breast cancer (MBC) is a subtype of TNBC characterized by 
poor outcome, and few therapeutic options (Lee et al. 2012). Staining of various 
mouse models of BCs showed squamous metaplastic breast cancer (SMBC) to be 
highly positive for RUNX2. This result suggests that the 15% of TN cases with high 
RUNX2 expression identified by McDonald et al., could belong to the metaplastic 
subgroup. To confirm this correlation, it will be interesting to examine human 
SMBC for RUNX2 to test if this expression pattern found in mouse models 
translates to the human disease. In addition the use of an in vivo model of SMBC 
(APC1572T) (Gaspar et al. 2009) combined with the Runx2flx/flx model will help to 
clarify the role of RUNX2 in cancer development and progression. This study 
could lead to important clinical outcomes such as the identification of RUNX2 as 
a new biomarker and/or therapeutic target for SMBC. 
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Bone metastasis are a frequent outcome of aggressive breast cancer, leading to 
intense pain and severe complications (Suva et al. 2011). For many years RUNX2 
has been described as a possible mediator of breast bone metastasis formation 
based on work from the Stein group (Javed et al. 2005; Barnes et al. 2004). 
However these studies have several limitations; first they are based on intra-
tibia injections, an orthotopic model which cannot recapitulate the seeding and 
homing of BC cancer cells in a bone microenvironment. Secondly, all these 
studies have been conducted using a single breast cancer cell line (MDA-MB-231). 
To address the first point, intracardiac injections, an in vivo model of bone 
metastasis needs to be used (Kretschmann & Welm 2012). In this model MDA-MB-
231 deleted for RUNX2 will be injected intracardically in nude mice; this will 
allow the spreading of BC cells into the entire body of the animal and the 
development of bone metastasis. In such a system the contribution of RUNX2 to 
the homing and the growth of MDA-MB-231 cells in the bone microenvironment 
can be assessed by in vivo luciferase imaging and histological analysis on bone 
lesions. The second point is not currently addressable with current available 
models (Kretschmann & Welm 2012); in fact excluding MDA-MB-231 cells, no 
alternative system for the study of breast cancer bone metastasis exist. Since a 
large percentage of all patients dying of breast cancer(∼70%) have evidence of 
metastatic bone disease (Coleman 2006) more research is needed to address this 
need. 
With recent deep sequencing efforts showing that RUNX1 is a putative tumour 
suppressor in breast cancer (Ellis et al. 2012; Banerji et al. 2012) it is timely to 
investigate the role of RUNX1 in human breast cancer as carried out in Chapter 
6. For the first time an assessment of RUNX1 protein expression on a large 
cohort of human breast cancers has been carried out. Interestingly RUNX1 was 
identified as an independent prognostic factor in TN patients, whose expression 
correlates with poorer survival. This result suggests a possible oncogenic role for 
RUNX1 in TNBC and it is in apparent contrast with the recent sequencing studies 
reporting inactivating RUNX1 mutations in human BC (Ellis et al. 2012; Banerji et 
al. 2012). However, Ellis et al. was focused on ER+ breast cancers while Banerji 
et al. on BC samples from a mixture of different subtypes. So these studies are 
not focused on TN breast cancer and that could be a reason why RUNX1 
oncogenic role has not been identified. Taken together these studies suggest 
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that RUNX1 could play different roles in different cancer subtypes: tumour 
suppressor in luminal-like BC and oncogene in TNBC.  The result from the human 
TMA suggests a possible oncogenic role for RUNX1 in TNBC but cannot exclude if 
RUNX1 is merely a marker of TNBC characterized by worse prognosis or it has an 
actual biological role in this subtype. Preliminary in vitro experiments tried to 
address this question; RUNX1 overexpression induced EMT in non-tumourigenic 
normal human mammary cells suggesting that this could be one of the 
mechanisms by which RUNX1 expression increases cancer aggressiveness. Taken 
together our results are indicating Runx1 as a new prognostic biomarker in TNBC. 
Moreover the availability of small-molecule inhibitors targeting RUNX1 
(Gorczynski et al. 2007; Cunningham et al. 2012) are opening exciting 
possibilities for the development of new targeted therapies for this lethal 
subgroup. 
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